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ABSTRACT 
 
 Sexual transmission of HIV remains the primary route (75 to 85%) of HIV infection among 
all new infection cases. Furthermore, women represent the most vulnerable population and are 
more susceptible to HIV infections than their male counterpart. Thus, there is an urgent need to 
develop topical (vaginal/rectal) microbicide formulations capable of preventing HIV sexual 
transmission. The objective of this dissertation is to develop a mannose specific, lectin-based 
topical microbicide formulation capable of targeting HIV gp120 for the prevention of HIV sexual 
transmission. In Chapters 1 and 2, the general hypothesis, aims and scope of this work are 
introduced. Chapter 3 covers the literature review of anti-HIV lectins and current delivery 
approaches. 
 In Chapter 4, the binding interactions between the mannose specific lectin Concanavalin 
A (ConA) and glycogen from Oster, as well as mannan from Saccharomyces cerevisiae, were 
studied using a quartz crystal microbalance (QCM). The equilibrium dissociation constant 
describing the interaction between Con A and glycogen (KD = 0.25 μM) was 12 fold lower than 
the equilibrium dissociation constant describing the binding between Con A and mannan (KD =
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2.89 μM). That is, Con A was found to have a higher affinity for the glucose-base polysaccharide, 
than for the mannose-based. This observation was mainly attributed to steric effects, the difference 
in molecular weight and branching pattern of both polysaccharides.  
 The knowledge gained in Chapter 4 was applied in Chapter 5 for the development of HIV-
1 gp120 and mannose responsive particle (MRP) formulations. Thus, core dissolved MRP 
(𝐶−𝑀𝑅𝑃) and core containing MRP (𝐶+𝑀𝑅𝑃) were prepared through the layer-by-layer coating 
of calcium carbonate (CaCO3) with the mannose specific lectin (Con A) and a polysaccharide 
cross-linker (Glycogen). Particles were characterized and tested in vitro on Lactobacillus 
crispatus, Human vaginal keratinocytes (VK2/E6E7) and murine macrophage [RAW 264.7 (TIB-
71)] cell lines. 𝐶+𝑀𝑅𝑃 average size and ζ-potential were 1130±15.72 nm [PDI = 0.153] and -
15.1±0.55 mV, (n=3). Similarly, 𝐶−𝑀𝑅𝑃 average size and ζ-potential were 1089±23.33 nm (n=3) 
and -14.2±0.25 mV (n=3). Tenofovir (TFV) encapsulation efficiency in CaCO3 was 74.4% with 
drug loading of 16.3% w/w and 6.0% w/w in 𝐶+𝑀𝑅𝑃 and 𝐶−𝑀𝑅𝑃, respectively. Both 𝐶−𝑀𝑅𝑃 
and 𝐶+𝑀𝑅𝑃 were nontoxic to L. crispatus and did not induce any significant pro-inflammatory 
nitric oxide release in VK2 and RAW 264.7 cell culture. However, 𝐶−𝑀𝑅𝑃 was found to 
significantly affect VK2 and RAW 264.7 cells viability at concentrations ≥ 100 µg/ml. Similarly, 
𝐶−𝑀𝑅𝑃 significantly increased pro-inflammatory cytokines (IL1α, IL1β, IL6, IL7, MKC and 
TNFα) release at concentrations ≥ 100 µg/ml. Conversely, 𝐶+𝑀𝑅𝑃 did not induce any significant 
changes in VK2 and RAW 264.7 cells viability nor in pro-inflammatory cytokines’ levels, in the 
concentration range tested (≤ 1000 µg/ml), for 24 h. 𝐶+𝑀𝑅𝑃 was then selected for further in vitro 
drug release studies as well as ex vivo vaginal mucoadhesion studies. HIV gp120 triggered TFV 
release from 𝐶+𝑀𝑅𝑃 in a concentration dependent manner, and following Hixson–Crowell and 
Hopfenberg kinetic models, consistent with drug release from diminishing surface or matrix 
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eroding drug particles. 𝐶+𝑀𝑅𝑃 was further optimized by varying the number of Con A layer in 
the formulation, and in order to achieve lower HIV gp120 sensitivity (≤ 100 µg/ml). Furthermore, 
bioadhesion studies, performed ex vivo on porcine vaginal tissue, demonstrated that 
FITC−𝐶+𝑀𝑅𝑃 adheres to vaginal tissue at levels varying between 10% ± 1 and 20% ± 2, 
depending on the number of Con A layers in the formulation.    
 In chapter 6, 𝐶+𝑀𝑅𝑃 preclinical safety was evaluated in 8-12 weeks old female C57BL/6 
mice model. First, mice were treated with Depo-Provera® to maintain them in a diestrus-like state. 
Then the microbicide formulation was delivered vaginally at a dose of 100 mg/kg in PBS. Vaginal 
histology, immunohistochemistry evaluations, as well as pro-inflammatory cytokines release 
(vaginal lavage and tissue extract) were investigated after 24 h. The vaginal retention of 
FITC−𝐶+𝑀𝑅𝑃 was also evaluated, up to 24 h. Vaginal and major reproductive organs’ histology 
did not show major damage of the epithelial layer. This result was also consistent with 
immunohistochemistry evaluation of CD45+ cells infiltration in the vaginal epithelial layer, unlike 
the positive control treated groups (BZK and N-9). Furthermore 𝐶+𝑀𝑅𝑃 did not induce any 
significant changes in pro-inflammatory cytokines IL1α, Ilβ, IL7, IP10 and TNFα. In addition, it 
was also observed that FITC labeled 𝐶+𝑀𝑅𝑃 does not have a long-term retention in mice vaginal 
tract. This result suggested that a precoital or multiple vaginal application (i.e., BID) approaches 
of 𝐶+𝑀𝑅𝑃 should be investigated. 
 Overall, this study demonstrates the feasibility of lectin-based microbicide formulations to 
target HIV gp120 for the prevention of HIV sexual transmission.  
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CHAPTER 1 
INTRODUCTION 
 
1.1 Problem Statement  
The Acquired Immunodeficiency Syndrome (AIDS) is an infectious disease caused by 
the Human Immunodeficiency Virus (HIV). AIDS is a debilitating condition in which a 
progressive failure of infected patients’ immune system render them vulnerable to life-
threatening opportunistic infections such as tuberculosis, pneumonia, salmonella infection, 
candidiasis, toxoplasmosis, and tuberculosis (TB). AIDS patients also have a higher risk of 
developing the so-called “AIDS-defining cancers” including Kaposi sarcoma, aggressive B-
cell non-Hodgkin lymphoma, and cervical cancer.1 In fact, on average, people infected with 
HIV have been shown to be 500 times more likely to develop Kaposi sarcoma, 12 times more 
likely to be diagnosed with non-Hodgkin lymphoma, and 3 times more likely to develop 
cervical cancer, among women.2 Furthermore, HIV patients have a higher risk of developing 
several other types of cancers known as “non-AIDS-defining cancers” including, Hodgkin 
lymphoma, liver cancer, anal cancer, oral cavity/pharynx cancer and lung cancer.3, 4 It was 
shown that people living with HIV are eight times more likely to be diagnosed with Hodgkin 
lymphoma, three times as likely to be diagnosed with liver cancer, nineteen times more likely 
to be diagnosed with anal cancer, twice as likely to be diagnosed with oral cavity/pharynx 
cancer and about two times as likely to be diagnosed with lung cancer.1-3 Besides their higher 
risk of developing various cancers, HIV patients have an increased risk of dying from cancer.5, 
6 According to the 2017 UNAIDS fact sheet, 36.7 million [30.8 million–42.9 million] of people 
were living with HIV/AIDS worldwide in 2016. On average, 1.8 million [1.6 million–2.1 
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million] new HIV infection were recorded in 2016.7 According to the same report, 1 million 
[830 000–1.2 million] people died from AIDS-related illnesses in 2016. Despite a steady 
increase in the proportion of HIV infected people receiving anti-HIV treatment and the increase 
in the global HIV expenditure, the overall number of people living with HIV has continue to 
grow over the years.8 More alarmingly, the rate of new HIV-1 infections is believed to be 
outpacing the rate of new individuals receiving antiretroviral therapy by an average of 2.5:1.9 
Figure 1-1 represents the number of HIV global infection since 1990. Figure 1-2 is a 
representation of HIV global expenditure and the percentage of HIV infected people receiving 
HIV treatment worldwide. 
 
 
 
 
 
 
 
 
 
 
Figure 1-1: Number of people living with HIV worldwide. 
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Although HIV/AIDS is a worldwide pandemic disease, the African continent remains 
the most affected with Sub-Saharan African regions accounting for about 70% of the 
worldwide HIV infections in 2016.8 This could be due to many factors including difficulties in 
raising awareness among rural communities, inter-generational relationships, cultural and 
social believes. In fact, the widely promoted “ABC” approach, (abstinence, being faithful, 
using condoms) aimed at fostering HIV prevention and reducing the rate of infection spread, 
has shown some limitations, especially in third world countries.10 Cohen stated that the practice 
of abstinence “is only theoretical, since one can only be certain of one’s own behavior, not the 
behavior of one’s partner”.11 Although HIV infection declines in Uganda and Thailand were 
attributed to reduction in partner number, its long term application remains a challenge in rural 
areas, where polygamy is often deeply rooted in traditional and religious believes.12, 13 
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Figure 1-2: HIV worldwide expenditure and proportion of infected people receiving treatment. 
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Condoms, which are known to be effective when used consistently and correctly, still 
face a strong rejection from certain users who often report reduced physical pleasure, 
embarrassment of purchasing condoms, and a general perception that condom use represents a 
sign of infidelity and/or HIV/STD-seropositive status.14 Figure 1-3 is a statistical 
representation of HIV global prevalence by region.                    
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Figure 1-3: HIV global prevalence by region. 
 
Since 2006, there has been noticeable gender gap in the global proportion of HIV 
infection. In fact, there has been a steady increase in the global proportion of women infected 
with HIV, which was estimated at 51.59%, in 2016.8 In Sub-Saharan Africa regions, the 
proportion of women infected with HIV was estimated at 59% in 2016.15 Figure 1-4 represents 
HIV global infection by gender. According to Ramjee and Daniels, biological, social, 
behavioral, cultural, economic and structural reasons might explained the gender gap in HIV 
infection, especially in Sub-Saharan Africa. In fact, women have a greater mucosal surface 
area exposed to pathogens and infectious fluid for longer periods during sexual intercourse and 
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are likely to face increased tissue injury than men.16 Furthermore, women hormonal cycle was 
shown to increase their vulnerability to HIV infection due to the suppressing influence of sex 
hormones on the innate, humoral and cell-mediated immune systems.17 The slowing economic 
growth affecting Sub-Saharan Africa is also known to be a driving force of women 
vulnerability in the region. In fact poverty has been associated with earlier sexual experience, 
lower condom use at last sex act, having multiple sex partners, increased chances that the first 
sex act is non-consensual, and a greater likelihood of having had transactional sex or physically 
forced sex, which increase their risk of HIV infection.18 Structural gender roles in Sub-Saharan 
Africa, including male sexual entitlement, the lack of social value and power for women, and 
ideas of manhood being linked to the control of women usually lead to lower levels of 
education, few public roles, the lack of family, social and legal support for women, which 
increase their vulnerability to HIV infections.16, 19, 20  
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Figure 1-4: HIV global infection by gender.  
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In addition to women’ vulnerabilities to HIV infection, sexual transmission of HIV is 
known to be the major route of the overall HIV infections. In fact, 75% to 85% of all HIV 
infections are believed to be occurring through sexual contact.21 In addition to having multiple 
sexual partners and the lack of male circumcision, another major reason for the increase in HIV 
sexual transmission is that 6 out of 10 people living with HIV do not know their HIV positive 
status making them a risk to other sexual partners.22, 23 Therefore, there is a crucial need to 
develop a safe, effective and compliant topical (vaginal/rectal) nanomicrobicide capable of 
preventing HIV sexual transmission. One expected benefit of such topical nanomicrobicides is 
their potential use as pre-exposure prophylaxis (PrEP) for women. 
The proof of concept for PrEP is primarily based on the success of oral antiretroviral 
therapy in the prevention of mother-to-child transmission of HIV and on animal studies, 
involving rhesus macaques and humanized mice, that show the efficacy of PrEP against 
mucosal and parenteral infection.24 Due to limited success and failure shown by oral PrEP 
clinical trials such as iPrEx, FEM-PrEP and CDC 4323, latest efforts in the field have shifted 
toward the vaginal and rectal application of anti-HIV microbicide drugs as “topical PrEP”. 
Thus, various microbicide drug delivery strategies (gels, films, rings, etc.) have been proposed, 
attempting to address this need, with limited success. Semisolid dosage forms (gels) which are 
the most common microbicide drug delivery systems, present major challenges of messiness, 
leakage and lack of controlled release.25 Besides their lack of retention, which constantly leads 
to leakages and therefore patience adherence and compliance issues, topical microbicide 
loaded gel formulation, such as CAPRISA 004, have shown minimal effectiveness against 
HIV.26, 27 Vaginal films, which are less untidy than gels, are fast dissolving with rapid drug 
clearance by mucus renewal cycle.25 Moreover, the ASPIRE study states that the silicone based 
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vaginal ring Dapivirine, although promising, still needs to address compliance issues with 
undesirable drug release kinetics.28 In fact, the major concern of a ring-based delivery system 
is a constant drug release even in the absence of HIV virus, which could eventually lead to 
drug waste, drug resistance issues, and potential side effects.  
 
1.2 Research hypothesis  
To address the problem mentioned above, the present study hypothesizes that 
Concanavalin A (Con A)-based topical vaginal and rectal nanomedicine formulation is capable 
of the safe and effective release of a pre-encapsulated HIV microbicide, "on-demand", in the 
presence of HIV gp120. Such an HIV specific microbicide delivery system will not only 
protect the active agent but may ultimately protect women, since more than half of all new 
HIV infections worldwide occur in females.29 
 
1.3 Objectives  
The objectives of this work are: 
1- To engineer a Con A biosensor to investigate the binding interactions of the mannose 
binding lectin to a mannose based polysaccharides (Mannan from Saccharomyces 
cerevisiae) and a glucose based polysaccharides (Glycogen from Oyster) using a quartz 
crystal microbalance. 
2- To develop and optimize a layer-by-layer engineered, Con A-based, mannose 
responsive drug delivery system capable of encapsulating the HIV reverse transcriptase 
inhibitor Tenofovir (TFV). Physico-chemical parameters including, particle mean 
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diameter, surface charge, morphology, percent encapsulation efficiency (%EE), 
percent loading efficiency (%LD) and chemical composition will also be assessed. 
Furthermore, percent mucoadhesion to porcine vaginal tissue will also be investigated. 
In-vitro cytotoxicity of the nanomicrobicide will also be investigated on Lactobacillus 
crispatus, Human vaginal keratinocytes (VK2/E6E7) and murine macrophage [RAW 
264.7 (TIB-71)] cell lines.  
3- To test the hypothesis that HIV gp120 and mannose can trigger TFV release from the 
Con A-based layer-by-layer engineered drug delivery system. Time and concentration 
dependent TFV release will be investigated in vaginal and seminal fluid simulants 
mixture. Drug release mechanism from the layer-by-layer drug delivery system will be 
investigated by fitting various kinetic models. 
4- To evaluate the preclinical safety of the mannose and HIV gp120 responsive 
microbicide formulation in C57BL6 mice. Vaginal and major reproductive organ’s 
tissues will be assessed for damage, inflammation signs and immune response. 
Furthermore, pro-inflammatory cytokines’ level in cervicovaginal lavage and tissue 
extracts will be assayed. 
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CHAPTER 2 
STATE OF THE ART IN HIV MICROBICIDE DRUG DELIVERY 
 
2.1  HIV life cycle   
Engineering an HIV targeted drug delivery system requires a thorough understanding 
of the steps involved in HIV life cycle. As represented in figure 2-1, HIV life cycle can be 
divided in seven (7) critical steps. 
 
 
 
 
 
 
 
 
Figure 2-1: HIV virus life cycle.30 
1- Binding and fusion: The first step in HIV life cycle is the binding to target cells (CD4+ 
cell). HIV binding is mediated through a specific interaction between the viral envelope 
glycoprotein (HIV gp120) and the CD4 receptor on target cells’ surface. This binding 
triggers a conformational change in HIV gp120 which, in turn, enhances its affinity to 
chemokine coreceptors CXCR4 and CCR5. This secondary binding to chemokine 
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coreceptor is considered to be the trigger for the following steps. In fact, in its original 
state, HIV transmembrane glycoprotein (HIV gp41) is thought to be in a high energy 
state, with its fusion peptide buried inwards. However, following the chemokine 
coreceptor binding, HIV gp41 undergo a conformational change, which releases it from 
its high energy state, and the previously buried fusion peptide extends towards the host 
cell membrane, bridging the gap between the virus and the host cell membrane. 
Therefore, HIV gp41 transiently becomes a component of both the viral membrane, 
which it is enchored in, and the host cell membrane, which it is grafted to. Following 
the insertion of the fusion peptide into the host cell membrane, HIV gp41 refolds itself 
in order to shorten the distance between the virus and host cell membranes. This 
refolding leads to the formation of a thermodynamically stable six helix bundle due to 
interaction between three (3) pairs of the so-called "heptad-repeat (HR)" regions HR1 
and HR2. 
 
 
 
 
 
 
 
 
 
Figure 2-2: Steps involved in HIV membrane fusion. 
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The refolding, which finally brings the viral and cell membranes in even closer 
proximity, leads to the formation of a hair-pin structure or “hemifusion stalk”, where 
the outer membranes have fused but not the inner membranes. The fusion process is 
completed with the formation of the fusion pore, where previously semi-fused viral and 
host cell membranes become a single lipid bilayer.31, 32  
2- Reverse transcription: A direct result of HIV membrane fusion process is the 
internalization of key viral proteins and the viral capsid into host cells cytoplasm.33 The 
viral capsid, which contains HIV viral RNA and critical enzymes such as HIV integrase 
and HIV reverse transcriptase, is believed to undergo a cytoplasmic uncoating upon 
entry into the host cell cytoplasm. Several models have been proposed to elucidate the 
exact mechanism of HIV capsid uncoating and, to date, three major theories have 
emerged. Early models have suggested a rapid and complete disassembly of HIV capsid 
in host cell cytoplasm. Other imaging-based studies show both uncoated and partially 
uncoated HIV capsid. Other recent studies suggest an intact capsid structure that only 
disassembled at the nuclear pore complex (NPC). This mechanism is also referred to 
as NPC uncoating. Regardless of the model considered, HIV reverse transcriptase 
generates a double-stranded HIV complementary DNA (cDNA) from the single-
stranded HIV RNA in the process known as reverse transcription.34 
3- Integration: In the integration phase, which occurs in the nucleus, the newly generated 
double-stranded HIV cDNA is incorporated into the host cells’ genome. The process 
of cutting host cells’ genome and clipping the viral cDNA is catalyze by the HIV 
integrase enzyme. Once completed, the integration process, which is non-reversible, 
leads to the so-called proviral DNA.35 
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4- Replication: In the replication phase, the proviral DNA, essentially serving as a 
template, is transcribed into new viral RNA copies by host cells’ enzymes, in the 
nucleus. In the cytoplasm, some of the viral RNA are further spliced into mature viral 
RNA copies (mRNA). The viral mRNA are further translated into long, non-functional 
polypeptide chains, which are, in turn, cleaved into functional viral proteins (HIV 
integrase, reverse transcriptase, HIV envelope glycoproteins, etc.) by HIV protease.36  
5- Assembly and budding: This represents the last step of HIV viral replication that leads 
to the generation of new virion particles. In the assembly and budding process, critical 
viral proteins and copies of viral RNA are packaged into new virion particles that are 
then excreted from host cells through the process known as budding. New virion 
particles’ surface are decorated with HIV envelope glycoproteins required to initiate 
binding and entry into new target cells. This cycle of viral binding/entry to the 
production of new virion particles sustains an increasing HIV viral count and 
eventually spreads the infection to other parts of the body. HIV viral burst, which 
represents the total number of virus particle produced from a single infected target cell, 
was shown to be 4.0 × 104 and 5.5 × 104 for the first and second inoculations, 
respectively.37 Eventually, the hijacked host cells die by apoptosis or pyroptosis, after 
few cycle of HIV virion production.38   
 
2.2 Vaginal physiology and HIV acquisition 
Normal vaginal physiology 
The development of appropriate vaginally applicable microbicide formulations 
intended for the prevention of HIV sexual transmission requires an understanding of the normal 
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vaginal physiology and its environment. The vagina is a highly expandable, slightly s-shaped, 
fibromuscular tube roughly 8 to 10 centimeters (3 to 4 inches) long across the posterior wall 
(rear), and about 7.5 centimeters (2.5 to 3 inches) long across the anterior wall (front).39, 40 It 
is located between the rectum, which lies posterior to it, and the urethra and bladder, which 
lies anterior to it, and extends from the vulva to the uterus. From the lumen outwards, the 
vaginal wall is composed of three distinctive tissue layers: the mucosa, the muscularis, and the 
tunica adventitia.39 Numerous studies have established that the vaginal epithelial layer remains 
relatively constant throughout the menstrual cycle in adult women (postpubertal and 
premenopausal).39 Nonetheless, the structure of the vaginal epithelium changes throughout the 
lifespan of women, and is also affected by hormonal and environmental conditions.41 One of 
the most striking changes observed among women of different ages, is the vaginal epithelium 
thickness (figure 2-4).42 In prepuberal girls and postmenopausal women, the vaginal epithelium 
is thin and mainly composed of basal and parabasal cells layers. In reproductive, adult women, 
the vaginal epithelium is thick and composed of a multicellular layer of nonkeratinized 
squamous cells. Cervical glands and local epithelial cells secrete a mucus that provides an 
innate barrier to invading pathogens. In fact, pathogens entrapped in the mucus layer could 
potentially be cleared through the natural mucus turnover cycle. Various immune cells, 
including Langerhans cells (LCs), γδCD4+ T cells, CD4+ T cells, dendritic cells (DCs), Natural 
Killer cells (NK) and macrophage, are located in and underneath the epithelial cell. 
Furthermore, hormonal differences, such as estrogen level, in women of different ages, have 
been associated with glycogen storage and level in the vaginal epithelium. Glycogen serves as 
substrate for lactobacilli, a major component of vaginal microbiota, in the production of lactic 
acid, which maintains the vaginal acidic pH in adult women.41 In fact, differences in the vaginal 
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microbiota as well as the vaginal pH are other noticeable structural changes in the vaginal 
mucosa during different stages of women’ life.  During childhood, the vaginal microbiota is 
mainly composed of gram-negative anaerobe bacteria such as Fusobacteria, Veillonella, 
Bacteroides and a subpopulation of Gram-negative cocci as well as Gram-positive anaerobe 
bacteria including Bifidobacteria, Peptococcus, Propionibacterium, Actinomyces and 
Peptostreptococcus.43, 44 The vaginal microbiota in healthy adult women is mostly dominated 
by Lactobacillus including  L. crispatus, L. gasseri, L. iners, and L. jensenii.45 In 
postmenopausal women, the vaginal microbiota is primarily domitated by L. iners and G. 
vaginalis and a lower abundance of Candida, Mobiluncus, Staphylococcus, Sneathia, 
Bifidobacterium, and Gemella. This stage is particularly characterized by a low lactobacilli 
bacteria population.46, 47 In prepuberal girls and postmenopausal women, the significant 
reduction in glucose-fermenting microorganisms, including lactobacilli, facilitates an increase 
in the vaginal pH (6.5 -7.5), while the vaginal pH in healthy pubertal women is acidic and vary 
between 3.5-4.5.42, 48 The acidic vaginal pH in reproductive adult women has been shown to 
significantly prevent HIV sexual transmission.49, 50 Furthermore, H2O2-producing 
Figure 2-3: Vaginal mucosa and microbiota at different stages of women’ life.42 
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Lactobacillus species, such as L. crispatus and L. jensenii provide an additional antimicrobial 
protective layer in adult women, compared to prepuberal girls and postmenopausal women.51, 
52 
 
Vaginal acquisition of HIV 
Unprotected vaginal intercourse is a high-risk route of HIV transmission for both men and 
women, in the case where one partner carries the virus.53, 54 Nonetheless, numerous studies 
established that women have a greater risk to contract HIV infection through sexual intercourse 
than their male partners.55 In addition to biological, social, behavioral, cultural, economic and 
structural differences explained in chapter I, this could also be due to male circumcision. In 
fact, it is now evident that male circumcision offers significant protections against HIV 
transmission in men.56 The model of HIV vaginal transmission presented in figure 2-5 
considers the primary infection of female from an infected sexual partner. Typically, HIV 
vaginal transmission can occur through six (6) main routes (figure 2-5).42 
1- First, mature HIV virion particles can be trapped in the vaginal mucus layer and migrate 
within gaps, intercellular spaces, in the epithelial cell layer to reach the stroma or the 
submucosa. Similarly, infected donor cells could be trapped in the mucus and release 
more HIV virion. These virions could reach and infect LCs which could then carry 
them to the submucosa.  
2- Moreover, HIV virion could infect γδ CD4+ T cells in the epithelium.  
3- Free HIV virions or those released from infected donor cells can be transferred through 
the epithelial cell layers by transcytosis. These virions could either infect epithelial 
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cells or migrate to the stroma where they could infect stroma DCs and seed the 
production of new virions.  
Figure 2-4: Mechanism of HIV vaginal acquisition.42 
 
4- Furthermore, free HIV virion particles and infected donor cells could migrate through 
lesions within a damage epithelial cell layer and reach the stroma. In the stroma region, 
donor cells may release more HIV virions.  
5- Free HIV virions that reach the stroma can further infect CD4+ T cells and 
macrophages. Infected DCs may also transport these virions to underlying CD4+ T 
cells.   
6- Infected immune cells including DCs, CD4+ T cells, macrophages, and LCs further 
spread the infection in the submucosa and to local lymph nodes and blood vessels.   
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2.3 HIV microbicides and classification 
 Before FDA approval of Indinavir, Nevirapine and Ritonavir in 1996, very few 
antiretroviral treatment options existed for HIV infection, and clinical management primarily 
consisted of prophylaxis against opportunistic diseases and AIDS related diseases.57 Today, 
nearly forty (40) HIV approved microbicides are marketed and many more are being 
investigated in ongoing clinical trials.58 HIV microbicides can be classified into six (6) main 
drug class based on their therapeutic target or mechanism of action. 
1- Entry inhibitors: HIV entry inhibitors prevent viral entry into target cells through 
interactions with either HIV or host proteins involved in the entry process. HIV entry 
inhibitors can be subdivided into five (5) distinct classes including gp41 inhibitors, 
gp120 inhibitors, CXCR4 inhibitors, CCR5 antagonists and CD4 inhibitors. Entry 
inhibitors such as Enfuvirtide and Sifuvirtide, mimic heptad-repeat (HR) of HIV gp41, 
thus  blocking the formation of the six-helix bundle structure critical for the membrane 
fusion process between HIV and host cells. CCR5 antagonist such as maraviroc bind 
the chemokine coreceptor CCR5 inducing a conformational change in the receptor 
which, in turn, prevents HIV gp120 binding to the coreceptor.57, 59 
2- Reverse-transcriptase inhibitors (RTI): RTI exert their microbicide activity by blocking 
the reverse transcription of HIV single-stranded RNA into its complementary double-
stranded cDNA. RTI are classified into two subgroups including nucleoside/nucleotide 
reverse transcriptase inhibitors (NRTI) and non–nucleoside reverse transcriptase 
inhibitors (NNRTI). NRTI, such as TFV and Zidovudin, which lack the 3′-hydroxyl 
group at the sugar (2′-deoxyribosyl) moiety, induce the proviral cDNA chain 
termination by preventing the formation of 3′-5′-phosphodiester bond between the 
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NRTIs and incoming 5′-nucleoside triphosphates. NNRTI such as Nevirapine and 
Etravirine are non/uncompetitive inhibitors of the reverse transcriptase enzyme. 
NNRTI essentially limit the special conformational flexibility of the reverse 
transcriptase, which in turn, reduces the polymerase activity.57, 59  
3- Integrase inhibitors: Integrase inhibitors (INI) prevent the integrase enzyme from 
catalyzing the formation of covalent bonds between the viral and host DNA. INI, such 
as  Raltegravir and Elvitegravir, essentially block three steps required for viral DNA 
incorporation into the host chromosome, which generally occurs within the first 15–20 
h of infection. INI prevent the assembly with the viral DNA, the endonucleolytic 
processing of the 3′ ends of the viral DNA, and the strand transfer or joining of the viral 
and cellular DNA.57, 59 
4- Protease inhibitors: Protease inhibitors (PI) exhibit their mechanism of action late in 
the HIV replication cycle by binding and inhibiting HIV proteases. Binding of PI, such 
as Ritonavir and Nelfinavir, blocks the proteolytic activities of the enzyme, which, in 
turn, prevents the formation of functional viral Gag and Gag-Pol proteins, resulting in 
the inability of formation of mature, infectious HIV virions.57, 59 
5- Capsid inhibitors: HIV capsid inhibitors interfere with the assembly and disassembly 
of the viral capsid that encloses the viral genome. Currently, there is no FDA approved 
capsid inhibitors. However, GS-CA1, a preclinical capsid inhibitor from Gilead, has 
shown potent inhibition of HIV-1 replication, with EC50 of 140 picomolar in peripheral 
blood mononuclear cells.60 
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Table 2-1: FDA approved anti-HIV microbicide and formulations.61 
Drug class Microbicide Formulation 
Entry 
inhibitors 
Enfuvirtide (Fuzeon) Injection 
Maraviroc (Selzentry) Oral tablet 
NRTI Zidovudine (Retrovir) Oral capsule, oral tablet, oral syrup, 
and injection. 
Didanosine (Videx)  Capsule 
Delayed-release didanosine (Videx EC) Capsule 
Stavudine (Zerit) Capsule 
Emtricitabine (Emtriva) Capsule, oral solution 
Lamivudine (Epivir) Oral tablet and oral solution 
Lamivudine and zidovudine (Combivir) Oral tablet 
Abacavir sulfate (Ziagen) Oral tablet, oral solution 
Abacavir and lamivudine (Epzicom) Oral tablet 
Abacavir, zidovudine, and lamivudine 
(Trizivir) 
Oral tablet 
Tenofovir disoproxil fumarate (Viread) Oral tablet 
Tenofovir disoproxil fumarate and 
Emtricitabine (Truvada) 
Oral tablet 
NNRTI Rilpivirine (Edurant) Oral tablet 
Etravirine (Intelence) Oral tablet 
Delavirdine mesylate (Rescriptor) Oral tablet 
Efavirenz (Sustiva) Oral tablet, capsule 
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Drug class Microbicide Formulation 
NNRTI Nevirapine (Viramune) Oral tablet, oral suspension 
Nevirapine extended-release (Viramune 
XR) 
Oral tablet 
INI Raltegravir (Isentress) Oral tablet, oral powder 
Dolutegravir (Tivicay) Oral tablet 
Elvitegravir (Vitekta) Oral tablet 
PI Tipranavir (Aptivus) Capsule, oral suspension 
Indinavir (Crixivan) Capsule 
Nelfinavir (Viracept) Oral tablet, oral powder 
Atazanavir (Reyataz) Oral capsule, oral powder 
Atazanavir/cobicistat (Evotaz) Oral tablet 
Saquinavir (Invirase) Oral tablet, oral capsule 
Lopinavir/ritonavir (Kaletra) Oral solution, oral tablet 
Ritonavir (Norvir) Oral tablet, capsule, oral suspension 
Fosamprenavir (Lexiva) Oral tablet, oral suspension 
Darunavir (Prezista)  
Darunavir/cobicistat (Prezcobix) Oral tablet, oral suspension 
Caspase 
inhibitor 
N/Aa N/Aa 
aN/A: Note available 
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 Lessons learned from HIV high susceptibility for mutation in microbicide 
monotherapy, has led to antiretroviral combination therapies. Today the highly active 
antiretroviral therapy (HAART) is a standard HIV treatment regimen which combines a 
“backbone” of 2-NRTI, plus one of these classes of drugs –  PI (usually boosted with ritonavir), 
NNRTI, INI, or CCR5 antagonist. Since its first use in 1995, HAART has dramatically 
improved HIV infected patient health and survival.59, 62 
 
2.4 Topical microbicide candidates’ formulation and delivery  
Given the elevated rate of HIV sexual transmission among all new HIV infections, 
vaginally applicable microbicide formulations have received a special attention in the past 
decades. Topical microbicide agents can be classified into two major groups or generations, 
based on their mechanism of action.63  
The first generation topical microbicide agents includes surfactants, polyanions and 
acid buffering agents. These agents are non-specific, with a broad spectrum of antimicrobial 
activity as well as contraceptive properties. Surfactants represent the first topical microbicides 
investigated for their ability to prevent HIV sexual transmission. They exert their mechanism 
of action by disrupting viral and cellular membranes.64 Surfactants such as Nonoxynol 9 (N-
9), a non-ionic surfactant, and C31G (SAVVY), an amphoteric surfactant, have been tested in 
this group. Despite success shown in vitro, both N-9 and C31G showed lack of effectiveness 
and possible harm in clinical trials, possibly linked to inflammatory changes in the 
cervicovaginal mucosa.63, 65 Polyanions-based topical microbicides prevent viral attachment to 
target cells via electrostatic interactions with viral envelope glycoprotein (HIV gp120). 
Cellulose sulfate (UsherCell), carrageenan (Carraguard), and sulfonated naphthalene 
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derivative (PRO 2000) are some of the Polyanions-based topical microbicides that have been 
clinically investigated. Similar to surfactants, these products did not demonstrate any 
protection against HIV-1 acquisition and in some cases enhanced HIV transmission instead. 
Polyanions failure was attributed to various  factors including low potency (in comparison to 
antiretrovirals), negligible mucosal absorption, reduced activity in seminal plasma, short 
duration of effect, and induction of mucosal and microflora changes facilitating HIV-1 initial 
infection.63 Buffering microbicide agents were developed to maintain an acidic pH in the 
vaginal environment, inactivate HIV (due to the acidic pH) and immobilized and killed 
potential HIV vectors, such as lymphocytes and macrophages. BufferGel® and lime juice are 
few acid buffering agents that have been studied clinically. Both products did not show any 
significant anti-HIV protection and lime juice was found to induce pronounce cervicovaginal 
epithelial toxicity.66, 67 Amphora™ (Acidform™) is an approved sexual lubricant gel that is 
being considered as a candidate microbicide given its acid-buffering and bioadhesive 
properties.63, 64 
Second generation topical microbicides are essentially composed of antiretrovirals 
formulations and are currently the main focus in topical microbicide development. They have 
emerged following repeated and significant setbacks observed with first generation topical 
microbicides. Thus, semi-solid (films, creams and gel), vaginal tablet as well as nanofibers and 
intravaginal ring (IVR) formulations are being investigated. Although many second generation 
topical microbicides have shown excellent safety profiles, only few formulations have been 
proven effective, to date. For example, although dapivirine film (a NNRTI) has demonstrated 
a reduced cervical tissue infectivity post HIV challenge, vaginal films are generally fast-
dissolving with a rapid clearance.68, 69 Dapivirine vaginal film potential to prevent HIV vaginal 
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transmission in women still needs to be tested, in addition to compliance issues that this 
formulation faces.70 TFV (NRTI) vaginal gel formulation is currently one of two vaginal 
microbicides that have demonstrated effectiveness in preventing HIV vaginal transmission in 
human. In fact, besides the lack of controlled release, the messiness and leakage associated 
with vaginal gels, 1% TFV (CAPRISA 004) was shown to reduce HIV acquisition by 39% and 
54% over 18 months period among women, and depending on the level of adherence.65 
However, a larger clinical trial study (FACTS 001) of 1% TFV, designed to confirm the 
effectiveness identified in CAPRISA 004, did not show any reduction in HIV infections.71 The 
IVR formulation of Dapivirine is the second vaginal microbicide that was recently shown to 
significantly prevent HIV transmission in a clinical trial (ASPIRE).28 Similar to CAPRISA 
004, the ASPIRE team identified women adherence to the microbicide formulation to be a 
critical factor affecting the level of effectiveness observed. Table 2 is a summary of first and 
second generation vaginal microbicides formulations.  
 
 Table 2-2: Current vaginal formulations for the prevention of HIV sexual transmission.72  
Mechanism of 
action 
Microbicide Dosage form Clinical trial 
outcome 
Current status 
Surfactants Nonoxynol-
9 
Gel 
Film 
Not safe  
Not effective 
Rejected 
Savvy gel® Gel Safe 
Not effective 
Rejected 
Acidifier BufferGel® Gel Safe 
Not effective 
Rejected 
Polyanions Carraguard® Gel Safe  
Not effective 
Use as carrier being 
assessed 
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Mechanism of 
action 
Microbicide Dosage form Clinical trial 
outcome 
Current status 
Polyanions PRO 2000® Gel Safe  
Not effective 
Rejected 
VivaGel® Gel Not safe Rejected 
gp120-
neutralizing 
monoclonal 
antibody 
Vitamin B12 Gel NDa Large amounts are 
required and expensive 
to produce 
Cyanovirin-
N 
Gel NDa Candidate for clinical 
trials It has been 
expressed and purified 
from transgenic plants 
Probiotics 
(genetically 
modified 
Lactobacillus 
jensenii strain) 
NDa In clinical trials 
Entry 
inhibitors 
Maraviroc Gel 
(Hydroxyethyl 
Cellulose) 
NDa Its period of 
effectiveness must be 
increased 
Gel (silicone) NDa Candidate for clinical 
trials 
IVR NDa Controlled release over 
28 days 
Viral enzyme 
inhibitors 
Tenofovir/ 
tenofovir 
disoproxil 
fumarat 
Gel Safe 
Effective 
The first microbicide 
that demonstrated 
efficacy in women 
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Mechanism of 
action 
Microbicide Dosage form Clinical trial 
outcome 
Current status 
Viral enzyme 
inhibitors 
Tenofovir/ 
tenofovir 
disoproxil 
fumarat 
IVR Safe In clinical trials. 
Provides lasting 
protection in animal. 
Nanoparticles 
(into a film) 
NDa Controlled release over 
24 hours. Further 
evaluation  needed. 
MIV-150 Gel Safe In clinical trials 
IVR NDa Candidate for clinical 
trials 
Dapivirine Gel Safe In clinical trials 
IVR Safe  
Effective 
Controlled release over 
28 days. Has 
demonstrated efficacy in 
women 
Film Safe In clinical trials 
aND: Note determined 
 
2.5 Guidance for preclinical assessments of vaginal microbicide candidates’ safety and 
efficacy.  
Similar to other therapeutics administered ocularly, orally or by injection; vaginal 
microbicides candidates need to demonstrate their preclinical safety and efficacy in order to be 
considered for clinical trials. The growing number of investigational vaginal microbicides 
formulations, partly governed by the urgent and critical need of topical formulation capable of 
preventing HIV sexual transmission, necessitate uniform guidelines for these products 
assessment and approval. To investigate their safety and efficacy, vaginal microbicide 
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formulations candidates are subject to rigorous preclinical evaluations in both cell based and 
animal subjects. These studies are mostly guided by prerequisites suggested or imposed by 
regulatory agencies that approve studies in humans, and help to follow a rational and ethical 
approach that will finally allow the start of clinical trials.73 
One of the first steps in the development of vaginal microbicides is to identify active 
pharmaceutical ingredients (APIs) that can block HIV entry or replication processes. Extensive 
evaluation of the physical and chemical properties of the unformulated and formulated API(s), 
as well as API compatibility with formulation excipients and chemical stability also need to be 
investigated. Additional tests and specifications on formulations include pH, osmolality, 
vaginal retention, rheological properties (in the case of a gel), appearance, odor, content 
uniformity of drugs, impurities, dose volume, product dimensions, and drug release kinetics.73 
Ideal candidate microbicide formulations need to demonstrate excellent safety profile, 
including lack of localized and systemic toxicity, not disrupt the vaginal epithelium, not induce 
inflammation or pro-inflammatory cytokine release, be inert towards the normal vaginal 
microbiota, and show no-effect on fertility and/or fetal abnormalities. These formulations also 
need to demonstrate evidence of anti-HIV activity and efficacy by efficiently preventing HIV 
infection of target cells, be active against a range of sexually transmitted pathogens, be fast 
acting with long-term efficacy, demonstrate irreversible efficacy and should not induce drug 
resistance. From both the safety and efficacy studies, some of the endpoints generally 
determined are the median effective concentration (EC50), the average cytotoxic concentration 
(CC50), and the therapeutic index (TI, or CC50/EC50). The 90% viral inhibition concentration 
(EC90) is also determined to inform a rational dose selection when formulating candidate 
microbicide. EC90 is also an important parameter to consider in pharmacokinetic (PK) and 
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pharmacodynamic (PD) studies. Typically, a minimum acceptable TI value ranges from 10 to 
100.73  
 
 
Scheme 2-1: GO/NO-GO algorithm in vaginal microbicides products development.73  
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Vaginal microbicide candidates must also be stable under diverse environmental 
conditions, such as, the vaginal acidic pH (3-4.5) and neutral pH values (7-8), which typically 
occur during sexual intercourse, due to the strong buffering capacity of human seminal fluid.74, 
75 Products must have adequate shelf life, with minimal need of cold chain distribution and 
storage that might limit their practical use in third world countries. Furthermore, ideal vaginal 
microbicide products should provide controlled, sustained and significant drug release (level) 
at the target site. Finally, microbicides candidates production must be economic, scalable and 
should be  affordable in high-risk populations and should not interfere with sexual pleasure.76, 
77 In their study on the Preclinical assessments of vaginal microbicide candidate safety and 
efficacy, Fernández-Romero et al.73 have established a possible go/no-go algorithm relevant 
for vaginal microbicide development. Scheme 2-1 is a modified version of the algorithm of 
Fernández-Romero et al. 
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CHAPTER 3 
LITERATURE REVIEW OF HIV SURFACE GLYCOPROTEINS AND ANTI-HIV 
LECTINS 
(AIMS Molecular Science, 2018, 5(1): 96-116) 
 
3.1 Introduction 
Among the different classes of anti-HIV microbicides currently in use, agents targeting 
and preventing viral entry into target cells have shown remarkable promises, partly favored by 
fewer barriers that could potentially hinder their mechanism of action. HIV entry inhibitors are 
subdivided into three main groups composed of attachment inhibitors, co-receptor binding 
inhibitors, and fusion inhibitors.78 Attachment inhibitors such as zintevir, BMS-378806 and 
BMS-488043 block a non-specific adsorption step between HIV virions and target cells’ 
membrane, which is due to an interaction between the positively charged regions of the 
envelope glycoprotein gp120 and oppositely charged proteoglycans on cell surface. Co-
receptor binding inhibitors are generally CCR5 antagonists such as aplaviroc, vicriviroc and 
maravirok that bind to CCR5 and prevent further HIV gp120/CCR5 interaction, which is 
critical for viral entry into host cells. Fusion inhibitors such as tifuvirtide, enfuvirtide and 
sifuvirtide prevent the formation of the fusion pore by mimicking either heptad repeat 
sequences (HR1 or HR2) in HIV gp41. These sequences block the formation of a six-helix 
bundle structure necessary for HIV entry into host cells.78  
Lectins, which are carbohydrate binding proteins, have long being considered for their 
diagnostic and therapeutic potentials, as well as their pathogenic implication in many human 
diseases and conditions, including various cancers,79 type 2 diabetes,80, 81 cardiovascular 
30 
  
disease,82 weight management,83, 84 and HIV/AIDS.85 The ability of lectins to recognize and 
bind several mannose oligosaccharides was long considered a viable example of anti-HIV 
therapeutic strategy.86 Primarily, anti-HIV lectins act as viral entry inhibitors by binding to 
oligosaccharides epitopes on HIV surface glycoproteins, which either hinder a proper 
interaction between HIV and receptors on target cells’ membrane or affect post-binding 
conformational alterations of key viral envelope and transmembrane glycoproteins (HIV 
gp120/ HIV gp41). In this chapter, we report on the current trend in anti-HIV lectins research 
and emerging lectins formulations aiming at improving the delivery of these sugar-binding 
proteins. 
 
3.2 HIV surface glycoproteins and glycans 
HIV surface glycoproteins (HIV gp120 and HIV gp41) mediate host cell entry through 
interaction with CD4 receptor and CCR5/CXCR4 coreceptors on target cells. These 
glycoproteins are first expressed as HIV gp160 precursor, before the proteolytic cleavage in 
the trans-Golgi by cellular furin or furin-like proteases that leads to the formation of the 
envelope glycoprotein HIV gp120 and the transmembrane glycoprotein HIV gp41. In mature 
HIV viruses, HIV gp120 and HIV gp41 remain linked by noncovalent interactions.33 Most 
anti-HIV lectins target and bind specific glycan structures on HIV envelope glycoproteins. 
Understanding the glycosylation pattern of these glycoproteins is useful not only for anti-HIV 
vaccine design, but also for the selection of appropriate lectins for potential vaginal 
microbicides formulation development. Glycans found on HIV surface glycoproteins may also 
help in understanding anti-HIV lectins overall mechanism of action. Moreover, the extent and 
variation in glycosylation pattern between HIV strands, as well as changes in the glycosylation 
31 
  
pattern during HIV maturation may help explain resistance to certain anti-HIV vaccines and 
lectins, as well as the lack of broad activity usually observed with anti-HIV lectins.87, 88 
 
HIV gp120 glycans and their function 
HIV gp120 is the external envelope glycoprotein of HIV. It is a homotrimer with each 
subunit having a nominal molecular weight of 120 kDa. HIV gp120 plays an essential role in 
HIV entry into host cells. In fact, HIV host cell entry is initiated by the binding of gp120 to 
CD4 receptor. This binding triggers a conformational change in HIV gp120 which, in turn, 
enhances its affinity to chemokine receptors CXCR4 or CCR5. This secondary binding induces 
another conformational change in the transmembrane glycoprotein HIV gp41 resulting in an 
intimate contact and fusion of both viral and host cell membranes. The membrane fusion 
process leads to the internalization of HIV viral capsid, containing the viral mRNA and key 
viral proteins, into host cells cytoplasm. Ultimately, new HIV virus particles are produced 
which then propagate the infection.32, 89 Literature abound of HIV gp120 biosynthesis, 
trafficking, and incorporation. Rather than the underlying biological mechanism involved in 
these processes, this section focuses on the nature of HIV gp120 glycosylation and its role in 
the membrane fusion.  
Ratner et al.,90 Allan et al.91 and Montagnier et al.92 have published some of the first 
studies that explored HIV gp120 glycosylation. Although these pioneering studies did not 
investigate HIV gp120 glycan structures in detail, they did report HIV gp120 glycosylation to 
account for approximately 27 to 50% of the overall glycoprotein molecular weight. Some of 
these early investigations also demonstrated the presence of 3191 or 3293  potential N-
glycosylation sites on HIV gp120. Subsequent studies by Mizuochi et al.94, 95 further 
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investigated HIV gp120 glycan structures. Mizuochi’s findings showed in part that HIV gp120 
is unique in its diversity of oligosaccharide structures. These studies also reported HIV gp120 
glycans to be predominantly oligomannoses that are mostly comprised of five to nine mannose 
residues accounting for approximately 33% of the overall glycoprotein’s carbohydrate 
structures.96 Furthermore, this study projected the number of potential N-glycosylation sites 
on HIV gp120 to be around 20. Besides the high-mannose type glycans, Mizuochi et al. also 
identified complex type glycan chains (34% of carbohydrate structures) mainly composed of 
four categories: mono-, bi-, tri- and tetra-antennary, with or without N-acetyllactosamine 
repeats, and with or without a core fucose residue.94, 96-98 A previous study by Geyer et al.97 
reported similar findings and showed that predominant oligomannose glycans in HIV gp120 
are composed of seven to nine mannose residues, depending on whether the glycoprotein is 
excreted or expressed intracellularly. Geyer et al. also showed that HIV gp120 complex-type 
oligosaccharide are fucosylated with partial sialylated bi- and triantennary structures. Recent 
advances in glycoscience, genomic, proteomics and mass spectrometry have led to more 
detailed and in depth characterization studies of HIV gp120 glycosylation. In fact, recent mass 
spectrometry studies have confirmed HIV gp120 high mannose proportion for various viral 
clades and expression systems,98-102 and it is widely accepted that HIV N-glycosylation sites 
number range from 20-35.33 Following a matrix-assisted laser desorption/ionization (MALDI) 
time-of-flight (TOF) analysis, Bonomelli et al. showed that HIV gp120 oligosaccharides, 
derived from virus [clade A (92RW009), clade B (JRCSF), and clade C (93IN905)] isolated 
from infected peripheral blood mononuclear cells (PBMCs), are almost entirely oligomannoses 
and varies from 62–79% for virion-associated, versus 30% for recombinant, monomeric HIV 
gp120.99, 103 These studies also identified an “intrinsic” mannose patch in HIV gp120 
33 
  
composed essentially of Man5–9GlcNAc2 and conserved across primary isolates and 
geographically divergent HIV clades. Many other studies have confirmed the presence of the 
mannose patch on HIV gp120 and its relevance in the development of a successful anti-HIV 
vaccine and microbicides.104-107 HIV gp120’s main glycan structures are summarized in figure 
3-1. HIV gp120’s heavy glycosylation is believed to play four (4) key roles: host immune 
evasion, pathogenesis, proper glycoproteins folding and host cell surface recognition.108 In 
fact, several studies have compared HIV gp120 extensive glycosylation to a protecting shield 
that prevents antibodies access to underlying amino acid sequences and therefore limits their 
efficacy.106, 109-112 More specifically, Sanders et al. determined that the carbohydrate at 
asparagine 386 on HIV-1 gp120 enhances HIV immune evasion.113 Furthermore, the general 
role of HIV gp120 glycosylation in HIV pathogenesis has widely been reported.114 Besides its 
major implication in HIV gp120 proper folding and lysosomal degradation, Francois et al.115 
and Mathys et al.116 showed that cleavage of glycan at asparagine 260 of HIV-1 gp120 results 
in loss of viral infectivity. 
 
 
 
 
 
Figure 3-1: High mannose and complex glycan structures found in HIV gp120. Structures are 
adapted from the following references.94, 96, 97, 117, 118 
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Similarly, Huang et al. demonstrated that deletion of HIV gp120 glycans from asparagine 
proximal to the CD4-binding region (156, 262 and 410) impairs HIV viral infectivity.119 The 
essential role of glycosylation in proper HIV gp120 folding was also elucidated by numerous 
reports.116, 120 For example, Li et al. showed that N-linked glycosylation is highly essential for 
a proper conformation of HIV gp120 capable of binding to CD4 receptor.121 In a separate study, 
Li et al. determined that deletion of the glycan at asparagine 448 can profoundly influence 
CD4+ T cell recognition of HIV-1 gp120.122 
 
HIV gp41 glycans and their function 
HIV gp41 is composed of 345 amino acid that are organized into three (3) major 
domains: extracellular domain (ectodomain), transmembrane domain, and C-terminal 
cytoplasmic tail.33, 123, 124 Unlike HIV gp120, the transmembrane glycoprotein contains fewer 
N-glycosylation sites. Nonetheless, there is an inconsistency pertaining to the number of N-
glycosylation sites in HIV gp41, as various communications often report different numbers. 
This may be due to differences in expression systems, cell lines and HIV strands. According 
to the current literature, the number of potential N-glycosylation sites in HIV gp41 vary 
between 3-8. In fact, Perrin et al. reported a poor glycosylation of HIV gp41 ectodomain with 
only 4 or 5 potential glycosylation sites.125 Following the screening of ten HIV-1 amino acid 
sequences, Johnson et al. determined that HIV gp41 typically contains 3 or 4 N-glycosylation 
sites, localized within a short stretch (20 to 30 amino acid residues) of the C-terminal half of 
the ectodomain.126 The same number of HIV gp41 potential N-glycosylation sites was reported 
by Fenouillet et al.127, 128, Lee et al.129, Ma et al.130 and Wang et al.131 Furthermore, citing the 
work of Montefiori et al.114, Checkley et al. reported HIV gp41 N-glycosylation sites to vary 
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between 3-5.33 The work of Balzarini et al. reported some of the highest number of  HIV gp41 
potential N-glycosylation sites, which was thought to be 7 with only 4 seemingly 
glycosylated.132 Further studies by Mathys and Balzarini have reported N-glycosylation sites 
in HIV gp41 between 4-8 with all 4 to 5 N-glycans on the ectodomain composed of complex-
type glycans.133, 134 
In contrast to HIV gp120, the transmembrane glycoproteins’ glycans are known to be 
primarily composed of more complex carbohydrate types. In fact, following the analysis of 
HIV gp41 expressed from two different producer cells (Chinese hamster ovary cells and human 
embryonic kidney cells [293T]), Pritchard et al. determined that, in combination with the 
presence of less oligomannose glycans (19%–34%) compared to HIV gp120 (60%–65%), HIV 
gp41 contains large populations of complex-type glycans on its ectodomain.118 Regardless of 
the expression system, HIV gp41 oligomannose population was also found to be composed of  
Figure 3-2: High mannose and complex glycan structures in HIV gp41. Structures are adapted 
from the following references.100, 117, 118 
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Man5-9GlcNAc2. Like HIV gp120, complex glycans in HIV gp41 are composed of sialilated 
and asialilated bi-, tri- and tetra-antennary structures usually containing N-lactosamine repeats, 
with or without core fucose residue.100, 117, 118  HIV gp41 main glycan structures are 
summarized in figure 3-2. 
HIV gp41 plays an equally critical role in HIV entry into target cells by mediating the 
membrane fusion process required for the internalization of the HIV viral capsid.32 Glycans in 
HIV gp41 are reported to play key roles in viral entry, immune evasion, and infectivity. In fact, 
Fenouillet et al., reported a loss of HIV ability to enter target cells after complete removal of 
the glycan cluster from asparagines at positions 621, 630, and 642 in HIV gp41.135 A follow 
up study by Perrin et al., determined the critical role of HIV gp41 glycosylation for an effective 
membrane fusion process.125 This study also reported that out of the 4 or 5 glycosylation sites 
in HIV gp41, only 2 sites are sufficient for efficient membrane fusion with a single site, at 
asparagine 621, being the most critical of all positions. Yuste et al. have also suggested that 
the function of HIV gp41 glycosylation, from both HIV and SIV, might be mainly for shielding 
underlying epitopes sequences, thereby allowing the virus to escape neutralizing antibodies.136 
Furthermore, Wang et al. reported that the glycan at asparagine 637 in HIV gp41 is composed 
of Man9GlcNAc2 and play a critical role in immune evasion through a facilitation of the 
membrane fusion process.131 A later study by Mathys and Balzarini lead to a rather different 
conclusion regarding the importance of the glycan at asparagine 637.134 In fact, by following 
the generation of several HIV-1 mutants, lacking HIV gp41 N glycans and assessing their 
influence on viral infectivity, this study determined that besides the glycan at asparagine 616 
that when deleted leads to a complete loss of HIV-1 infectivity, deletion of glycans on 
asparagine at position 611 and 637 displayed marginal effect on overall viral infectivity. In 
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addition, this study concluded that glycans on asparagines 625 and 674 do not play any 
significant role in HIV infectivity, since their deletion did not influence viral infectivity.  
 
3.3 Anti-HIV lectins 
Natural lectins 
Owing to HIV-gp120 high mannose content, various mannose binding natural lectins 
have been investigated as potential HIV entry inhibitors. Primarily, these lectins specifically 
bind mannose oligosaccharides on HIV-gp120, thus hindering a proper interaction between the 
envelope glycoprotein and its host cell receptor (CD4). This may ultimately prevent the 
membrane fusion step and the production of new HIV virions. Actinohivin (AH), a prokaryotic 
lectin derived from the gram-positive bacteria actinomycete Longispora albida (K97-0003T) 
successfully prevented HIV-1 entry into CD4+ T lymphocytes (IC50 ≈ 2–110 nM).137 It was 
determined that AH binds α(1-2)-mannose oligosaccharides present in HIV gp120 and HIV 
gp41. Furthermore, AH did not induce any mitogenic activity, or cytokine/chemokine 
production in PBMC cultures, suggesting that this lectin could be a safe and potentially 
effective microbicide candidate.138 Recently, Zhang et al. reported that Man1 and Man2 
residues, found in HIV gp120 high-mannose-type glycans structures, occupy 2 of the three 
carbohydrate binding sites of AH while Man3 residues interact with conserved hydrophobic 
amino acid residues Tyr and Leu of AH.139 Cyanovirin-N (CV-N) is a cyanobacterial lectin 
with broad-spectrum antiviral activity. The potential use of CV-N as anti-HIV microbicide has 
widely been reported (IC50 ≈ 3.9-31 nM).140-144 CV-N inhibits HIV replication, in part, by 
binding to HIV-gp120 high mannose glycans, thus preventing the envelope glycoprotein 
binding to its cell surface receptor (CD4), thereby blocking the glycoprotein-mediated 
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membrane fusion process required for HIV-1 entry.145 Hu et al. have determined that CV-N 
binding interaction is mediated through 3-5 high-mannose residues from 289 to 448 in the C2-
C4 region of HIV gp120 and deglycosylation of these residues resulted in a resistance to CV-
N.146, 147 It was also shown that CV-N inhibits HIV replication by interacting with the 
chemokine receptors CXCR4 and CCR5.148 Recently, a CV-N oligomer (CV-N2) was designed 
and demonstrated an increased HIV-1 neutralization activity by up to 18-fold compared to the 
wild-type CV-N (IC50 ≈ 0.1-41 nM).147 Oscillatoria agardhii agglutinin (OAA) is a newly 
discovered cyanobacterial lectin that was shown to prevent HIV transmission, replication and 
syncytium formation between HIV-1-infected and uninfected T cells (IC50 ≈ 24-30 nM).149 
OAA is known for having two sugar binding sites that recognize Manα(1-2)Man, Manα(1–
6)Man and the branched core unit of Man9 (3α,6α-mannopentaose).149-152 Like OAA, 
scytovirin (SVN) is a cyanobacterium lectin isolated from Scytonema varium.153 SVN was also 
shown to possess potent anti-HIV activity through its binding interaction with HIV gp160, 
HIV gp120 and HIV gp41 and binds Manα(1–2)Manα(1–6)Manα(1–6)Man tetrasaccharide in 
high mannose type oligosaccharides (IC50 ≈ 24.1 nM).154-156 In addition, MVL, a lectin isolated 
from the cyanobacterium Microcystis viridis also showed strong anti-HIV activity in 
nanomolar concentration by binding to Manα(1–6)Manβ(1–4)GlcNAcβ(1–
4)GlcNAc  oligosaccharides on the surface of HIV gp120 (IC50 ≈ 30 nM).157, 158 Another 
cyanobacterial lectin, microvirin (MVN), isolated from Microcystis aeruginosa has shown 
anti-HIV activity comparable to CV-N with a much better cytotoxicity profile (IC50 ≈ 2-12 
nM).159 It was further shown that MVN bind Manα(1–2)Man residues on HIV gp120.159, 160 
Plant lectins such as Narcissus pseudonarcissus lectin (NPL) (EC50 ≈ 0.17-2.76 μg/ml)161, 162 
and Myrianthus holstii lectin (MHL) (EC50  ≈  150 nM)163 have also shown potential HIV 
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inhibition in vitro. Concanavalin A (Con A), one of the most studied plant lectins, is a mannose 
binding lectin extracted from jack bean. Con A binds sugars, glycoproteins, and glycolipids, 
containing internal and nonreducing terminal α-D-mannosyl and α-D-glucosyl groups (KD ≈ 
0.05 μM to 1.5 μM).164, 165 Several studies have demonstrated the ability of Con A to bind HIV 
gp120 and inhibit the fusion process during HIV infection (EC50 ≈ 98 nM).166-169 Furthermore, 
BanLec is a lectin isolated from the banana fruit (Musa acuminata), which has shown potent 
anti-HIV activity (IC50 ≈ 2.5-694 nM).170 Similar to Con A, BanLec inhibits HIV by binding 
to high mannose carbohydrate structures found in HIV gp120, thus blocking the virus 
entry into the host cells. In fact, in a comparative study, BanLec showed similar inhibitory 
activity like T-20 and maraviroc, two FDA approved HIV entry inhibitor microbicides.9   
Griffithsin (GRFT), a lectin isolated from the red algae Griffithsia inhibited cell-to-cell 
fusion between HIV infected and uninfected cells (IC50 ≈ 4 nM).171 GRFT also inhibited HIV-
1 transmission by binding to glucose, mannose, and N-acetylglucosamine residues in HIV 
glycoproteins (HIV gp120, HIV gp41 and HIV gp160).172 Emau et al.173 have also established 
that GRFT strongly blocked CXCR4 and CCR5-tropic viruses at concentrations less 
than 1 nM, with low cytotoxicity, rapid onset of antiviral activity and long-term stability in 
cervical/vaginal lavage. GRFT tandemers recently reported by Moulaei et al. have shown anti-
HIV activities 5 to 10 fold higher than native GRFT (IC50 ≈ 0.02-0.274 nM).174  
Chaetopterus variopedatus lectin (CVL) is a β-galactose-specific lectin extracted from 
the marine worm Annelida. CVL was shown to inhibit both HIV attachment to host cells and 
the fusion process between HIV and target cells (EC50 ≈ 73 nM)175; suggesting that CVL might 
be exerting its action through interaction with complex glycan type found in HIV gp120 and 
HIV gp41.176 In addition, Mermaid, a calcium (Ca2+) dependent lectin isolated from the marine 
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nematode (Laxus oneistus) was shown to have structural similarities and similar glycan 
specificity with the Dendritic Cell-Specific Intercellular Adhesion Molecule-3-Grabbing Non-
integrin (DC-SIGN). Mermaid, which bind mannose oligosaccharides on HIV gp120, 
prevented HIV-1 binding to DC-SIGN on dendritic cells, which ultimately blocked HIV 
transmission (IC50 ≈ 3.1 μg/ml).177, 178 Another marine lectin Serpula vermicularis lectin (SVL) 
isolated from the sea worm Serpula vermicularis was also shown to bind GlcNAc and inhibited 
the production of viral p24 antigen and cytopathic effect induced by HIV-1 (EC50 ≈ 0.15-0.23 
μg/ml).179, 180 
 
Table 3-1:  Example of natural anti-HIV lectins. 
Lectin Glycan preference Target Origin References 
AH 
Manα(1-2)Man, 
Manα(1– 3)Man, 
Manα(1– 6)Man, 
GlcNAc 
gp120 and gp41 
Actinomycete 
Longispora albida  
138 
CV-N 
Manα(1-2)Man in 
Man8 or Man9 
gp120, CXCR4 
and CCR5  
Nostoc 
ellipsosporum 
146, 147 
OAA 
Manα(1-2)Man, 
Manα(1– 6)Man, 
3α,6α-
mannopentaose 
gp120 
Oscillatoria 
agardhii 
149-152 
SVN Man gp120 Scytonema varium 154, 155 
41 
  
Lectin Glycan preference Target Origin References 
MVL 
Manα(1–6)Manβ(1–
4)GlcNAcβ(1–
4)GlcNAc 
gp120 Microcystis viridis 157 
MVN Manα(1–2)Man gp120 
Microcystis 
aeruginosa 
159, 160 
NPL 
Manα(1-3)Man; 
Manα(1-2)Man 
gp120 
Narcissus 
Pseudonarcissus 
161, 162   
MHL GlcNAc gp120 Myrianthus Holstii 163 
Con A 
α-D-Man and α-D-
Glc  
gp120 Jack bean 164 
BanLec Man gp120 Musa acuminata 9 
GRFT Glc, Man and GlcNac  
gp120, gp41, 
gp160, CXCR4 
and CCR5 
Griffithsia 172 
CVL β-Gal gp41, gp120 
Chaetopterus 
variopedatus 
176 
Mermaid 
Manα(1-3)Manα(1-
6)Man 
gp120 Laxus oneistus 177, 178 
SVL GlcNAc gp41, gp120 
Serpula 
vermicularis 
179 
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Synthetic lectins 
Carbohydrate binding agents (CBA) can bind to carbohydrate residues on viral 
envelope proteins, such as HIV gp120. This binding could lead to an inhibition of viral entry. 
Moreover, mutations of the envelope glycoproteins can improve drug pressure and lead to viral 
neutralization by host’s immune response. Because manufacturing natural plant-based lectins 
can be expensive, synthetic lectins have been considered as potential inhibitory alternative.181 
Synthetic lectins are cheaper to mass-produce as compared to their plant-based counterparts. 
As a response to the high cost and potential mitogenecity of natural lectins, Mahalingan et al. 
developed a benzoboroxole (BzB) polymeric synthetic lectin. Like natural plant-based lectins, 
BzB targets and binds carbohydrates on HIV viral envelope. At pH 7, BzB demonstrated 
increased binding efficiency to reducing sugars, such as fructose and weak binding affinity to 
non-reducing sugars, such as galactopyranose, a terminal sugar found on the surface of HIV 
gp120 complex glycans. This study further showed that BzB polymers of high molecular 
weight increased antiviral activity, proving that polyvalent interactions between inhibitor and 
glycosylated sites on HIV viral envelope improved with increased molecular weight. For 
example, increasing the mole percent of BzB functionalization showed an increase in EC50 
[EC50=15uM (25 mol%); EC50=15nM (75 mol%)]. Moreover, substituting the polymer 
backbone with 10% sulfonic acid, resulted in an increased synergistic anti-HIV activity, as 
well as a 50 fold increase in aqueous solubility of the polymer. Furthermore BzB-sulfonic acid 
showed an improved selectivity to HIV gp120, and the presence of fructose from seminal fluid 
did not decrease its anti-viral activity.182 Similarly, synthetic lectins containing phenylboronic 
acid (PBA) could potentially exhibit carbohydrate recognition similar to that of CBA. For 
instance, Trippier et al. synthesized mannose selective PBA-based synthetic lectins that were 
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tested for binding affinity against HIV gp120.183 Because the mono-PBA synthetic lectins 
tested did not bind HIV gp120 and were not good antiviral candidates, bis-PBA synthetic 
lectins were further investigated.184 Although the bis-PBA did not demonstrate pronounced 
antiviral activity, these compounds were however found to be relatively noncytotoxic. It was 
also suggested that the lack of HIV gp120 binding could be due to the lack of multivalency 
and the small size of the PBA compounds.  
 
 3.4 Challenges in anti-HIV lectins formulation development 
The clinical translation of anti-HIV natural lectins faces numerous challenges including 
stability, solubility, resistance, toxicity and manufacturing. These factors have seriously 
limited the progress in the field and often overshadowed the potential benefits that anti-HIV 
lectins may have. For example, BanLec has been shown to partially dissociate into its 
monomeric forms in acidic conditions (pH 2) while maintaining a dimeric structure at neutral 
pH. The monomeric form of BanLec also offered more resistance towards chemical 
denaturation than the native dimeric form.185 In addition, AH was shown to display low 
solubility in neutral buffer solutions with an enhanced solubility in acidic conditions 186. This 
lack of solubility in neutral pH conditions could dramatically limit AH use as a topical 
microbicide for the prevention of HIV sexual transmission, given that vaginal pH increases 
from acidic (pH ≈ 4.5) to neutral (pH ≈ 7.5) during intercourse.75 Furthermore, lectin resistant 
HIV strands have been reported.87 The mutation of certain glycan structures in HIV gp120 was 
shown to be responsible for CV-N and Con A resistant HIV strands.166 Although the 
development of HIV resistance to lectins may ultimately undermine the potency of these 
proteins, this is however viewed as an indirect route for exposing underlying amino acid 
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sequences that could potentially be targeted by antibodies.146 Anti-HIV lectins have also been 
associated with strong toxicity. In particular, Con A was shown to be mitogenic toward T-cells 
and induced cytotoxicity at high concentrations (>10mg/ml).187, 188 Similarly, CV-N and 
BanLec induced pronounced mitogenic activities on PBMCs and T-cells respectively.189, 190 
Nonetheless, by replacing histidine 84 with a threonine in BanLec, Swanson et al. have 
demonstrated the possibility to bioengineer anti-HIV lectins in order to suppress their 
mitogenicity while maintaining their antiviral activity.170 The high cost of natural anti-HIV 
lectins mass production and purification presents another particularly difficult challenge.191 
Although recombinant technology was proposed to overcome this limitation, improving 
fermentation yield, controlling mutation and addressing potential immune system insults need 
to be studied.192 Besides their ability to address some of the limitations aforementioned and 
inhibit HIV transmission with relatively good safety profiles, synthetic lectins usually lack 
carbohydrate specificity and often require extensive optimizations to improve their binding 
affinity for HIV surface glycoproteins.183, 184, 191 
 
3.5 Anti-HIV lectin formulations 
A potential barrier in developing antibody based vaccines against HIV is the 
oligosaccharide layer that provide a protective covering to the underlying antigens on the viral 
envelope surface.193 Carbohydrate-lectin complexes are a promising therapeutic strategy 
because various proteins interact with oligosaccharides on the surface of many human cells. 
Glycoproteins and glycolipids can also interact with lectins and enhance mucosal absorption 
of drugs and vaccines.194 Taking advantage of the so-called “lectin direct targeting”, potential 
efficacious HIV vaccine nanoformulations have targeted endogenous lectins for antigen 
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delivery to immune cells.195 Dendritic cell lectins are often targeted in this strategy. Those anti-
HIV vaccines strategy activate various receptors on antigen presenting cells or C-type lectins, 
in order to illicit immune responses.  
The mannose receptor, a C-type lectin found on the vaginal epithelium, is known to 
bind HIV gp120.196, 197 Binding of the mannose receptor to HIV gp120 allows the virus to cross 
the  vaginal epithelium.196 Humans have two types of mannose receptors, type 1 (MRC1) and 
type 2 (MRC2) and both can stimulate active and adaptive immunity. Because mannose 
receptors are highly expressed on dendritic cells as well as macrophages, these receptors are 
important for antigen recognition. Mannose receptors on dendritic cells take up antigen, which 
stimulates robust T-cell activation via both major histocompatibility complexes (MHC) I and 
II molecular uptake mechanisms. This T-cell activation plays a critical role in the successful 
anti-HIV vaccine development.196 When HIV-1 DNA was encapsulated in mannan coated-
cationic liposomes targeting MRC, the nanoformulation successfully activated immunological 
responses, such as cytotoxic T cells, IgA, and other hypersensitivity responses.196 These 
cationic nanoparticles showed 50% higher uptake than non-coated mannan nanoparticles in the 
macrophage cell line J774E.198 Similarly, Espuelas et al. showed that a liposome 
nanoformulation containing mono-, di-, and tetraantennary mannosyl lipid derivatives could 
potentially achieve identical mannose receptor targeting on dendritic cells for a potential 
mannose-targeted vaccination strategy.199 Nonetheless, this study proved that liposome 
formulations containing higher mannose density result in more efficient interactions with 
mannose receptors. Furthermore, DC-SIGN, a Ca2+ binding adhesion lectin present on the 
surface of immature dendritic cells, plays an important role in modulating host response to 
infection and inflammatory stimuli.200 Because of its implications for antigen targeting and 
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stimulation of T cell responses, DC-SIGN has been considered a potential receptor for HIV 
vaccine targeting. In fact, DC-SIGN recognizes various high mannose oligosaccharides on 
HIV gp120.201 In vitro studies using DC-SIGN-targeted PLGA nanoparticles have shown that 
these nanoformulations deliver antigens to human dendritic cells.202 DC-SIGN also increased 
antigen presentation, which translated into an improved activation of CD4+ and CD8+ T-cells.  
 
Table 3-2:  Summary of anti-HIV lectin nanoformulations. 
Formulation Lectin Target Reference 
Mannan coated-cationic 
liposomes 
Mannose 
receptors, C type 
lectins 
MRC (Dendritic 
cells) 
196, 198 
 
Mannosylated liposome  
Mannose 
receptors, C type 
lectins 
MRC (Dendritic 
cells) 
199 
PLGA nanoparticles DC-SIGN Dendritic cells 202 
High density enveloped HIV 
glycoprotein liposomes  
N/A 
BRC (B cells 
receptor) 
203 
Con A immobilized 
polystyrene nanospheres 
Con A HIV gp120 204 
Con A immobilized 
polystyrene/methacrylate 
nanospheres 
Con A HIV gp120 205 
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The development of additional HIV nanovaccine immunogens utilized envelope glycoprotein 
mimetics. Ingale et al. investigated liposomes-grafted high density enveloped HIV 
glycoprotein trimers that were recognized by anti-HIV-1 antibodies and activated B cells.203 
These liposome constructs may lead to a promising HIV neutralization vaccine. Moreover, He 
et al. designed nanoparticles containing native like trimeric structures of V1V2 and gp120. 
These nanoformulations presented a variety of gp140 trimers that displayed 20 spikes similar 
to that of other virus like particles. This study achieved high B cell stimulation, which may 
lead to further investigations in the development of a multivalent HIV vaccine.206  
Other lectin based anti-HIV strategies have focused on “lectin indirect targeting” 
instead. In this case, lectins (natural or synthetic) are included in formulations to target HIV 
envelope glycoproteins. This “virion capture” approach may lead to a successful HIV 
prevention by hindering a proper interaction between HIV virus and its targets. Virion and HIV 
gp120 antigen capture could potentially lay the foundation for a mucosal anti-HIV vaccine. 
Akashi et al. proposed Con A immobilized polystyrene nanospheres capable of capturing HIV 
virions through binding interactions with HIV gp120 high mannose glycans.204 A similar 
strategy was investigated by Hayakawa et al. using nanoparticles prepared via co-
polymerization of polystyrene and poly methacrylate.205   
 
3.6 Conclusion 
In general, the field of lectinology has greatly contributed in the structural elucidation, 
the mechanistic understanding and the advancement of lectin based alternative antiviral 
therapy for various enveloped viruses including HIV, zika, ebola, marburg, herpes, hepatitis-
C, influenza severe acute respiratory syndrome (SARS), feline infectious peritonitis virus 
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(FIPV) and many more.207-214 Despite test tube promises shown by lectins (natural and 
synthetic) against these pathogens, lectin-based antiviral clinical translation still faces great 
challenges including, resistance, cytotoxicity, immunogenicity, antigen specificity, and limited 
stability.215 Nonetheless, advance research on selected lectin candidates inclusion BanLec and 
Griffithsin may potentially lead to the first clinically available lectin-based antiviral therapy in 
the near future.9, 216 Even though anti-HIV lectins research is projected to grow, future 
investigations in the field would likely have to address novel delivery strategies to significantly 
improve CBAs clinical translation. 
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CHAPTER 4 
SCREENING OF CONCANAVALIN A - POLYSACCHARIDES BINDING AFFINITY 
USING A QUARTZ CRYSTAL MICROBALANCE 
(Biosensor and Bioelectronics, 2014, 59: 404–411) 
 
4.1 Introduction and rationale 
The design of core-shell novel drug delivery systems relies mostly on the interaction 
between a coating agent and a triggering element. In the case of using Con A, such delivery 
systems rely primarily on a competitive binding between a free carbohydrate/glycoprotein and 
a carbohydrate crosslinker.217 This then makes the binding constants a fundamental parameter 
for a rational design of lectin based drug delivery systems, especially when a control release is 
expected. The binding of Con A to mannose and glucose containing oligosaccharides has been 
extensively studied, and to date, several carbohydrate binding constants to Con A are 
known.218-221 Yet, a thorough investigation of the binding constants of polysaccharides to Con 
A remains to be investigated. Particularly, it is crucial to understand the interaction of Con A 
and glycogen considering the emerging interest in drug delivery systems using such interaction 
as a design strategy.222-226 In addition, this study intends to provide binding affinity constants, 
based on the determined molecular weights by Size Exclusion Chromatography (SEC), for a 
thorough characterization of ConA-glycogen and Con A-mannan interactions. Furthermore, 
the present study may provide a model for a better understanding of protein-polysaccharides 
in vitro interaction. 
In this study, it is hypothesize that a Quartz Crystal Microbalance (QCM) can be used 
in a flow injection setting to monitor the binding affinities of polysaccharides (glycogen and 
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mannan) to an immobilized lectin, Con A. The binding constants of Con A to these 
polysaccharides could then be utilized rationally in the design of stimuli-sensitive drug 
delivery systems to target high mannose or glucose containing glycoproteins or surfaces, such 
as HIV gp120. 
Introduced in 1959 by Sauerbrey, the basic QCM theory correlates the mass change per 
unit area at the QCM electrode surface to the observed change in oscillation frequency of the 
crystal.227 QCMs have been proven to be reliable in the field of electrochemistry,228-230 in 
petroleum characterization,231, 232 in environmental chemistry,233 material science234 and more 
interestingly in the development of biosensors,235-238 which  are valuable for disease diagnosis. 
QCMs have also found a great interest in the study of binding affinity constants defining  
substrate-ligand interactions.239-242  Besides the fact that it does not require any calibration, one 
of the most exciting features of the QCM is its ability to quantify a mass change at the nano-
gram level. This makes QCM an easy to setup and robust technique for bioaffinity analysis. 
Data obtained from QCMs are shown to be in accordance with other well-established 
techniques such as surface plasmon resonance (SPR),243, 244 fluorescence spectroscopy,217, 245 
atomic force microscopy246, 247 and photoelectron microscopy.248 
  Polysaccharides and glycoconjugates are known to play crucial roles in biological 
processes, such as, cell activation, differentiation and apoptosis,239 but also in cellular 
recognition, transmission of information, immunity and tumorigenesis.241, 249-252 Glycogen, 
known as “animal starch" for its resemblance with starch found in plants, is the principal 
storage form of glucose (energy) in animal cells.253 It is a highly branched polymer in which 
small chain of glucose molecules are linked by α-D-(1→4) linkage and α-D-(1→6) branching 
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points.254 In human, glycogen is mostly found in the liver but can also be found in muscles and 
brain glial cells where its proportion is significantly lower. 255-257  
Originally extracted from jack bean, Con A is a member of the legume lectin family 
and binds to sugars, glycoproteins, and glycolipids, containing internal and nonreducing 
terminal α-D-mannosyl and α-D-glucosyl groups.221, 258-260 Like most lectins, Con A is a 
homotetramer with each subunit composed of 235 amino acids and having a molecular weight 
of 26.5 kDa. At pH below 6, Con A exists as a dimer and is in its tetrameric form at pH above 
6. To depict its binding activity, the protein requires metal ions. Agrawal and Goldstein have 
shown that each subunit has one Ca+2 and Mn2+binding sites.258, 261   
  
4.2 Material and methods     
Quartz Crystal Microbalance 
Stanford Research System (SRS) QCM200 apparatus (Sunnyvale, CA, USA) is used 
in this experiment. The QCM200 System is a stand-alone instrument with a built-in frequency 
counter and resistance meter. It includes controller, crystal oscillator electronics, crystal holder, 
and quartz crystals. In this study, 1 inch diameter, 5 MHz AT-cut, plano-plano Chromium/gold 
(Cr/Au) quartz crystals from SRS are used for each measurement in a flow injection mode. 
Two single injection syringe pumps are used to deliver the analytes (polysaccharides) and the 
free buffer (Tris Buffer Saline). Series resonance frequency and resistance are measured and 
displayed directly on the front panel. However, Labview V7.0 software (Sunnyvale, CA, USA) 
is installed on a computer for real-time data collection, display, analysis and storage. 
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Chemicals 
 Concanavalin A (Con A) from Canavalia ensiformis (Jack bean) Type VI, glycogen 
from Oyster, mannan from Saccharomyces cerevisiae, N-Hydroxysuccinimide (NHS), 11-
mercaptoundecanoic acid (MUA, 95%), 4-Morpholineethanesulfonic acid sodium salt (MES), 
sulfuric acid (H2SO4, puriss. p.a., 95-97% (T)), hydrogen peroxide solution (H2O2, 30 wt. % 
in H2O, ACS reagent), 200 proof absolute ethanol, hydrochloric acid (ACS reagent, 37%), 
calcium chloride dehydrate (CaCl2•2H2O, ACS reagent, ≥99%) and manganese (II) chloride 
tetrahydrate (MnCl2•4H2O, Reagent Plus®, ≥99%), phosphate buffered saline (PBS) pH 7.4 
and Tris Buffer Saline (TBS) pH 8.0 were purchased from Sigma-Aldrich (Milwaukee, WI, 
USA). 1-ethyl-3-[3-dimethylaminopropyl]carbodiimide hydrochloride (EDC) was purchased 
from Thermo Scientific (Rockford, IL, USA).  PBS and TBS were prepared according to the 
manufacturer protocol and the pH was verified before any experiment. TBS was supplemented 
with Mn2+ and Ca2+ and used as ruining buffer without any further treatments. 
 
Methods 
Fourier Transform Infrared Spectroscopy (FTIR) 
Agilent Cary 630 FTIR instrument (Newark, DE) equipped with a diamond crystal 
having a single reflection and a nominal angle of 45° is used in its Attenuated Total Reflectance 
(ATR) mode for the acquisition of all IR spectra. A resolution of 4 cm-1 and a sample scan of 
32/s is set as parameters and the effective pathlength is 1.1 μm. Prior to any IR analysis, QCM 
crystals are dried under a nitrogen gas stream and allowed to make an intimate contact with 
the ATR diamond crystal surface by pressing them with a pressure clamp. FTIR spectra are 
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collected and analyzed with MicroLab PC and MicroLab Lite softwares (versions 4.0, Newark, 
DE, USA), respectively.   
Size Exclusion Chromatography (SEC) 
Glycogen and mannan molecular weight are determined by size exclusion 
chromatography. Briefly, seven (7) dextran standards covering a molecular weight range from 
5.2 kDa to 668 kDa are run on SEC (Waters, Milford, MA, USA) equipped with a differential 
refractometer detector to draw a calibration curve.  The equation of the calibration curve is 
Y = −0.3367X + 10.351 with a coefficient of determination of R² = 0.9877 indicating a 
strong correlation between the retention time (X) and the base 10 logarithm (log10) of the 
molecular weights (Y). Samples are dissolved in 0.1M of sodium nitrate (NaNO3) at pH 7 and 
each experiment is conducted at a flow rate of 1 ml/min on a 7.8×300 mm WAT011525 
Ultrahydrogel column (Waters, Milford, MA, USA). Data are acquired and analyzed on 
Millennium32 software version 3.20 (Waters, Milford, MA, USA). Glycogen and mannan 
molecular weights are derived from their respective retention time using the calibration curve.   
 
QCM measurement 
Preparation of the gold crystal surface 
 Prior to any experiment, a Cr/Au QCM crystal is cleaned by exposing it to a piranha 
cleaning solution. Basically, the cleaning solution is prepared in an appropriate container by 
carefully adding 1 part per volume of hydrogen peroxide to 3 parts per volume of sulfuric acid 
to reach a ratio of 1:3.246 Caution: Piranha solution should be handled with extreme care and 
only small volume should be prepared at any time. For safety purposes, the piranha solution 
should be prepared under a well-functioning hood and crystals should be handled with 
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appropriate tweezers. After 5 minutes in the piranha solution, the crystals are removed and 
cleaned twice with Millipore Q water (DI water) and ethanol before drying under a nitrogen 
stream. 
 
Con A immobilization  
 To study the binding kinetics of the polysaccharides to Con A, the lectin is first 
immobilized onto a gold crystal by EDC chemistry and the immobilization is validated by 
Fourier Transform InfraRed spectroscopy (FTIR).  As shown earlier by Lebed et al.239, Con A 
can readily adsorb onto a clean gold crystal surface. Even though the mechanism involved in 
such physisorption is not fully explained, it appears that the lectin binds loosely and can easily 
be detached off the crystal’s surface when the free buffer is allow to flow onto the surface. To 
avoid such an undesirable effect, a covalent attachment of the lectin is performed through zero 
linker (EDC/NHS) chemistry by coupling the N-terminal of the protein with the carboxylic 
head group of MUA. 
 To immobilize Con A on the quartz crystal, the method of Caruso et al.246 is used with 
minor adaptations. Briefly, in order to provide the gold surface with the carboxylic acid 
function, a clean gold crystal is incubated in an ethanolic solution of 5 mM of MUA at pH 2.0 
for 48 h. To avoid thiol oxidation and ensure the success of the self-assembling, the container 
is tightly sealed and backfilled with dry nitrogen prior to storage. The success of MUA 
attachment relies on the intrinsic property of the alkanethiols moieties to chemisorb onto gold 
surfaces.262 Love et al.263 have proven that the sulfur atom of the alkanethiol forms a dative 
bond with the gold metal surface. After 48 h of incubation, the crystal is removed and 
thoroughly rinsed with ethanol and DI water before immersion in a 0.1 M MES buffer 
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containing 0.5 M NaCl at a pH 5.8. EDC and NHS are subsequently added to the buffer to 
reach a concentration of 2 mM and 5 mM, respectively. The mixture is allowed to react for at 
least 15 minutes (min). The crystal is then retrieved and redisposed in 1 mg/ml of Con A in 
PBS for 3 hours, after which the surface is cleaned again with free PBS buffer and placed in 
the flow cell chamber for QCM frequency acquisition. Scheme 4.1 shows an illustration of the 
steps involved in the lectin immobilization. 
Scheme 4-1: Step-by-step illustration of Con A immobilization onto the QCM gold surface. 
Special care should be taken in handling Piranha solution under a fume hood. Once the crystal 
is cleaned and dried under nitrogen, it is disposed in 5 mM of Mercaptoundecanoic acid for 
48h for carboxylic acid functionalization. Con A is then immobilized by EDC chemistry using 
2 mM EDC and 5 mM NHS in MES buffer (pH5.8). The reagent mixture is gently shaken to 
insure even distribution of reagents during EDC coupling. 
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QCM frequency acquisition 
QCM200 is used in a flow injection mode to monitor the lectin and polysaccharides 
interaction (figure 4-1). Briefly, two injection pumps, one for the free running buffer and the 
second for the polysaccharide solutions, are connected to a dual flow connector. The flow rates 
are set to 3 ml/h in each measurement. The free buffer is first run to rule out the buffer effect 
and the flow is switched to the polysaccharide solution after a baseline is reached. Five 
different concentrations covering a range from 0.1 to 1mg/ml are prepared in the running buffer 
for both glycogen and mannan, and the relative frequency shifts and mass increases following 
the binding are recorded on a computer through the QCM200 software. The Sauerbrey’s 
equation 4-1 is used to fit the frequency shift to the mass change onto the crystal surface. 
 
Figure 4-1: Typical single flow injection QCM200 experimental setup. (A) QCM200 digital 
controller, (B) syringe pump, (C) crystal controller, (D) crystal holder and (E) waste collector. 
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 𝛥𝐹 = −𝐶𝑓 × 𝛥𝑚       (4-1) 
 Where 𝛥𝐹, 𝐶𝑓  𝑎𝑛𝑑 𝛥𝑚 are respectively the frequency shift (resonance frequency 
change), the crystal sensitivity factor, and the relative mass change. 𝐶𝑓 is a fundamental 
property of the quartz crystal and is expressed by equation 4-2. 
𝐶𝑓 =
2𝑛𝑓0
2
(𝜌𝑞𝜇𝑞)0.5
       (4-2) 
 In equation 4-2, n is the number of harmonic at which the crystal is driven, 𝑓0 the 
resonant frequency of the fundamental mode of the crystal, 𝜌𝑞 the density of quartz and 𝜇𝑞 the 
shear modulus of quartz. In this experiment, these parameters are 𝑛 = 1, 𝑓0 = 5.0 𝑀𝐻𝑧, 𝜌𝑞 =
2.648 𝑔 𝑐𝑚−3and 𝜇𝑞 = 2.947 × 10
11𝑔 𝑐𝑚−1 𝑠−2, respectively. The sensitivity factor 𝐶𝑓 is 
56.6 𝐻𝑧 𝜇𝑔−1 𝑐𝑚2. 
 
4.3 Results and discussion 
Figure 4-2A summarizes the FTIR spectra obtained at each step of the lectin 
immobilization process. The spectrum A-a is obtained from the clean and unmodified QCM 
gold crystal. The FTIR spectrum acquired after MUA attachment (A-b) onto the gold crystal 
shows distinctive peaks between 2980 and 2850 cm-1, which are due to the symmetric and 
asymmetric stretch mode of CH2 in MUA backbone.
264, 265 Furthermore, features at around 
1440 and 1700 are related to the COOH groups in MUA.266 The spectrum obtained after the 
EDC/NHS chemistry (A-c) shows two bands at around 1715 cm-1 and 1650 cm-1, which are 
bands responsible for the carbonyl stretch mode of the COO-NHS ester moiety.264, 265 After 
Con A attachment, amide I and amide II bands at 1540 and 1640 cm-1 can be distinguished and 
are indicative of a successful Con A covalent attachment on the gold surface (A-d).267, 268 
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Glycogen and mannan molecular weights, determined by SEC/GPC, are found to be 604±4.852 
kDa and 54±6.562 kDa (n=3), respectively. Typical chromatograms from these analyses are 
shown in figure 4-2B.  
Figure 4-2: (A) FTIR spectra of clean QCM gold crystal (a) followed by 11-
mercaptoundecanoic acid (MUA) attachment (b), before EDC/NHS chemistry (c) and finally 
Con A immobilization (d) onto the QCM crystal. (B) Size exclusion chromatograms of sodium 
nitrate (NaNO3) (buffer), glycogen and yeast mannan. 
 
59 
  
Once Con A is immobilized onto the gold surface, different analyte concentrations are 
flowed on the Con A-immobilized QCM crystal. In this work, each experiment is run on a 
separate crystal and the polysaccharide solutions are injected when a stable baseline is reached, 
as shown in figure 4-3. The resonance frequency is gradually decreasing while increasing the 
glycogen and mannan concentration as displayed in figure 4-4 (A&B) and are found to be 
following a Langmuir-type adsorption isotherm (equation 4-3) as shown in figure 4-5 (A&B).
   
  
 
 
 
 
 
 
Figure 4-3:  Frequency shift observed with polysaccharide injection after a baseline is reached 
with free buffer (0.05 M Tris-buffer saline, 1 mM Ca2+, 1 mM Mn2+, pH 8.0). 
  
∆𝐹 = ∆𝐹𝑚𝑎𝑥
𝐾𝐴[𝑎𝑛𝑎𝑙𝑦𝑡𝑒]
1+𝐾𝐴[𝑎𝑛𝑎𝑙𝑦𝑡𝑒]
       (4-3) 
 In equation 4-3, ΔF represents the frequency shift observed on the QCM frequency 
counter, ΔFmax the maximum frequency shift at saturation, and KA represents the equilibrium 
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association constant and [analyte] the concentration of polysaccharide. At saturation, the 
binding and dissociation rates of analytes to the available binding sites of the lectin are identical 
and reach a steady state.269  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-4: Time dependent QCM resonance frequency shifts for glycogen (A) and mannan 
(B) at different concentrations. 
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The reciprocal of equation 4-3 gives the equation of a straight line (equation 4-4) from 
which one can derive ΔFmax from the y-intercept and the equilibrium association constant (KA) 
from the slope, as shown in figure 4-5 (A’&B’). The equilibrium dissociation constant is 
obtained from equation 4-5 which is the reciprocal of KA.  
1
∆𝐹
=
1
𝐾𝐴×∆𝐹𝑚𝑎𝑥×[𝑎𝑛𝑎𝑙𝑦𝑡𝑒]
+
1
∆𝐹𝑚𝑎𝑥
       (4-4) 
 𝐾𝐷 =
1
𝐾𝐴
       (4-5) 
Figure 4-5: Saturation binding curves for glycogen (A) mannan (B) and their respective 
reciprocal curves (A’) and (B’) obtained from equation (4-4). 
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The expression of equation 4-4 for glycogen is 𝑌 = 4 ∗ 10−10X + 1.57 ∗ 10−3 with a 
coefficient of determination of R2 = 0.9940 indicating a very good correlation for this 
polysaccharide. The calculated ΔFmax is 637 Hz and the equilibrium association and 
dissociation constants value are KA = 3.93 ∗ 10
6M−1 and KD = 0.25 μM, respectively. These 
values are found to be consistent with those of Tan et al.270 obtained using an electrochemical 
piezoelectric quartz crystal impedance (EPQCI) method (KA = 1.48 ∗ 10
6M−1and KD =
0.4 μM). 
 For mannan, the fitted equation 4-4 is Y = 4.15 ∗ 10−9X + 1.43 ∗ 10−3 with a 
coefficient of determination of R2 = 0.9772, suggesting a good correlation. ΔFmax is found to 
be 697 Hz and the equilibrium association and dissociation constants are KA = 3.46 ∗
105M−1 and KD = 2.89 μM, respectively. Equilibrium dissociation constants (KD) reported so 
far for the interaction of the yeast mannan with Con A measured on QCM are in the range of 
0.1-1.1μM.271, 272 The binding affinity (KA) obtained for the binding between Con A and an 
immobilized yeast mannan  is reported to be 0.4μM.249 Compared to our study, in which the 
lectin was immobilized, Pei et al. opted instead for a method in which yeast mannan was 
immobilized onto the gold crystal, which might explained the slight difference in affinity 
values. In fact, Duverger et al.220 have proven that different affinity values can be obtained in 
SPR experiments for the same interaction, considering whether the lectin or the ligand is 
immobilized onto the crystal.  
 Con A is known to have higher affinities to mannose containing oligosaccharides 
compared to glucose containing moieties.241, 273 However, in this study, a greater affinity was 
found for Con A to glycogen compared to yeast mannan. Initially observed by Tan et al.270 
using a EPQCI method, this pattern may be partly due to the greater compaction of the  
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Figure 4-6: Molecular branching pattern in glycogen from Oyster (A) and mannan from 
Saccharomyces cerevisiae (B). Mannan main chain’s monomers are linked by 1→6 glycosidic 
bonds with several 1→3 linkages throughout the branches. Those linkages are shown in blue 
color in mannan’s structure. Glycogen main chain’s monomers are 1→4 linked with only few 
1→6 glycosidic bonds occurring each 12 glucose residues. The 1→4 linkages are shown in 
blue in glycogen’s structure and the 1→6 linkage in green. Hydroxyl groups at position 3, 4 
and 6, shown in red are critical for Con A interaction with a greater requirement at position 6. 
Unavailability of the critical hydroxyl groups prevents binding to Con A. 
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association between Con A and glycogen compare to mannan and Con A. The steric hindrance 
caused by the glycogen macromolecule is also thought to have an influence on the combination 
between Con A and glycogen. In addition to the steric effect, the huge difference in the 
polysaccharides molecular weights could explain the result obtained in this study. Indeed, 
Mueller et al.274 observed that the binding affinity of glucans polymers to (1→3)-β-D-glucan 
receptors in a human monocyte-like cell line is in part dependent on their molecular weights. 
In fact, this group observed that higher glucan molecular weights resulted in higher affinity 
values. Similar results are reported by Kojima et al. in their study on the antitumor activity of 
Schizophyllan.275 
Furthermore, the higher affinity to glycogen could be due to the branching pattern of 
both glycogen and yeast mannan (figure 4-6). Indeed, in the past decades, it has been 
extensively proven that sugar residues must obey a set of criteria in order to interact with Con 
A. Thus, it is generally accepted that hydroxyl groups at the C-3, C-4 and C-6 positions are 
critical in Con A and a sugar residue interaction, with a higher requirement at the C-6 position, 
as shown by Goldstein and others.258, 276 Moreover, glycogen main chain’s glucose monomers 
are connected by 1→4 glycosidic bonds, with only few 1→6 branches linkages at every 12 
glucose residues.277 This branching arrangement allows more glucose residues to be available 
for interaction with Con A. Unlike for glycogen, yeast mannan main chains monomers are 
linked by 1→6 glycosidic bonds with several 1→3 glycosidic linkages found throughout the 
branches of the macromolecule.278-280 Kwiatkowski and Kwiatkowski281 have also shown the 
presence of 1→4 glycosidic bonds in yeast mannan. This arrangement, in contrast, does not 
allow a wide range of mannose residues to successfully interact with Con A because of a higher 
unavailability of the C-6, C-4 and C-3 hydroxyl groups compared to glycogen. 
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 Along with the frequency shift, the motional resistance shift following the binding of 
the polysaccharides to Con A is recorded in each experiment. The motional resistance 
expresses the loss in mechanical energy dissipated to the medium and the quartz interior and 
is induced by viscoelasticity changes occurring onto the quartz surface and changes of solution 
viscosity and density.239 Using a Butterworth-Van Dyke equivalent circuit model Stephan et 
al.282 derived a linear relationship (equation 4-6) between the change in series resonance 
resistance (ΔR) of the quartz oscillator and the liquid density and viscosity during a liquid 
loading. 
∆𝑅 =
𝑛∗𝜔𝑠∗𝐿𝑢
𝜋
∗ √
2𝜔𝑠∗𝜌𝐿∗Ƞ𝐿
𝜌𝑞∗𝜇𝑞
       (4-6) 
 Where ΔR represents the change in series resonance resistance in Ω, n the number of 
sides in contact with the liquid, ωs the angular frequency at series resonance (2πfs) and Lu the 
induction for the unperturbed (dry) resonator. ρL and ηL are the density and shear viscosity of 
the liquid, respectively. ρq and 𝜇𝑞 are the density and shear modulus of quartz. In our study, 
the resistance is recorded from the frequency counter as the experiment progresses.  
  Figure 4-7 shows the relationship between the motional resistance change and the 
resonant frequency shift (ΔR vs ΔF) corresponding to the polysaccharides binding to Con A. 
The fitting equations are 𝑌 =  0.027 ∗ 𝑋 +  0.303 for glycogen and 𝑌 =  0.029 ∗ 𝑋 −  0.086 
for mannan and the coefficients of determination are R2 = 0.9908 and R2 = 0.9963, respectively. 
From the fitting curves, it is found that the reciprocal of the slopes (ΔF/ΔR) are 37.29 Hz.Ω-1 
for glycogen and 34.86 Hz.Ω-1 for mannan. Lebed et al. 239 found a ΔF/ΔR value of 29.41 
Hz.Ω-1 for the interaction of carboxypeptidase Y to an immobilized Con A on a 5 MHz QCM 
gold electrode in Tris-buffered saline. Characterizing the interaction between Con A and 
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glycogen, Tan et al. found ΔF/ΔR values ranging from 41.6 to 43.2 Hz.Ω-1 for the adsorption 
of glycogen, BSA and Con A onto a 9 MHz quartz crystal in PBS.270 Low ΔF/ΔR values are 
generally associated with viscoelastic or damping effects.239 However, the values obtained in 
this study, as compared to others, are typical of a bulk liquid effect instead of the process 
related to the association of the polysaccharides to Con A.239, 270 That is, the frequency shift 
observed is primarily due to the mass effect, and Sauerbrey’s rigidity approximation is valid.283 
 
Figure 4-7: Relationships (ΔR vs ΔF) between the motional resistance (ΔR) and the resonant 
frequency (ΔF) changes corresponding to specific glycogen (a) and mannan (b) adsorption on 
a Con A layer on QCM crystal surface. 
 
4.4 Conclusion 
 Using a Quartz crystal microbalance in its flow injection mode, we have been able to 
obtain affinity binding constants describing the interaction between two polysaccharides 
(glycogen and mannan) and Con A. The equilibrium dissociation constant for the interaction 
Con A-glycogen is KD = 0.25 μM which is about 12 fold lower than the equilibrium 
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dissociation constant describing the interaction Con A-mannan (KD = 2.89 μM). That is, Con 
A, a mannose specific lectin, is found to have a higher affinity to glycogen from Oyster, a 
glucose base polysaccharide, than to mannan from Saccharomyces cerevisiae, a mannose 
based polysaccharide. This observation was mainly due to a steric effect, the molecular weight 
and the branching pattern of both polysaccharides. Based on the underlying results, as for Con 
A/glycogen agglutinate, it is hypothesized that carbohydrate responsive drug delivery system 
could also be designed based on Con A/mannan interaction. Nonetheless, due to the lower 
binding affinity between Con A and mannan, the stability of such system will need to be 
thoroughly investigated in various pH and thermal conditions.   
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CHAPTER 5 
DEVELOPMENT OF A MICROBICIDE LOADED HIV-1 gp120 TARGETED VAGINAL 
FORMULATION 
(Molecular Pharmaceutics, 2017, 14(10): 3512–3527) 
 
5.1 Introduction and rationale  
Since its discovery in 1983, Human Immunodeficiency Virus infection and Acquired 
Immune Deficiency Syndrome (HIV/AIDS) has remained a global threat, given that a complete 
eradication strategy is yet to be effective.284, 285 According to the 2016 UNAIDS fact sheet, it 
is estimated that 36.7 million [34. million – 39.8 million] of people are currently living with 
HIV worldwide.286 Owing to the Highly Active Antiretroviral Therapy (HAART), which 
decreases the risk of opportunistic infections and maintains the immune system function, HIV 
patients can now live longer. However, sexual transmission of HIV, which accounts for 75 to 
85 % of the overall HIV infections, is still a major hurdle in the complete eradication of HIV.21 
In addition to having multiple sexual partners and the lack of male circumcision, another major 
reason for the increase in HIV transmission is that 6 out of 10 people living with HIV do not 
know their HIV positive status, making them a risk to their sexual partners.22, 23 Therefore, 
there is an urgent and crucial need to develop a safe, effective and patient compliant topical 
drug delivery system capable of preventing HIV sexual transmission. Recently, various 
microbicide drug delivery strategies (gels, films, rings, etc.) have been proposed, attempting 
to address this need with limited success. Semisolid dosage forms (gels), which are the most 
common microbicide drug delivery systems, present major challenges of messiness, leakage 
and lack of controlled release.25 Besides their lack of retention, which constantly leads to 
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leakages and therefore patience adherence and compliance issues, topical microbicide loaded 
gel formulation, such as CAPRISA 004, have shown a lack of effectiveness against HIV.26, 27 
Vaginal films, which are less untidy than gels, are fast dissolving with rapid drug clearance by 
mucus renewal cycle.25 Moreover, the ASPIRE study states that the silicone based vaginal ring 
Dapivirine, although promising, still has to address compliance issues with undesirable drug 
release kinetics.28 In fact, the major concern of a ring-based delivery system is a constant drug 
release even in the absence of HIV virus, which will eventually lead to drug waste, drug 
resistance issues, and potential side effects. To address this problem, the present study 
hypothesizes that Concanavalin A (Con A) based topical vaginal and rectal nanomedicine 
formulation is capable of the safe and effective release of a pre-encapsulated HIV microbicide, 
"on-demand". Such a microbicide delivery system would not only protect the active agent but 
could ultimately protect women, since more than half of all new HIV/AIDS infections 
worldwide occur in females.29  
Carbohydrate-binding agents (CBA) are a class of proteins that have high affinities for 
sugar moieties. They have been shown to be highly effective against HIV, as microbicides.287-
289 Lectins, which represent a subclass of CBA, are proteins that specifically recognize 
carbohydrate (glycan) structures.290, 291 One of the most studied lectins is Canavalia ensiformis 
(Con A), extracted from jack beans. Con A is known to bind sugars, glycoproteins, 
and glycolipids, containing internal and nonreducing terminal α-D-mannosyl and α-D-
glucosyl groups.258, 260, 292 Like most lectins, Con A is a homotetramer with each subunit 
composed of 235 amino acids and having a molecular weight of 26.5 kDa. At pH below 6, Con 
A exists as a dimer, and is in its tetrameric form at pH above 6. Con A has an isoelectric point 
(PI) that ranges from 4.5 to 5.5, depending on its isoforms. Like all proteins, above its pI, Con 
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A is negatively charged, and bears a positive charge at pH values below the pI value. Con A 
has previously been shown to bind HIV-1 and HIV-2 viruses’ envelope glycoprotein 120 (HIV 
gp120).167 More recently, Con A-immobilized polystyrene nanospheres were successfully 
designed for HIV-1 virions captured through Con A/HIV-1 gp120 binding interactions.205 HIV 
gp120 plays a critical role in HIV infection. In fact, the binding of HIV gp120 (on HIV virus’ 
membrane) to CD4 receptors (on host cells’ membrane) represents the first step in the course 
of HIV attachment and host cells entry. This leads to the fusion of both membranes and the 
incorporation of the viral material into the host cell cytoplasm.293 This process ultimately leads 
to the production of new HIV virions and the spreading of the disease. 
In the last few decades, HIV gp120 has been extensively studied. To date, more is 
known about its structure and composition than ever before. Several groups have shown that 
HIV gp120 is composed of high proportions of carbohydrates. It is estimated that 50% of the 
apparent molecular mass of HIV gp120 is composed of carbohydrates.294 More specifically, 
Mizuochi et al. found that about 40% of the total oligosaccharide structures released from HIV 
gp120 are hybrid and/or high mannose-type oligosaccharides and 60% are of the complex 
type.94, 95 These studies also highlighted the unique and high mannose oligosaccharides content 
in recombinant HIV-1 envelope glycoprotein gp120 (HIV-1 rgp120) compared to other 
Chinese hamster ovary-cell-derived glycoproteins. Furthermore, Geyer et al.97 found that high 
mannose-type oligosaccharides account for approximately 50% of the carbohydrate structures 
of HIV gp120. More recently, Bonomelli et al.99 reported that HIV gp120 derived from virions 
prepared by infecting peripheral blood mononuclear cells (PBMC) with viruses from clade A 
(92RW009), clade B (JRCSF), and clade C (93IN905), show a predominantly oligomannose 
glycan composition (62–79%) Man5–9GlcNAc2 with a predominant population of 
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Man5GlcNAc2. These oligomannoses bind to Con A with equilibrium dissociation constant 
(KD) values ranging from 0.05 μM to 1.5 μM.295 Binding of Con A to HIV gp120 glycans 
either prevent HIV virus binding to receptors on target cells membrane or affect key 
conformational changes of HIV gp120 following binding.85 Our group recently published Con 
A binding affinities to glycogen from Oyster (0.25 μM) and mannan from Saccharomyces 
cerevisiae (2.89 μM).164  
In the present study, we intend to engineer an HIV-1 gp120 responsive, Con A cross-
linked polysaccharide, drug delivery system to deliver a pre-encapsulated microbicide. In the 
long term, we envisage this drug delivery system to address some of the deficiencies shown by 
previous approaches in HIV prevention including undesired drug release, retention and 
effectiveness.  
 
5.2 Materials and methods 
Reagents. The following reagents were purchased from Sigma-Aldrich (St. Louis, MO, 
USA); Concanavalin A (Con A) from Canavalia ensiformis (Jack bean) type VI, glycogen 
from Oyster, polyethylenimine (PEI) 50 wt. % solution in water, poly(sodium 4-
styrenesulfonate) (PSS) average Mw ~70.000 powder, calcium chloride dehydrate 
(CaCl2•2H2O, ACS reagent, ≥99%), sodium carbonate anhydrous (≥99%), fluorescein 
isothiocyanate labeled Concanavalin A (FITC-Con A) type IV lyophilized powder, 
tetramethylrhodamine isothiocyanate–Dextran (TRITC-Dextran), manganese (II) chloride 
tetrahydrate (MnCl2.4H2O, Reagent Plus, ≥99%), methyl α-D-mannopyranoside (Man) 
(≥99%), Tris Buffer Saline (TBS) pH 8.0, resazurin sodium salt, neutral red (NR), sodium 
nitroprusside dehydrate (SNP), Dulbecco's Phosphate-Buffered Saline (DPBS), acetic acid, 
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ethyl alcohol (ethanol) pure 200 proof ACS reagent (≥99.5%), Triton™ X-100 and 
lipopolysaccharides (LPS). Fluorescein Isothiocyanate Isomer I (FITC) 90% pure ACROS 
Organics™, Dulbecco's Modified Eagle Medium (DMEM) and keratinocyte serum-free 
medium (1X) (K-SFM) were purchased from Thermo Fisher Scientific (Waltham, MA, USA). 
3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium 
inner salt (MTS) was purchased from Promega Corporation (Madison, WI, USA). Human 
Immunodeficiency Virus type 1 recombinant envelope glycoprotein (HIV-1 rgp120) was 
purchased from Sino Biological Inc. (Beijing, China). Tenofovir (TFV) (99%) was purchased 
from Zhongshuo Pharmaceutical Co. Ltd. (Beijing, China).  
 
Layer-by-layer preparation. The potential for layer-by-layer engineered particles to 
deliver therapeutics has previously been investigated.296-299 In the present study, HIV-1 gp120 
and mannose responsive particles (MRP) were prepared via the layer-by-layer coating of a core 
template with the mannose specific lectin (Con A) and a polysaccharide cross-linker 
(Glycogen).300, 301 The core particle [calcium carbonate (CaCO3)] was prepared by mixing 
equal volume (15 ml) of 0.2 M CaCl2 and 0.2 M sodium carbonate (Na2CO3) in the presence 
of a dispersant (PSS), and under vigorous stirring at 13,500 rpm for two (2) minutes with the 
IKA Ultra-Turax model T25 homogenizer (Wilmington, NC, USA). A preliminary screening 
had led to the selection of PSS as the optimal dispersant at a concentration of 4 mg/ml (data 
not shown). TFV was encapsulated into the core particle by dissolving the microbicide in CaCl2 
(3 mg/ml) prior to the addition of Na2CO3/PSS solution. Core particles prepared in the presence 
of PSS depicted a negative charge and were subsequently dispersed in a positively charged 
layer initiator solution (4 mg/ml PEI in 0.5 M NaCl, pH 8.0) for at least 30 minutes. This 
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allowed the negatively charged lectin (1 mg/ml Con A in TBS, pH 8.0) to adhere to the 
previous molecular assembly after 1 h exposure time. After a washing step in deionized water 
(DI water) and centrifugation at 1000 rpm, Con A coated particles were redispersed in 
glycogen solution (1 mg/ml in TBS, pH 8.0), for 1 h, to allow the addition of the first 
polysaccharide layer. After a washing step, glycogen coated particles were further dispersed 
in Con A solution, and the process was repeated until a desired number of layer was attained. 
After each layer addition, average particles size and ζ-potential were measured by Dynamic 
Light Scattering (DLS), as explained below. In order to visualize MRP by confocal 
microscopy, FITC-Con A was used for the first lectin layer addition and TRITC-Dextran for 
the last polysaccharide layer. After this initial preparation phase, part of the layer-by-layer 
assembled MRP are dispersed in 0.1 M EDTA solution under gentle stirring to dissolve the 
CaCO3 core. Core dissolved MRP (𝐶−𝑀𝑅𝑃) are then washed twice with DI water to remove  
Scheme 5-1: Illustration of MRP’s layer-by-layer preparation. 
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residual EDTA and are then freeze dried for twelve (12) hours (Labconco FreeZone 1 Liter 
Benchtop Freeze Dry System, Kansas City, MO). Scheme 1 summarizes the layer-by-layer 
preparation procedure for core containing MRP (𝐶+𝑀𝑅𝑃) and core dissolved MRP (𝐶−𝑀𝑅𝑃). 
A regular increase in average particle size after each layer addition and the change in ζ-
potential were critical parameters to ensure a successful preparation. After preparation, MRP 
was freeze-dried for 12 h (Labconco FreeZone 1 Liter Benchtop Freeze Dry System, Kansas 
City, MO) and stored at 4 °C. 
 
Average particle size and zeta potential determination. MRP’ [both (𝐶+𝑀𝑅𝑃) and 
(𝐶−𝑀𝑅𝑃)] particle size and zeta potential (ζ-potential) measurements were conducted on 
Malvern instrument 3600 Zetasizer Nano (Worcestershire, UK). Briefly, 1 ml of sample 
suspension, in distilled water, was prepared in the measurement cuvette and sonicated by bath 
sonication (Qsonica LLC, Newtown, CT, USA). The cuvette was then placed in the cell area 
and experiments were performed at 25 °C on the Zetasizer. Data acquisition and analysis were 
conducted using Zetasizer software (version 6.01, Worcestershire, UK).  
 
Encapsulation and loading efficiency determination. TFV percent encapsulation 
efficiency (%EE) and loading efficiency (%LD) in MRP were estimated by liquid state and 
solid state phosphorus (31P) nuclear magnetic resonance (NMR), respectively. Previous reports 
by our group have established 1H NMR and 31P NMR methods for TFV quantification.302, 303  
31P solution state NMR: TFV %EE was measured by quantifying the free drug amount 
in the supernatant by 31P solution state NMR. Equation 5-1 was then used to compute %EE.   
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%EE =
Total amount of TFV−Free TFV 
Total amount of TFV
× 100                        (5-1) 
31P solution state NMR experiment was carried out on a Varian (Palo Alto, California) 400 
MHz spectrometer with a Varian two channel probe and operated by Vnmrj 2.2. Typically, 
spectra were acquired with a 45º pulse length of 5.05 μs. The relaxation delay and the number 
of scans were 5 and 256 seconds, respectively. The spin–lattice relaxation time (T1) of the 
target phosphorus in TFV was 5 s and typically required up to 25 s (5 × T1) for relaxation. 
Shimming was applied to every sample to obtain a similar linewidth in each spectrum. Baseline 
correction, phase adjustment, and integral calculations were carried out using MestReNova 
Lite 5.2.5-4731 software (Escondido, CA, USA) and Matlab 6.1 (Natick, MA, USA), and all 
experimental measurements were conducted at 37ºC. To determine TFV amount in the 
supernatant, a standard curve was performed across a concentration range of 0-500 µg/ml in 
DI water. Equation 5-2 describing the calibration curve was Y = 9675.2 X - 29.677 and the 
coefficient of determination R2 = 0.9999, indicative of a strong correlation between 31P solid 
state NMR peak area (Y) and TFV concentration (X). 
31P solid state NMR: After freeze drying, TFV %LD was determined by comparing 
MRP’ 31P solid state NMR peak area to a pure TFV standard of the same mass. Thus, solid 
state NMR spectra for 30 mg of MRP and pure TFV samples were taken at room temperature 
in triplicates, and signals were represented as chemical shift value δ: ppm. Equation 5-3 was 
used to compute %LD. 
%LD =
31P NMR peak area for 30 mg MRP
 P 31  NMR peak area for 30 mg TFV standard
× 100                     (5-3) 
Practically, 31P-P90 Solid-State Magic Angle Spinning (MAS SS) NMR spectra was 
acquired on a Tecmag Apollo console (Houston, TX, USA) operated by NTNMR software 
package (v.2.4.29, Houston, TX, USA) with 8.45 T magnet and a 3 mm, homebuilt, 2-channel, 
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wide-bore NMR probes. The 1H and 31P Larmor frequencies were 357.2 MHz and 144.596 
MHz, respectively. The MAS spinning frequency and 45º pulse length were 8 KHz and 2 μs, 
respectively.  
 
Fourier transform infrared spectroscopy. IR spectroscopy was conducted following 
a published method.164  Briefly, Agilent Cary 630 Fourier transform infrared spectroscopy 
(FTIR) instrument (Newark, DE, USA), equipped with a diamond crystal with a single 
reflection and a nominal angle of 45°, was used in the Attenuated Total Reflectance (ATR) 
mode for IR spectra acquisition. A resolution of 4 cm-1, a sample scan of 32/s and an effective 
pathlength of 1.1 μm were selected as parameters. IR spectra were acquired between 4000 and 
400 cm-1. For better spectral resolution, all samples were allowed to make intimate contact 
with the ATR diamond crystal surface by pressing them with a built-in pressure clamp. FTIR 
spectra were collected and analyzed with MicroLab PC and MicroLab Lite softwares (versions 
4.0, Newark, DE, USA), respectively.  
 
Morphological analysis of MRP. To confirm the inclusion of both the lectin and 
polysaccharide in the self-assembly, 𝐶+𝑀𝑅𝑃 (3 Con A layers formulation/3L) prepared using 
FITC-Con A and TRITC-Dextran was imaged by confocal microscopy. Briefly, few drops of 
the fluorescently labeled MRP solution were placed on a microscope glass slide (25×75×1.0 
mm) and sealed with a nail varnish after covering with a coverslip. Z-stack imaging was then 
performed on Leica TCS SP5 II confocal microscope (Mannheim, Germany) at 100X 
magnification. LAS-AF lite software (version 3.x, Buffalo Grove, IL) was used for data 
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collection and analysis. Furthermore, MRP (3L) was visualized by transmission electron 
microscopy (TEM) and scanning electron microscopy (SEM).303   
 
L. crispatus viability assay. L. crispatus viability assay was performed following a 
published method.304 Although vaginal microbiota is composed of different species, 
Lactobacillus are the dominant bacterial species in majority of women (73% of bacterial 
community).305 Briefly, L. crispatus was grown overnight at 37 °C in broth culture media. The 
density was adjusted to an OD670 value of 0.06, corresponding to 0.5 McFarland Standard or 
108 CFU/ml.306 Then, hundred microliters (100 μl) of the adjusted L. crispatus culture were 
placed in 96-well plates before addition of MRP (3L) suspension. 𝐶+𝑀𝑅𝑃 and 𝐶−𝑀𝑅𝑃 
concentrations ranging from 1 to 1000 µg/ml were prepared by successive log10 dilutions of 
the working standard solution in broth culture media, and homogenized before addition to L. 
crispatus. Broth media and 1% Triton X-100 were used as negative (untreated) and positive 
controls, respectively. Plates were initially incubated at 37 °C for 24 h before addition of 20 μl 
of MTS reagent to each well and further incubated at 37 °C for 4 h. This allowed the reduction 
of MTS compound by viable L. crispatus into the colorful formazan product. Bacterial viability 
was determined by measuring the absorbance at a wavelength of 490 nm on a microplate reader 
(Beckman Coulter DTX 880 Multimode Detector, Fullerton, CA, USA). Percent viability was 
calculated using equation 5-4. 
𝑉𝑖𝑎𝑏𝑖𝑙𝑖𝑡𝑦 (%) =
𝐴𝐵𝑆𝑇𝑒𝑠𝑡−𝐴𝐵𝑆𝐵𝑎𝑐𝑘𝑔𝑟𝑜𝑢𝑛𝑑
𝐴𝐵𝑆𝑁𝑒𝑔𝑎𝑡𝑖𝑣𝑒 𝑐𝑜𝑛𝑡𝑟𝑜𝑙−𝐴𝐵𝑆𝑏𝑎𝑐𝑘𝑔𝑟𝑜𝑢𝑛𝑑
× 100                       (5-4) 
All experiments were conducted in triplicates and cytotoxicity results were rated according to 
ISO-standard 10993-5 as non-cytotoxic (cell viability higher than 75%), slightly cytotoxic (cell 
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viability ranging from 50% to 75%), moderately cytotoxic (cell viability ranging from 25% to 
50%), and severely cytotoxic (cell viability lower than 25%).307, 308  
 
Cell culture conditions. Human vaginal keratinocytes cell line (VK2/E6E7, ATCC 
Number CRL-2616) was obtained from the American Type Culture Collection (Manassas, VA, 
USA). VK2/E6E7 cell line was used as model epithelial cell types of the female reproductive 
tract with relevance for vaginal drug delivery and topical microbicide development. Its 
differentiation pattern and immune responses closely resemble those of the normal tissues of 
origin.309 Cells were cultured in antibiotic-free K-SFM supplemented with 0.1 ng/ml of EGF 
human recombinant, 0.05 mg/ml of bovine pituitary extract and 0.4 mM CaCl2. Culture 
medium was replaced every 2–3 days. Before confluence, cultures were washed with DPBS 
and subsequently detached by enzymatic treatment with 0.25% trypsin/EDTA solution for 3-5 
minutes at 37 °C. After trypsin inhibition by soybean inhibitor at a molar ratio of 1:1, cells 
were washed, and seeded in new flasks or 96-well plates. All experiments were performed on 
cells in the logarithmic growth phase. Murine macrophage [RAW 264.7 (TIB-71)] cell line 
was purchased from the American Type Culture Collection (Manassas, VA) and cultured in 
antibiotic-free DMEM media supplemented with 10% heat-inactivated fetal bovine serum 
(FBS). All incubations were performed in the same conditions (37 °C in a humidified 
atmosphere of 5% carbon dioxide (CO2), 95% air) throughout the experimental studies unless 
otherwise specified. 
 
Experimental procedure for cell exposure to MRP.  
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VK2/E6E7 cells. 𝐶+𝑀𝑅𝑃 and 𝐶−𝑀𝑅𝑃 suspensions were prepared in concentrations 
ranging from 1 to 1000 µg/ml by successive log10 dilutions of a working standard (1000 µg/ml) 
in K-SFM medium. Suspensions were homogenized by vortexing immediately before 
exposure to VK2 cells. Cells (100 μl per well, 2.0 x 105 cells/ml) were seeded into 96-well flat-
bottomed plates (TPP, Switzerland; growth surface: 0.32 cm2 per well; Thermo Fisher 
Scientific (Waltham, MA, USA)) and incubated as explained above, for 48 h. Culture medium 
was subsequently substituted with 100 µl of fresh culture medium containing increasing MRP 
concentrations (1 to 1000 µg/ml), and cells were further incubated for 24 h. Complete culture 
medium was used as negative controls while various positive controls of 1% Triton X-100 and 
1 mg/ml SNP were used as benchmarks against MRP.  
RAW 264.7 cells. 𝐶+𝑀𝑅𝑃 and 𝐶−𝑀𝑅𝑃 working standard suspensions were freshly 
prepared in DMEM with 5% FBS at 1000 µg/ml, and a range of concentrations from 1 to 1000 
µg/ml was prepared. Cells (100 μl per well, 2.0 x 106 cells/ml) were seeded into 96-well flat-
bottomed plates and incubated, as explained above. Cells were subsequently exposed to 100 
µl of fresh medium containing increasing 𝐶+𝑀𝑅𝑃 and 𝐶−𝑀𝑅𝑃 concentrations (1 to 1000 
μg/ml) and incubated for 24 h. Culture medium and LPS (10 µg/ml), were used as negative 
and positive controls, respectively. 
 
Assessment of cell membrane integrity. Dose-response effect of 𝐶+𝑀𝑅𝑃 and 
𝐶−𝑀𝑅𝑃 on plasma membrane integrity was assessed using the uptake and specific 
accumulation of the vital dye neutral red (NR) in lysosomes.310, 311 NR is a weak cationic dye 
that penetrates viable cells membrane and accumulates intracellularly in lysosomes where it 
binds with anionic sites of the lysosomal matrix.312 Cell membrane alterations are generally 
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irreversible and result in the loss of the NR from the lysosome.313 After exposure to 𝐶+𝑀𝑅𝑃 
and 𝐶−𝑀𝑅𝑃, cells were washed twice with DPBS and supplemented with fresh culture 
medium (100 μl) containing 50 µg/ml NR. Assay plates were incubated for 3 h to allow viable 
cells to accumulate NR in their lysosomes. After the incubation time, cells were further washed 
twice with DPBS followed by membrane disruption with an aqueous solution of 1% acetic 
acid/50% ethanol (100 µl/well). Fluorescence intensity (FI) measurement (530-560 nm 
excitation, 590 nm emission) was performed on Cary Eclipse Fluorescence Spectrophotometer 
and membrane integrity was determined using equation 5-5. Membrane integrity result was 
analyzed following ISO-standard 10993-5. 
𝑀𝑒𝑚𝑏𝑟𝑎𝑛𝑒 𝐼𝑛𝑡𝑒𝑔𝑟𝑖𝑡𝑦 (%) =
𝐹𝐼𝑇𝑒𝑠𝑡−𝐹𝐼𝐵𝑎𝑐𝑘𝑔𝑟𝑜𝑢𝑛𝑑
𝐹𝐼𝑁𝑒𝑔𝑎𝑡𝑖𝑣𝑒 𝐶𝑜𝑛𝑡𝑟𝑜𝑙−𝐹𝐼𝐵𝑎𝑐𝑘𝑔𝑟𝑜𝑢𝑛𝑑
× 100                              (5-5) 
 
Assessment of mitochondrial metabolism. Resazurin assay is based on the ability of 
viable, metabolically active cells to convert the redox dye resazurin from the oxidized (non-
fluorescent) dark blue form to the reduced (highly fluorescent) pink form, resorufin.314 This 
conversion occurs intracellularly by a pool of oxidoreductase or diaphorase-type enzyme 
derived from mitochondria by accepting electrons from nicotinamide adenine dinuleotide 
phosphate (NADPH), flavin adenine dinucleotide (FADH), flavin mononucleotide (FMNH), 
nicotinamide adenine dinucleotide (NADH), as well as from numerous cytochromes.315 After 
exposure to 𝐶+𝑀𝑅𝑃 and 𝐶−𝑀𝑅𝑃, cells were washed twice with DPBS and supplemented with 
fresh culture medium (100 μl). Ten (10) microliters of resazurin working solution (0.1 mg/ml, 
DPBS) was added directly to each well and plates were incubated for 3h to allow viable cells 
to convert resazurin into resorufin. Then, fluorescence intensity (FI) measurement (530-560 
nm excitation, 590 nm emission) was performed on Cary Eclipse Fluorescence 
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Spectrophotometer, and cell viability was calculated using equation 5-6. Mitochondrial 
metabolism result was analyzed following ISO-standard 10993-5. 
𝑀𝑖𝑡𝑜𝑐ℎ𝑜𝑛𝑑𝑟𝑖𝑎𝑙 𝑚𝑒𝑡𝑜𝑏𝑜𝑙𝑖𝑠𝑚 (%) =
𝐹𝐼𝑇𝑒𝑠𝑡−𝐹𝐼𝐵𝑎𝑐𝑘𝑔𝑟𝑜𝑢𝑛𝑑
𝐹𝐼𝑁𝑒𝑔𝑎𝑡𝑖𝑣𝑒 𝐶𝑜𝑛𝑡𝑟𝑜𝑙−𝐹𝐼𝐵𝑎𝑐𝑘𝑔𝑟𝑜𝑢𝑛𝑑
× 100                  (5-6) 
 
Determination of nitric oxide production. Nitric oxide (NO) production in culture 
supernatant, a measure of inducible NO Synthase (iNOS) activity, was assessed by measuring 
nitrite accumulation, the stable end product of the autoxidation of NO in aqueous solution.316 
After cells were incubated with different concentrations of 𝐶+𝑀𝑅𝑃 and 𝐶−𝑀𝑅𝑃, for 24 h at 
37 °C; supernatants were collected, centrifuged (1000 rpm) and NO content was determined 
using Griess reagent system kit (Promega Corp., Madison, WI, USA). Briefly, 50 µl of 
supernatant was placed in a new 96 well plate and mixed with Griess reagents according to the 
manufacturer.317 Absorbance was measured at 540 nm on DTX 880 microplate reader. NO 
concentration was calculated using the sodium nitrite standard curve, according to the 
manufacturer. Equation 5-7, describing the calibration curve, was Y = 0.0045 X, where Y and 
X represent the absorbance value and NO concentration (μM), respectively. The coefficient of 
determination was R2 = 0.9991, suggesting a good correlation between absorbance value and 
NO content. As positive controls, the generation of NO was achieved for RAW 264.7 with 
LPS and 1 mg/mL SNP for VK2/E6E7 cells.318  
 
Multiplex immunoassay analysis of cytokines secretion. After macrophages RAW 
264.7 exposure to 𝐶+𝑀𝑅𝑃 and 𝐶−𝑀𝑅𝑃, cell free supernatants were harvested and analyzed 
for various cytokines susceptible to enhance HIV infectivity. The cytokines level were assayed 
using a high-sensitivity multiplexed bead-based immunoassay (Milliplex MAP Mouse 
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Cytokine/Chemokine Magnetic Bead Panel, Millipore Corp., Billerica, MA; and Luminex 
MAGPIX instrument, Luminex Corp., Austin, TX, USA). Supernatants from untreated cells 
(negative control) and LPS-treated cells (positive control) were also evaluated. Seven 
cytokines including IL-1α, IL-1β, IL-6, IP10, MKC, TNF-α and IL-7 were measured according 
to the manufacturer's procedure.319 Pre-mixed magnetic beads conjugated to antibodies for all 
7 analytes were mixed with equal volumes of supernatants (25 μl) in 96-well plates. Plates 
were protected from light and incubated on a microplate shaker overnight at 4 °C. Then, 
magnetic beads were washed twice with 200 μl of washing buffer. The detection antibodies 
were added to each well and the mixtures incubated at room temperature for 1 h. Streptavidin-
phycoerythrin conjugate compound was added to each well, and the mixtures were incubated 
for an additional 30 min at room temperature. The magnetic beads were subsequently washed 
and resuspended in the washing buffer for 5 min. Plates were then assayed on the Magpix 
system with Luminex xPONENT software (version 4.2, Austin, TX). Median fluorescence 
intensities were analyzed using a 5-parameter logistic method from a standard curve of 
respective analytes to determine cytokines concentration in the supernatants. All assays were 
conducted in duplicate. 
 
Drug release conditions and kinetics. Based on initial cytotoxicity indicators for both 
𝐶−𝑀𝑅𝑃 and 𝐶+𝑀𝑅𝑃 (see results and discussion section), drug release experiments were 
conducted only for 𝐶+𝑀𝑅𝑃. Thus, TFV release from several 𝐶+𝑀𝑅𝑃 formulations (1L, 2L 
and 3L corresponding to 1, 2 and 3 Con A layers in formulation) was performed in the presence 
of Man and HIV-1 rgp120. TFV level was quantified using a previously published LC/MS/MS 
method.320 TFV was detected with electrospray ionization (ESI)-MS/MS in the positive ion 
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mode using 288/176.2 m/z transition. The mobile phase consisted of 30% H2O (0.1 % FA)/70% 
Acetonitrile (0.1% FA). Flow rate was maintained at 0.3 ml/min, and a calibration curve 
relating TFV concentration to 176.2 m/z ion peak area was used to determine the concentration 
of unknowns. Equation 5-8 describing the calibration curve was Y = 595.6 X with R2 = 0.9946. 
This suggested a strong correlation between 176.2 m/z ion peak (Y) area and TFV 
concentration (X), in the range of 0-500 μg/ml. The average volume of human vaginal fluid 
(VFS, pH 4.2) and seminal fluid (SFS, pH 7.6), during intercourse, have previously been 
reported to be 0.75 ml and 3.4 ml, respectively.302 Therefore, to mimic the intercourse situation, 
for each time point, 6 mg of MRP was weighed and dispersed in 4.15 ml of SFS:VFS (4.5v:1v) 
mixture under gentle stirring at room temperature. Vaginal and seminal fluids simulant were 
prepared following the method of Owen et al.321, 322 The release media was then filtered on a 
0.2 μm whatman syringe filter before any MS spectral acquisition. In the current study, HIV-
1 rgp120 was tested at in vitro concentrations ranging from 25 μg/ml to 1000 μg/ml, which is 
consistent with other reported studies [1 pM to 1 μM (0.12 ng/ml to 120 μg/ml)].323 The model-
independent method was used to determine whether TFV release profile was similar or 
different from the control condition (SFS:VFS; taken as reference). Thus, to assess the 
significance level in the drug release profiles, a pair-wise comparison of the release profiles 
was conducted using the US FDA similarity factor (𝑓2) and dissimilarity factor (𝑓1).
324 𝑓1 
measures the percent error while 𝑓2 measures the sum-squared error between a test and 
reference compound’s overall time points. 
𝑓1 = (
[∑ |𝑅𝑗−𝑇𝑗|
𝑛
𝑗=1 ]
[∑ 𝑅𝑗
𝑛
𝑗=1 ]
) × 100                                                                (5-9) 
𝑓2 = 50 × log {[1 + (
1
𝑛
) ∑ |𝑅𝑗 − 𝑇𝑗|
2𝑛
𝑗=1 ]
−0.5
× 100}                       (5-10) 
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In equations 5-9 and 5-10, n is the sampling number, R and T are the percent dissolved 
of the reference and test products, respectively at each time j. Furthermore, to elucidate the 
drug release mechanism, zero order, first order, Higuchi, Hixson–Crowell and Hopfenberg 
kinetic models, given by equation 5-11, 5-12, 5-13, 5-14 and 5-15, respectively, were applied 
to the release profiles. 
 𝑄𝑡 = 𝑄0 + 𝐾0𝑡                                           (5-11) 
log 𝑄𝑡 = log 𝑄0 +
𝐾1𝑡
2.303
                               (5-12) 
𝑄𝑡 = 𝐾𝐻𝑡
1
2                                                   (5-13) 
(1 − 𝑓𝑡)
1/3 = 1 − 𝐾𝛽𝑡                                (5-14) 
𝑓𝑡 = 1 − [1 − 𝐾2𝑡
𝑥]                                    (5-15) 
In the above equations, 𝑄𝑡 is the amount of drug dissolved in time t, 𝑄0 represents the 
initial amount of drug in solution (usually, 𝑄0 = 0) and 𝐾0 is the zero order release constant. 
𝐾1 is the first order release constant. 𝐾𝐻 is the Higuchi dissolution constant and 𝑓𝑡 represents 
the fraction of drug dissolved in time t. Kβ represents the Hixson–Crowell release constant and 
K2, indicative of the erosion rate, is the Hopfenberg release constant. The parameter x, 
describing the drug particle shape, is 1, 2, or 3 for slab, cylinder and spheres, respectively. In 
the present study, the Hopfenberg’s drug particle shape parameter was x = 3. 
 
Bioadhesion test. 𝐶+𝑀𝑅𝑃 mucoadhesion was tested ex vivo, on porcine vaginal tissue, 
following the immersion method, according to previously published reports.325, 326 Briefly, 
fluorescently labeled MRP (1L, 2L and 3L) were prepared using FITC-Con A, as explained 
above. Fresh porcine tissue was obtained from the local abattoir (Fairview Farm Meat Co., 
Topeka, KS, USA), within 2 h of the animal death. The tissue was washed with normal saline, 
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frozen in liquid nitrogen, and kept at −80 °C. Frozen porcine tissue were thawed at 4 °C and 
cut into pieces of 8 cm/1 cm (L/W) for mucoadhesion assessment. Cyanoacrylate glue (water 
resistant and safe to porcine tissue) was used to stick sample tissues onto microscope slides, 
with luminal side facing up. The tissue slides were further immersed into tubes containing 
FITC labeled 𝐶+𝑀𝑅𝑃 (10 mg/ml) in 10 ml of VFS. A control experiment was conducted with 
FITC alone. The tubes were kept in a shaking water bath (37 °C) at 100 rpm, and removed for 
analysis of the remaining fluorescence in the VFS at 4 h and 24 h. The difference in VFS 
fluorescence, before and after treatment, was analyzed on Cary Eclipse Fluorescence 
Spectrophotometer (λex 490 nm/λem 520 nm) operated by Cary Eclipse advance reads 
application (Version 1.1 (132), Santa Clara, CA, USA). Tissue images were also acquired on 
Nikon Labophot-2 microscope (Nikon Instruments, Inc., Melville, NY, USA) equipped with 
PAXCam digital microscope camera and PAX-it! image management and analysis software 
(version 7.9, Midwest Information Systems, Inc., Villa Park, IL, USA). The percent 
mucoadhesion was determined using equation 5-16, where FI and F represent VFS initial and 
final fluorescence, respectively.326 
𝑀𝑢𝑐𝑜𝑎𝑑ℎ𝑒𝑠𝑖𝑜𝑛 (%) =
(𝐹𝐼−𝐹)
𝐹𝐼
× 100      (5-16) 
 
5.3 Results and discussion  
Layer-by-layer preparation of MRP.  
 
Figure 5-1 summarizes size and ζ-potential measurement for MRP and CaCO3-PSS 
core particle. The average size (diameter) of CaCO3-PSS core particles was 259.1±1.87 nm 
(n=3) with a polydispersity index (PDI) of 0.250 (figure 5-1A). The ζ-potential of freshly  
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Figure 5-1: Average particle size and cumulative size distribution for CaCO3-PSS (A), 
𝐶+𝑀𝑅𝑃 (B) and 𝐶−𝑀𝑅𝑃 (C), and their respective ζ-potential measurements (A’, B’ and C’).  
 
prepared CaCO3-PSS particles was -26.9±2.14 mV (n=3) (figure 5-1A’), partly due to the 
negatively charged PSS present onto the particles surface. 𝐶+𝑀𝑅𝑃 average size and ζ-potential 
were 1130±15.72 nm [PDI = 0.153] and -15.1±0.55 mV, (n=3). Similarly, 𝐶−𝑀𝑅𝑃 average 
size and ζ-potential were 1089±23.33 nm (n=3) and -14.2±0.25 mV (n=3) (Fig.1-C’). The 
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shrinking from 𝐶+𝑀𝑅𝑃 to 𝐶−𝑀𝑅𝑃 could be due to a rearrangement of the layers upon removal 
of the supporting inner core. Similar observations have been reported by Gao et al.327   
Figure 5-2: Average size and ζ-potential fluctuation during 𝐶+𝑀𝑅𝑃 layer-by-layer 
preparation. 
 
Figure 5-2 summarizes the overall average size and zeta potential variations during the 
layer-by-layer preparation of 𝐶+𝑀𝑅𝑃. After addition of the positively charged PEI layer (layer 
1) onto the negatively charged CaCO3-PSS, the average size increased from 259.1±1.87 nm to 
486.3±70.18 nm [PDI = 0.314] and the ζ-potential switched from -26.9±2.14 mV to 
+27.4±2.08 mV. This suggested the success of PEI layer adsorption onto the particles surface, 
through electrostatic attractions between the negatively charged core and the positively 
charged PEI. The addition of Con A layer (layer 2) brought the average particle size to 
540.8±6.62 nm [PDI = 0.261] and the ζ switched back from positive to a negative value (ζ-
potential = -6.74±1.11 mV). The first lectin layer successfully adhered to the assembly through 
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electrostatic interactions between the positively charged PEI and the negatively charged Con 
A. Both the size increase and the change in ζ-potential were due to the addition of the Con A 
layer to the molecular assembly. With the adsorption of glycogen layer (layer 3), the average 
particle size increased by 63% and was 881.7±15.45 nm [PDI = 0.341], while the ζ-potential 
became +2.23±0.3 mV. The glycogen layer was successfully added through the specific 
binding between Con A and α-D-glucose moieties in glycogen 258. The addition of the next, 
Con A layer (layer 4) increased the average particle size to 918.6±132.6 nm [PDI = 0.284] and 
the ζ-potential was -5.53±0.73 mV. The second glycogen layer (layer 5) induced an overall 
20% increase in average particle size, which was 1091±21.07 nm [PDI = 0.254], and the ζ-
potential decreased roughly from -5.53±0.73 mV to -14.3±0.21 mV. The third Con A layer 
(layer 6) brought the average particle size to 1130±15.72 nm (n=3) [PDI = 0.153] (figure 5-
1B) and the ζ-potential to -15.1±0.55 mV (n=3) (figure 5-1B’). Percent increase or decrease in 
particle size was estimated using equation 5-17. 
𝐶ℎ𝑎𝑛𝑔𝑒 𝑖𝑛 𝑠𝑖𝑧𝑒 (%) =
𝐹𝑖𝑛𝑎𝑙 𝑠𝑖𝑧𝑒−𝐼𝑛𝑖𝑡𝑖𝑎𝑙 𝑠𝑖𝑧𝑒
𝐼𝑛𝑖𝑡𝑖𝑎𝑙 𝑠𝑖𝑧𝑒
× 100                               (5-17) 
 
TFV entrapment in MRP. TFV %EE in CaCO3-PSS core particle was 74.4% and 
%LD obtained for 𝐶+𝑀𝑅𝑃 (3L) and 𝐶−𝑀𝑅𝑃 (3L) were 16.3% ± 0.1 w/w and 6.0% ± 0.1 w/w, 
respectively. TFV %LD in 𝐶+𝑀𝑅𝑃 was ~ 3 folds higher than 𝐶−𝑀𝑅𝑃. This difference in %LD 
is probably due to a lost in Tenofovir during core dissolution because of its relatively high 
water solubility (13.4 mg/mL). Figure 5-3 and 5-4 show the 31P solid state NMR spectra (figure 
5-3) and a typical supernatant’ 31P solution state NMR spectrum (figure 5-4). The TFV 
phosphorus chemical shifts values were 15.7 ppm and 13 ppm for 31P solid state NMR and 31P 
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solution state NMR, respectively. TFV encapsulation in CaCO3-PSS particles was possible due 
to two major factors. First, after the nucleation phase, leading to the formation of CaCO3-PSS 
crystal precursors, the crystal growth phase involved a coprecipitation. Thus, drug molecules 
can be physically entrapped in CaCO3-PSS particles during the crystallization process. 
Coprecipitation has previously been used to successfully load both small molecule and protein 
drugs in CaCO3.
328-330 However, coprecipitation alone does not explain the overall TFV 
entrapment in MRP. In fact, along with aluminum hydroxide [Al(OH)3], calcium acetate 
[Ca(C2H3O2)2], lanthanum carbonate [La2(CO3)3] and magnesium carbonate [MgCO3]; 
Figure 5-3: 31P solid state NMR spectra of TFV standard, 𝐶+𝑀𝑅𝑃 and 𝐶−𝑀𝑅𝑃.  
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CaCO3 is a member of the phosphate binders family.
331-334 Phosphate binders form complexes 
with phosphorus atoms through ionic interactions. In CaCO3, it is the calcium ion (Ca
2+) that 
interacts with the phosphate group. Therefore, it was expected that TFV, which structure 
contains a phosphate group (figures 5-3 & 5-4), would be entrapped in the core particles. 
Taking advantage of this principle, Ueno et al. were able to achieve 90% loading of 
betamethasone phosphate into CaCO3 nanoparticles.
335 
TFV payload in MRP could provide satisfactory drug strength capable of exerting 
desired therapeutic activity. In fact, it was previously shown that vaginal suppositories’ weight 
vary from 1000-2000 mg.336, 337 Potential MRP suppositories weighing between 1000-2000 mg 
 
Figure 5-4: TFV 31P solution state NMR spectrum following layer-by-layer encapsulation.  
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would have TFV strength ranging from 163 – 326 mg, respectively. These TFV strengths are 
4 to 8 fold higher than TFV strength tested in both 1% TFV vaginal gel and TFV reservoir 
intravaginal ring (40 mg).338, 339  
 
FTIR analysis. In order to characterize and confirm the composition of the coating 
layers, FTIR spectra of 𝐶+𝑀𝑅𝑃, 𝐶−𝑀𝑅𝑃, glycogen, Con A, CaCO3-PSS core particle and Con 
A/Glycogen agglutinate were acquired (figure 5-5). Glycogen IR spectrum showed distinctive 
weak peaks at 1160 cm-1, 1080 cm-1 and a strong absorption at 1000 cm-1 characteristic of 
polysaccharides C-O-C, C-O and C-H stretches, respectively.340, 341 The bands at 3300 cm-1 
and 2900 cm-1 were due to OH and CH2 stretches in glycogen, respectively. Con A IR spectrum 
showed strong bands at 1620 cm-1 and 1520 cm-1, attributed to amide I and II, respectively.164, 
342 Spectrum obtained for CaCO3-PSS core particle showed a strong peak at 870 cm
-1, 
characteristic of carbonate band in CaCO3.
343 Features at 1400 cm-1-1480 cm-1 were attributed 
to both CaCO3 and S=O asymmetric stretching vibration mode in CaCO3-PSS.
298, 344 𝐶+𝑀𝑅𝑃 
spectrum showed a distinctive Con A amide I band at around 1620 cm-1 and glycogen C-O-C, 
C-O and C-H stretches at 1160 cm-1, 1080 cm-1 and 1000 cm-1, confirming the presence of both 
the lectin and the polysaccharide in the layer-by-layer assembly. These features were similar 
to bands observed in Con A/Glycogen agglutinate spectrum. The bands between 1400 cm-1-
1480 cm-1, as well as the strong absorption at 870 cm-1 in 𝐶+𝑀𝑅𝑃 IR spectrum further 
confirmed the presence of CaCO3-PSS core particle in the assembly. As expected, bands 
attributed to the carbonate band are not seen in 𝐶−𝑀𝑅𝑃 IR spectrum. The band at 1000 cm-1 
and the amide I stretching band at 1620 cm-1 further confirm the presence of Con A/Glycogen 
agglutinate in 𝐶−𝑀𝑅𝑃 assembly. 
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Figure 5-5 : FTIR spectra for 𝐶+𝑀𝑅𝑃, 𝐶−𝑀𝑅𝑃, glycogen, Con A, CaCO3-PSS core particle 
and Con A/Glycogen agglutinate. 
 
Morphological analysis. Figure 5-6 shows TEM (A & B) and SEM (A’& B’) images 
of 𝐶+𝑀𝑅𝑃 and 𝐶−𝑀𝑅𝑃 particles. These images suggested that individual MRP particles 
exhibit spherical shape with diameter ranging from 800-1100 nm (n=5). 𝐶+𝑀𝑅𝑃 SEM image 
(A’) showed a distinctive layer covering the core particle and the TEM image (A) showed an 
optically dense core of CaCO3-PSS surrounded by less dense layers of Con A/Glycogen 
agglutinate, confirming 𝐶+𝑀𝑅𝑃 core shell structure and the success of the layer-by-layer 
preparation procedure. For 𝐶−𝑀𝑅𝑃, the SEM image (B’) shows particles with a rough surface, 
probably dues to the removal of the supporting CaCO3-PSS core particles. The absences of the 
electron dense cores in 𝐶−𝑀𝑅𝑃 TEM images (B) suggest the complete or partial removal 
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Figure 5-6: TEM (A & B), SEM (A’& B’) and confocal microscopy (C & C’) images of 
𝐶+𝑀𝑅𝑃, 𝐶−𝑀𝑅𝑃. Scale bars are 2 μm for A, A’, B, B’ and 100 nm for C and C’. 
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of the CaCO3-PSS. The difference in optical density was due to a difference in material 
properties between the core and shell, as previously shown by Dahl et al.345 These 
morphological descriptions were consistent with the work of Zhu et al.346 When FITC-Con A 
and TRITC-dextran were used in 𝐶+𝑀𝑅𝑃 preparation, fluorescent particles were prepared and 
visualized under a confocal microscope. The presence of both TRITC (red fluorescence C) and 
FITC (green fluorescence C’) in 𝐶+𝑀𝑅𝑃 layers confirmed the success of Con A and the 
polysaccharide attachment in the assembly. These fluorescent images further confirmed 
𝐶+𝑀𝑅𝑃 particles size, geometry, and ultrastructure.  
 
In vitro cytotoxicity analysis. The normal vaginal flora represents a critical natural 
barrier against HIV transmission, by contributing to the vaginal acidic pH and hydrogen 
peroxide (H2O2) production.
347, 348 Lactobacillus is a predominant vaginal floral species that 
produces H2O2.
349 To be considered safe for vaginal delivery, microbicide formulations should 
not disturb the normal vaginal flora, therefore should not be toxic to Lactobacillus.306 As 
summarized in figure 5-7, both 𝐶+𝑀𝑅𝑃 and 𝐶−𝑀𝑅𝑃 are non-cytotoxic to Lactobacillus 
crispatus suggesting that both MRPs might be safe for vaginal microbicide delivery. 
Furthermore, inflammation has been shown to increase HIV transmission because of the 
increase in the body innate and specific immune response at an inflammation cites 350, 351. That 
is, there is a high recruitment of HIV receptive cells at the inflammation site which increases 
HIV infectivity. Because it is an important pro-inflammatory mediator 352, 353, nitric oxide 
released upon incubation of vaginal keratinocytes cells (VK2) with MRP is determined. For 
both 𝐶+𝑀𝑅𝑃 and 𝐶−𝑀𝑅𝑃, no significant nitric oxide release is observed compared to the 
negative control (culture media) in the concentration range tested, suggesting that no 
95 
  
inflammation of VK2 cells is associated with both MRPs’ treatment (figure 5-8C), up to 24h. 
Figure 5-8 also summarizes the in vitro safety profile of 𝐶+𝑀𝑅𝑃 and 𝐶−𝑀𝑅𝑃 on VK2 cells. 
It appears that across the concentration range tested, 𝐶+𝑀𝑅𝑃 is non-cytotoxic on VK2 cells 
with a CC50 value of 1433 μg/ml. Moreover, this formulation did not induce any loss in cell 
membrane integrity up to 1000 μg/ml in 24h. However, 𝐶−𝑀𝑅𝑃 is non-cytotoxic up to 10 
μg/ml, slightly cytotoxic at 100 μg/ml and severely cytotoxic at 1000 μg/ml. The cytotoxicity 
observed at 1000 μg/ml is consistent with a significant decrease in cell membrane integrity at 
the same concentrations. The CC50 value for 𝐶−𝑀𝑅𝑃 on VK2 cells is 200 μg/ml. 
 
 
 
 
 
 
 
 
 
Figure 5-7: L. crispatus viability. Percent viability and standard deviations values are 
computed from quintuplicates (n=5). One-way anova test is performed in GraphPad (version 
6.0) to determine statistical signifiance. * (P ≤ 0.05) shows statistically significant difference 
from the negative control (culture media). 
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Figure 5-8: VK2 cytotoxicity. A, B and C shows the mitochondial metabolism, cellular 
membrane integrity and nitric oxide production, respectively, for 𝐶+𝑀𝑅𝑃 and 𝐶−𝑀𝑅𝑃. D and 
E represent the CC50 curves for 𝐶+𝑀𝑅𝑃 and 𝐶−𝑀𝑅𝑃, respectively. Values are computed from 
quintuplicates (n=5). One-way anova test is performed in GraphPad (version 6.0) to determine 
statistical signifiance. * (P ≤ 0.05) shows statistically significant difference from the negative 
control (culture media). NS indicates non-significance (P > 0.05). 
 
Upon murine macrophages RAW 264.7 cells’ treatment with both MRP, 𝐶+𝑀𝑅𝑃 is 
found to be non-cytotoxic and does not induce any loss in cell viability nor in membrane 
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integrity in the concentration range tested in 24h (figure 5-9). The CC50 value for 𝐶+𝑀𝑅𝑃 
treatment associated with murine macrophages RAW 264.7 is 1413 μg/ml. 𝐶−𝑀𝑅𝑃 
formulation is non-cytotoxic up to 100 μg/ml and slightly cytotoxic at 1000 μg/ml, when 
Figure 5-9: RAW 264.7 cytotoxicity. A, B and C shows the mitochondial metabolism, cellular 
membrane integrity and nitric oxide production, respectively, for 𝐶+𝑀𝑅𝑃 and 𝐶−𝑀𝑅𝑃. D and 
E reprresent the CC50 curves for 𝐶+𝑀𝑅𝑃 and 𝐶−𝑀𝑅𝑃, respectively. Values are computed 
from quintuplicates (n=5). One-way anova test is performed in GraphPad (version 6.0) to 
determine statistical signifiance. * (P ≤ 0.05) shows statistically significant difference from the 
negative control (culture media). NS indicates non-significance (P > 0.05). 
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tested on murine macrophages RAW 264.7 cells. Similar to VK2 cells, 𝐶−𝑀𝑅𝑃 cell viability 
result is consistent with the membrane integrity test measured in the same conditions. Indeed, 
a significant decrease in cell membrane integrity is observed for 𝐶−𝑀𝑅𝑃 at 1000 μg/ml which 
could explain the low viability observed at the same concentration. Moreover, potential EDTA 
residues present in 𝐶−𝑀𝑅𝑃 formulation might explain the inherent cytotoxicity observed at 
1000 μg/ml. In fact, when tested on murine resident macrophages culture, EDTA (17%) 
induced 50% to 70% reduction in cell viability during 0–24h 354. The CC50 value calculated for 
𝐶−𝑀𝑅𝑃 on murine macrophages RAW 264.7 cells is 668 μg/ml and is twofold lower than the 
value obtained for 𝐶+𝑀𝑅𝑃 in the same conditions. For both 𝐶+𝑀𝑅𝑃 and 𝐶−𝑀𝑅𝑃, no 
significant nitric oxide release is observed compared to the negative control (culture media) in 
the concentration range tested, suggesting that no inflammation is associated with both MRPs’ 
treatment of RAW 264.7 for 24h. However, to further confirm this result, pro-inflammatory 
cytokines (IL1α, IL1β, IL6, TNFα) and the mouse functional analogue of human IL-8, MKC 
355, as well as IL7 and IP10 levels are determined in RAW 264.7 cells culture supernatant 
(figure 5-10). IL-1, the first discovered and most studied cytokine consists of two distinct 
subtypes (IL1α and IL1β).356 Binding of these subtypes to the IL-1 receptor (IL-1R1) activates 
the NF-κB pathway which can result in more pro-inflammatory cytokines secretion, such as 
TNFα, IL6 or IL8.357, 358 TNFα, which is associated with free radical production, is well known 
for its contrasting role as both HIV entry inhibitor and replication facilitator in chronically 
infected cells.359, 360 IL6 and IL8 have also been shown to induce HIV upregulation.361 
Similarly, IL7 facilitates HIV infection mainly by prolonging the life of infected cells and 
preventing apoptosis of non-infected CD4+ T cells 362. Interferon-γ-inducible protein 10 (IP10) 
stimulates HIV replication by attracting 
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Figure 5-10: IL1α, IL1β, TNFα, IL6, IL7, IP10 and MKC cytokines levels measured in RAW 264.7 cell culture supernatant for 
𝐶+𝑀𝑅𝑃 and 𝐶−𝑀𝑅𝑃.  Values are computed from quintuplicates (n=5). One-way anova test is performed in GraphPad (version 6.0) 
to determine statistical signifiance. * (P ≤ 0.05) shows statistically significant difference from the negative control (culture media). 
NS indicates non-significance (P > 0.05).
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activated T lymphocytes and monocytes.363, 364 No significant differences in pro-inflammatory 
cytokines IL1α, Ilβ, MKC and IL6 levels was observed when macrophage RAW 264.7 are 
treated with 𝐶+𝑀𝑅𝑃 for 24h. Although, no significant increase in TNFα level is observed for 
𝐶+𝑀𝑅𝑃 treatment, between 1-100 μg/ml; nonetheless, a significant increase of this cytokine 
is associated with 𝐶+𝑀𝑅𝑃 at 1000 μg/ml. Similarly, 𝐶+𝑀𝑅𝑃 did not induce a significant 
change in IL 7 and IP10 levels suggesting that this formulation might be safe for topical 
application in the concentration range tested for 24h. Conversely, other than IP10, where it did 
not induce any significant changes in the cytokine levels, 𝐶−𝑀𝑅𝑃 formulation is associated 
with significantly high pro-inflammatory cytokines production at 1000 μg/ml. In fact, this 
formulation is non-cytotoxic only at concentration ranging between 1-100 μg/ml as previously 
suggested by the cell viability testing. These results suggest that 𝐶+𝑀𝑅𝑃 formulation might 
be safer for in vivo applications compare to 𝐶−𝑀𝑅𝑃 which is not only associated with cell 
death, but also induces pro-inflammatory cytokines release at concentration above 100 μg/ml. 
 
 Assessment of HIV-1 gp120-triggered drug release. Due to the pronounced 
cytotoxicity observed for on both VK2 and RAW RAW 264.7, as well as the pro-inflammatory 
cytokines release it induced; 𝐶−𝑀𝑅𝑃 formulation was not tested for HIV-1 gp120-triggered 
drug release. Thus, stimuli sensitivity was tested by monitoring TFV release from  𝐶+𝑀𝑅𝑃, 
up to 24 h, in the presence of Man and mannose-rich HIV-1 rgp120 (figure 5-11 and 5-12). In 
general, a maximum drug release was reached within 4 to 8 h. An increasing dose response 
effect was also observed with increasing HIV-1 rgp120 concentration. HIV-1 virus is known 
to cross the mucosal barrier in 2 to 6 h and, during the first 3 to 6 days, disseminates locally to 
reach draining lymph nodes.365 Thus 𝐶+𝑀𝑅𝑃 could potentially offer the advantage of 
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neutralizing HIV-1 virus in the vaginal or rectal track before completion of its migration 
through the mucosal barrier. For 𝐶+𝑀𝑅𝑃 formulation containing three Con A layers (3L) 
(figure 5-11), a maximum drug release ((75% ± 6.5) [176.75 µg/ml]) was observed in the 
presence of Man (1000 µg/ml) while HIV-1 rgp120 induced 61% ± 3.7 [143.75 µg/ml], 39% 
± 1.7 [91.91 µg/ml] and 22% ± 1.4 [51.84 µg/ml] of TFV release at 1000 µg/ml, 500 µg/ml 
and 100 µg/ml, respectively. Previous studies show that TFV intravaginal ring completely 
protected macaques from multiple vaginal HIV challenges for average TFV vaginal fluid 
concentration of 180 µg/ml and a range stretching from 11-660 µg/ml.366 Similarly, 1% TFV 
gel offered 76% protection against HIV infection for TFV vaginal fluid concentrations higher 
than 1 µg/ml.367 Moreover, TFV EC50 values range from 0.021 µg/ml to 4.4 µg/ml. These 
studies strongly suggest that TFV concentrations achieved with 𝐶+𝑀𝑅𝑃 could effectively 
protect against HIV infections. The maximal drug release observed with Man could be due, in 
part, to a higher binding affinity of Con A for the monosaccharide, as previously shown by 
Goldstein et al.260 Moreover, Man smaller molecular weight might favor a better diffusion 
through Con A/glycogen layers resulting in a faster and greater layer degradation which  
 
 
 
 
 
Figure 5-11: TFV release profiles from 𝐶+𝑀𝑅𝑃 (3L) in the presence of Man (1000 μg/ml) 
and HIV-1 rgp120 (100-1000 μg/ml).
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translates into higher drug release and release rate constants (Table 2: Hixson–Crowell and 
Hopfenberg release kinetic models). Although a therapeutic concentration of TFV [51.84 
µg/ml] was released from 𝐶+𝑀𝑅𝑃 (3L), when exposed to 100 µg/ml of HIV-1 rgp120, this 
was, however, not significantly different from the drug release observed in the untreated 
conditions [SFS:VSF]. In fact, the model-independent method yielded dissimilarity factor (𝑓1) 
and similarity factor (𝑓2) values of 15.58 and 77.62, respectively for the release profile 
observed for HIV-1 rgp120 (100 µg/ml) (Table 5-1). According to the FDA guideline, 𝑓1 
values lower than 15 (0-15) and 𝑓2 values higher than 50 (50-100) show the similarity of two 
release profiles.  
 
 Optimization of 𝑪+𝑴𝑹𝑷. This study is justified due to the lack of significant drug 
release observed for HIV-1 rgp120 concentrations ≤ 100 µg/ml, and the relatively lower in 
vitro HIV-1 gp120 levels reported in various studies [0.12 ng/ml to 120 μg/ml].323 After fitting 
TFV release from 𝐶+𝑀𝑅𝑃 (3L) to various release kinetics models (Table 5-2), it was observed 
that TFV release profiles best follow Hixson–Crowell and Hopfenberg kinetic models. 
Traditionally, Hixson–Crowell model has been used to describe drug release profiles from 
diminishing surfaces of drug particles.368 Likewise, Hopfenberg kinetic model explains drug 
release profiles from matrix eroding drug particles. More specifically, Hopfenberg kinetic 
model assumes matrix erosion to be the rate-limiting step of drug release, instead of time 
dependent diffusional resistance (internal or external) to the eroding matrix.369 This suggested 
that drug release from 𝐶+𝑀𝑅𝑃 occurred through an erosion of the Con A/Glycogen layers, 
primarily due to the binding of mannose moieties in Man and HIV-1 rgp120 to Con A. This 
competitive binding is possible due to the preference of Con A for mannose
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Table 5-1:  FDA similarity and dissimilarity factors for TFV release from 𝐶+𝑀𝑅𝑃 (1L, 2L and 3L)a. 
 aThe number of Con A layers (1, 2 and 3) in the 𝐶+𝑀𝑅𝑃 formulations are referred to as 1L, 2L and 3L, respectively.  
Release conditions 1L  2L  3L 
f1 f2  f1 f2  f1 f2 
SFS:VFS (4.5V:1V) NA NA  NA NA  NA NA 
Man (100 μg/ml) 80.04 36.39  51.11 46.75  NA NA 
Man (1000 μg/ml) NA NA  NA NA  69.33 20.43 
HIV-1 rgp120  (25 μg/ml) 51.86 49.31  30.99 67.64  NA NA 
HIV-1 rgp120 (50 μg/ml) 56.67 46.42  49.50 52.10  NA NA 
HIV-1 rgp120 (100 μg/ml) 67.46 40.60  62.68 48.03  15.58 77.62 
HIV-1 rgp120 (500 μg/ml) NA NA  NA NA  33.46 47.95 
HIV-1 rgp120 (1000 μg/ml) NA NA  NA NA  67.68 22.20 
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Table 5-2: Kinetic models describing TFV in vitro release profiles from 𝐶+𝑀𝑅𝑃 (3L)a. 
aThree Con A  inlayers containing 𝐶+𝑀𝑅𝑃 is referred to as 3L. 
 
Zero order  First order  Higuchi  Hixson–Crowell  Hopfenberg 
K0 
(μg/min) 
r2  
K1 
(min-1) 
r2  
KH 
(μg/min) 
r2  
Kβ 
(min-1) 
r2  
      K2 
(µg.µm-2.min-1) 
r2 
SFS/VFS 
(4.5v/1v) 
0.014 0.36  0.0002 0.36  0.8 0.56  0.0001 0.97  0.0002 0.97 
Man 
(1000 μg/ml) 
0.054 0.55  0.0003 0.51  2.78 0.69  0.0008 0.97  0.0019 0.95 
HIV-1 rgp120 
(1000 μg/ml) 
0.01 0.05  0.00007 0.06  0.83 0.16  0.0005 0.78  0.0009 0.79 
HIV-1 rgp120 
(500 μg/ml) 
0.042 0.60  0.0005 0.52  2.18 0.79  0.0003 0.96  0.0004 0.97 
HIV-1 rgp120 
(100 μg/ml) 
0.013 0.25  0.0003 0.22  0.75 0.42  0.0004 0.94  0.0005 0.94 
  
105 
   
compared to glucose.370 As a result, 𝐶+𝑀𝑅𝑃 coating undergo a degradation, exposing TFV 
loaded CaCO3 core particle to calcium chelating agents, such as citric acid and lactic acid, 
present in the seminal and vaginal fluid simulants. The calcium chelating property of citric 
acid and lactic acid has previously been established. Amaral et al.354 have shown that 10% 
citric acid has a greater chelating power compared to 17% EDTA. Citric acid concentration in 
seminal fluid varies from 300 mg/100 ml to 750 mg/100 ml and was 523 mg/100 ml in the 
present study.322 Although the primary role of citric acid in semen is not well understood; 
several studies have suggested that it plays a major role in preventing the premature 
capacitation of sperm by chelating calcium ions in the seminal fluid.371 In the present study, 
citric acid chelates calcium ions from CaCO3 core particles contributing to core dissolution and 
enhanced drug release. This was further proved by exposing 𝐶+𝑀𝑅𝑃 to citric acid and lactic 
acid free DI water with no quantifiable drug release observed, up to 24 h (figure 5-11). In 
contrast, 6% [~14 µg/ml] of TFV was released in vaginal fluid simulant alone, probably due 
to its lactic acid content 200 mg/100 ml.321 This non-specific drug release observed in vaginal 
fluid could potentially provide a basal drug level and a protecting barrier against HIV-1 vaginal 
infection.  
In regard to results obtained with Hixson–Crowell and Hopfenberg kinetic models, 
𝐶+𝑀𝑅𝑃 was optimized by decreasing the number of Con A layers in 𝐶+𝑀𝑅𝑃 formulation. 
Thus, one (1) and two (2) Con A layers containing formulations (1L & 2L) were prepared and 
tested for TFV release at HIV-1 rgp120 concentrations ≤ 100 µg/ml (figure 5-12; 1L & 2L). 
For 𝐶+𝑀𝑅𝑃 (2L), a maximum drug release of 33% ± 3.9 [77.8 µg/ml] was observed in the 
presence of Man. Although up to 28% ± 1.8 [66.88 µg/ml] and 22% ± 1.7 [52.5 µg/ml] drug 
release were observed for 50 and 25 µg/ml HIV-1 rgp120, respectively; statistically significant 
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drug release was only obtained for 100 µg/ml HIV-1 rgp120, compared to control blank vaginal 
and seminal fluids mixture (SFS:VFS) (Table 5-1). Nonetheless, TFV levels released from 
𝐶+𝑀𝑅𝑃 (2L) at 50 and 25 µg/ml HIV-1 rgp120 were therapeutically relevant (cumulative drug 
released at 2 h ranged from 35.83 to 45.38 µg/ml), given that TFV EC50 values range from 
0.021 to 4.4 µg/ml. Upon testing 𝐶+𝑀𝑅𝑃 (1L), compared to SFS:VFS release profile, 
 
Figure 5-12: TFV release profiles from 𝐶+𝑀𝑅𝑃 (2L & 1L) in the presence of Man (1000 
μg/ml) and HIV-1 rgp120. 
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significant drug release was achieved for all three HIV-1 rgp120 concentrations (≤ 100 µg/ml) 
with a slight increase in cumulated TFV released (Table 5-1). This difference in drug release 
profile, relative to the number of Con A layers in 𝐶+𝑀𝑅𝑃 formulation (decreased layer 
thickness), was consistent with the diminishing surface or matrix eroding drug particles, as 
explained above. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5-13: 𝐶+𝑀𝑅𝑃 mucoadhesion to porcine vaginal tissue (A) with corresponding thin 
sections fluorescent images (B). 
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Bioadhesion. 𝐶+𝑀𝑅𝑃 (1L, 2L and 3L) mucoadhesion was tested ex vivo on porcine 
vaginal tissue. Previous studies have demonstrated strong similarities between porcine vaginal 
and human vaginal tissues. These similarities are found in: histology, ultrastructural 
organization, lipid composition, secretions, pH and inflammatory responses.372 The similarity 
between both tissues was also shown to translate into strong correlations between ex vivo 
studies on porcine vaginal tissue and human vaginal tissue.326 When exposed to porcine vaginal 
tissue, 𝐶+𝑀𝑅𝑃 showed mucoadhesion ranging from 10% ± 1 to 21% ± 2 (figure 5-13A). 
Porcine tissues images also showed FITC labeled 𝐶+𝑀𝑅𝑃’ green fluorescence onto tissues 
surface (figure 5-13B). 𝐶+𝑀𝑅𝑃 mucoadhesion was attributed to the presence of Con A in the 
self-assembly. Numerous studies have shown that Con A significantly improves mucoadhesion 
of drug delivery systems.373-375 Lectins, such as Con A, increase bioadhesion by binding to 
carbohydrates and glycans in glycoproteins found on mucus layer.376, 377  
 
5.4 Conclusion 
HIV-1 gp120 and mannose responsive microbicide drug delivery system (MRP) was 
prepared through the layer-by-layer deposition of Con A and glycogen onto a CaCO3-PSS core 
particle. Tenofovir is encapsulated in CaCO3 and the encapsulation efficiency is 74.4%.  TFV 
was successfully loaded in MRP owing to CaCO3 phosphate binding properties and the 
coprecipitation process involved in CaCO3 crystallization. TFV loading efficiency in core 
containing MRP (𝐶+𝑀𝑅𝑃) and core removed MRP (𝐶−𝑀𝑅𝑃) are 16.3% w/w and 6.0% w/w, 
respectively. It is determined that 𝐶−𝑀𝑅𝑃, prepared through the layer-by-layer method 
followed by EDTA core dissolution, is cytotoxic to vaginal keratinocytes (VK2) and murine 
macrophage (RAW 264.7) cells at concentrations higher than 10 μg/ml. That is, 𝐶−𝑀𝑅𝑃 might 
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not be appropriate for vaginal or rectal drug delivery. However, 𝐶+𝑀𝑅𝑃 is non-cytotoxic to 
both VK2 and macrophage RAW 264.7 cells and does not induce any significant changes in 
pro-inflammatory cytokines or nitric oxide levels in 24h. Moreover, 𝐶+𝑀𝑅𝑃 was non-
cytotoxic to L. crispatus, suggesting a safe and suitable template for future in vivo testing. 
HIV-1 rgp120 triggered TFV release from 𝐶+𝑀𝑅𝑃 in a concentration dependent manner, 
which followed Hixson–Crowell and Hopfenberg kinetic models, consistent with diminishing 
surface or matrix eroding drug particles. 𝐶+𝑀𝑅𝑃 also showed significant mucoadhesion to 
porcine vaginal tissue, ex vivo. The one Con A layer containing 𝐶+𝑀𝑅𝑃 system was found to 
be the most sensitive (~2-fold increase in drug release vs. control SFS:VFS) at the lowest HIV 
gp120 concentration tested (25 µg/mL). Altogether, this study strongly suggests that 𝐶+𝑀𝑅𝑃 
formulation of TFV might be suitable for further in vivo toxicity, retention and efficacy testing. 
One of the limitations of this study is the use of reported in vitro HIV gp120 concentrations as 
basis for the in vitro optimization. Although HIV gp120 seminal and vaginal fluid 
concentrations are not well studied, Oh et al. reported HIV gp120 concentration in majority of 
HIV/AIDS patients’ sera in the range of 0.1-0.8 nM.111 Moreover, in its unbound state, Con A 
was reported to be unstable at 37 °C.112 However,  it is unclear how the lectin behaves in the 
𝐶+𝑀𝑅𝑃 system, given that Con A denaturation in the presence of carbohydrate ligands is 
reported to vary between 91 °C and 96 °C.113 Therefore, future studies will investigate MRP’s 
stability and sensitivity optimization with respect to clinically relevant HIV gp120 
concentrations. 
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CHAPTER 6 
IN VIVO PRECLINICAL SAFETY EVALUATION OF A MICROBICIDE LOADED  
HIV-1 gp120 TARGETED VAGINAL FORMULATION IN FEMALE MOUSE 
REPRODUCTIVE TRACT 
 
6.1 Introduction and rationale 
In the past decades, numerous microbicides candidates have been proposed in the 
attempt to address HIV sexual transmission, with marginal success. Some of the microbicide 
formulation tested include gels, films and intravaginal ring.73 Some of the most publicized 
microbicide clinical trials, such as CAPRISA 004, FACTS 001, VOICE, FAME-02 and 
CONRAD 128, have either failed due to safety concerns or remained to demonstrate their 
effectiveness in human.69, 71, 72, 378 For example, two first generation microbicide formulations, 
Nonoxynol-9 (N-9) and Cellulose Sulfate (CS) have failed to protect against HIV sexual 
transmission due to major safety issues, including mucosal inflammation and increase in pro-
inflammatory mediators, which ultimately increased the risk of HIV infection.379 Furthermore, 
the VOICE study did not show any efficacy and was stopped early due to epithelial damage.380 
Likewise, CAPRISA 004 trial showed that innate immunity activation increases HIV 
acquisition.381 Nonetheless, these studies have greatly informed the scientific community and 
laid down the standards in microbicide research and testing.  
 As explained in chapter 2, it is widely accepted that physical damage to vaginal mucosa 
substantially increases vaginal susceptibility to HIV infection.42 An inflammation of the 
vaginal mucosa could lead to an increase in HIV infection by promoting the recruitment of 
HIV target cells, such as macrophages, CD4+ T cells, monocytes, natural killer cells and 
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dendritic cells at the site of inflammation.382 In addition, the ability of  pro-inflammatory 
cytokines to enhance HIV vaginal infectivity has been widely studied.383 Furthermore, the 
normal vaginal microbiota, dominated by Lactobacillus species, is known to provide an 
inherent antimicrobial protective layer in adult women compared to prepuberal girls and 
postmenopausal women.384 This is primarily due to the breakdown of glycogen into lactic acid, 
which maintains the vaginal acidic pH in adult women, as well as H2O2 production by 
Lactobacillus species, such as L. crispatus and L. jensenii.41, 51, 52 Therefore, the in vivo safety 
evaluation of vaginal microbicide formulations is of paramount importance to ensure, not only 
their suitability for the desired application, but ultimately to assess any potential adverse 
effects, such as vaginal mucosa damage, inflammations, irritations, localized and/or systemic 
toxicity, as well as any compromise of the vaginal microbiota.73  
The potential of lectins, a class of carbohydrate binding proteins, to prevent HIV 
infection has long being contemplated.85 Lectins primarily exert their antiviral activity by 
recognizing and binding major glycan structures onto HIV surface. Considering the selectivity 
of mannose binding lectins to HIV gp120, we have previously reported a layer-by-layer 
engineered, lectin-based microbicide drug delivery system targeting HIV‑1 gp120, for the 
prevention of HIV sexual transmission.383 Major physicochemical and biological properties of 
the proposed HIV-1 gp120 and mannose responsive particles (𝐶+𝑀𝑅𝑃) were also discussed. 
In the present study, we investigate the preclinical safety of Tenofovir (TFV) loaded 𝐶+𝑀𝑅𝑃 
in C57BL/6 mice model. If successful, this study may represent a major advance in lectin-
based microbicide formulation for the prevention of HIV sexual transmission. 
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Figure 6-1: Model of HIV vaginal infection following mucosal disruption (b) from an intact 
mucosal layer (a).382 
 
6.2 Material and methods 
Reagents  
The following reagents were purchased from Sigma-Aldrich (St. Louis, MO, USA); 
Concanavalin A (Con A) from Canavalia ensiformis (Jack bean) type VI, glycogen from 
Oyster, polyethylenimine (PEI) 50 wt. % solution in water, poly(sodium 4-styrenesulfonate) 
(PSS) average Mw ~70.000 powder, calcium chloride dehydrate (CaCl2•2H2O, ACS reagent, 
≥99%), sodium carbonate anhydrous (≥99%), fluorescein isothiocyanate labeled Concanavalin 
A (FITC-Con A) type IV lyophilized powder, tetramethylrhodamine isothiocyanate–Dextran 
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(TRITC-Dextran), manganese (II) chloride tetrahydrate (MnCl2.4H2O, Reagent Plus, ≥99%), 
methyl α-D-mannopyranoside (Man) (≥99%), Benzalkonium chloride (BZK, 2 %v/v), Crystal 
Violet, Phosphate Buffered Saline (PBS) pH 7.4 and Tris Buffer Saline (TBS) pH 8.0. 
Fluorescein Isothiocyanate Isomer I (FITC) 90% pure ACROS Organics™ was purchased 
from Thermo Fisher Scientific (Waltham, MA, USA). Tenofovir (TFV) (99%) was purchased 
from Zhongshuo Pharmaceutical Co. Ltd. (Beijing, China). Medroxyprogesterone acetate 
(Depo-Provera®) was purchased from Greenstone, (Peapack, NJ, USA). Nonoxynol-9 (N-9, 
Conceptrol®) was from Revive Personal, (Madison, NJ, USA). Human Immunodeficiency 
Virus type 1 recombinant envelope glycoprotein (HIV-1 rgp120) is purchased from Sino 
Biological Inc. (Beijing, P. R. China). All other chemicals were reagent grade and used without 
further purifications. 
 
Methods 
Layer by layer preparation of 𝑪+𝑴𝑹𝑷  
As detailed in chapter 5, 𝐶+𝑀𝑅𝑃 was prepared by successively coating a calcium 
carbonate (CaCO3)/PSS core particle with PEI, Glycogen and Con A. Prior to preparing 
(CaCO3)/PSS, a saturated solution of TFV (3 mg/ml) was prepared in CaCl2. Then TFV loaded 
CaCO3/PSS was prepared by mixing equal volume (15 ml) of 0.2 M CaCl2/TFV and 0.2 M 
sodium carbonate (Na2CO3) in the presence of a dispersant (PSS). The mixture was vigorously 
stirred at 13,500 rpm for two (2) minutes with the IKA Ultra-Turax model T25 homogenizer 
(Wilmington, NC, USA). After an initial dispersion in PEI (4 mg/ml in 0.5 M NaCl, pH 8.0) 
for at least 30 minutes, particles were successively dispersed in Con A (1 mg/ml in TBS, pH 
8.0) and Glycogen (1 mg/ml in TBS, pH 8.0) solutions, at room temperature. After preparation, 
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𝐶+𝑀𝑅𝑃 was washed twice with DI water and freeze-dried for twelve (12) hours (Labconco 
FreeZone 1 Liter Benchtop Freeze Dry System, Kansas City, MO). Following freeze-drying, 
𝐶+𝑀𝑅𝑃 was kept in refrigeration at 4ºC. Particle mean diameter (size), zeta potential (ζ-
potential), polydispersity index (PDI), percent encapsulation efficiency (%EE) and loading 
efficiency (%LD) measurements were all conducted as explained in chapter 5. 
 
 Osmolality determination of the tested samples. Osmolality, a measure of the 
number of osmoles of solute per kilogram of solvent, is a critical parameter in vaginal and 
rectal microbicide formulation development.385 Various vaginal microbicide formulation 
candidates were thought to have failed due to their hyperosmolality nature.386, 387 In fact, 
hyperosmolar (> 400 mOsm/kg)388 vaginal formulations can cause brisk transudation of fluid 
across the cervico-vaginal epithelium which can result in increase vaginal wetness and watery 
discharges.386 Vaginal epithelial damage and increase HIV transmission have also been 
associated with hyperosmolar vaginal formulations385-387, 389 Furthermore, hyposmolar vaginal 
formulations increase water uptake in epithelial cells, which can lead to vaginal dehydration, 
vaginal lesions, and epithelial cells’ rupture (figure 6-2).  Ideally, a microbicide formulation 
candidate should be isosmolar (280 - 400 mOsm/Kg).390, 391 Before mice treatments, samples 
osmolality was determined on a Vapor Pressure 5520 Osmometer (Wescor, Inc., UT, USA). 
The instrument was calibrated following the Maximum Calibration Accuracy protocol using 
the 100 mOsm/kg standard and according to the manufacturer instructions. Typically, a single 
1/8″ solute-free Whatman No.1 sample disc (Wescor, Inc., UT, USA) was placed onto the 
sample slide and 20 microliters of sample was allowed to fully cover the filter paper. The 
sample holder was then inserted into the instrument and the osmolality measurement conducted 
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for 80 s. Samples were measured in triplicates and average osmolality values recorded in 
mOsm/kg. 
 Figure 6-2: Vaginal epithelial layer in different osmolality conditions 
 
In Vivo safety evaluation of 𝑪+𝑴𝑹𝑷 in mice Model.  
𝐶+𝑀𝑅𝑃 in vivo safety evaluation was conducted following an approved University of 
Missouri - Kansas City Institutional Animal Care and Use Committee (IACUC) animal 
protocol, and according to methods described in previous publications.392, 393 Briefly, 𝐶+𝑀𝑅𝑃 
safety was evaluated on 8-12 weeks old female C57BL/6 mice with an average body weight 
of 20 g. C57BL/6 mice, known for their easy breeding and robustness, were obtained from 
Jackson Laboratories (Harbor, ME) and allowed to acclimate for 7 days. Mice were housed 
(maximum of 5 per cage) in the UMKC Laboratory Animal Resource Center (LARC) under a 
12 h light/dark regime. UMKC’ LARC is a fully AAALAC (the Association for Assessment 
and Accreditation of Laboratory Animal Care) accredited with HEPA-filtered, temperature, 
humidity, and lighting control systems.  
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Mouse vaginal cytology 
Unlike in humans, where the menstrual cycle last approximately 28 days, in female 
mice, the reproductive cycle (estrous cycle) lasts about 4-5 days and is divided into four main 
stages (proestrus, estrus, metestrus, and diestrus)  (figure 6-3).394 The proestrus stage, which 
represents the pre-ovulatory day, is characterized by the predominance of nucleated epithelial 
cells, which can appear in cluster or individually. In this stage occasional cornified epithelial 
cells may appear (figure 6-3A). As the estrous cycle advances to the estrus stage, cells may 
 
 
 
 
 
 
 
 
 
 
 
Figure 6-3: Mouse vaginal cytology representing each stage of estrous. The stages of estrous 
include proestrus (A), estrus (B), metestrus (C), diestrus (D). Three cell types are identified: 
leukocytes (circle), cornified epithelial (black arrow), and nucleated epithelial (white arrow).394 
  
117 
   
appear (figure 6-3A). As the estrous cycle advances to the estrus stage, cornified squamous 
epithelial cells, which occur in cluster, become predominant (figure 6-3B). Following the 
estrus stage (figure 6-3C), the metestrus stage will begin if the cycle is not interrupted by 
pregnancy, pseudopregnancy, or other phenomena. The mestrus stage is relatively brief and 
characterized by a mix of polymorphonuclear leukocytes and a few nucleated epithelial and/or 
cornified squamous epithelial cells. Diestrus (figure 6-3D) is the last and longest stage, lasting 
for more than 2 days. Vaginal swabs during diestrus show primarily polymorphonuclear 
leukocytes and a few epithelial cells during late diestrus. In this stage, leukocytes remain the 
predominant cell type after removing cellular debris.394, 395 
 
General protocol for mice treatment with 𝑪+𝑴𝑹𝑷 
In the current study, mice were maintained in a constant diestrus-like vaginal cytology 
state, for reproducible experimental conditions and to avoid variability in vaginal histology 
data analysis. Thus, mice were subcutaneously injected with 2 mg of medroxyprogesterone 
acetate (Depo-Provera®, Greenstone, Peapack, NJ, USA) in 200 μl of Lactated Ringer’s saline 
solution, 4-5 days prior to 𝐶+𝑀𝑅𝑃 exposure. To further confirm the diestrus-like state, vaginal 
cytology analysis was performed by visualizing nucleated and cornified squamous epithelial 
cells and polymorph nuclear leukocytes.396 Once the diestrus-like state was achieved, mice 
were divided in 4 groups (n=3). Group 1 and 2 were treated with N-9 (4% w/v) and BZK (2% 
v/v), respectively, and were used as positive control groups. N-9 and BZK were used as 
positive control because their toxic effects on genital tract are well established.397, 398 Group 3 
was treated with PBS and taken as negative control. Group 4 represented the treatment group 
and was exposed to freshly prepared 𝐶+𝑀𝑅𝑃 at a dose of 100 mg/kg corresponding to TFV 
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Table 6-1: Selected physico-chemical and biological properties of formulations tested. 
Treatment 
formulation 
API  
Physico-chemical properties 
API 
Toxicology 
API 
PK 
Formulation properties 
𝑪+𝑴𝑹𝑷 
Suspension 
Tenofovir 399, 400 
MW: 287.21 Da 
pKa : 3.8 
LogP: -1.6 
IC50: 1.81 µM 
401 
EC50: 0.021 
μg/mL402 
LD50: 2.49 mol/kg
403 
Cmax:  247.87 ng/mL 404 
Tmax:  0.87 h 
AUC: 2.11 µg∙hr/mL 
T1/2: 20.45 h 
Dose: 100 mg/kg  
Size: 857.8 nm 
ζ-potential: +2.37 mV 
%EE: 70.1% 
%LD: 16.3% 
Osmol: 304.33 mOsm/kg 
N-9 solution 
Nonoxynol-9 405, 406 
MW: 616.82 Da 
pKa: 15.12 
LogP: 4.02 
IC50: 2 µg/ml 
407 
EC50: 81 µM 
408 
LD50: 2.24 mol/kg 
406 
 
Cmax: 4.87 ng/mL 409 
Tmax: 1h 
AUC: 9.89 ng∙hr/mL 
T1/2: 1.45 h 
Dose: 4% w/v  
ζ-potential: -27 mv 
Osmol: 745.33 mOsm/kg 
BZK 
solution 
Benzalkonium Chloride 410, 411 
MW: ~ 375 Da 
pKa: 12.77 
LogP: 5.98 
IC50: ND 
EC50: < 0.025% 
412 
LD50: 150 mg/kg 
 
 
ND 
Dose: 2% v/v  
ζ-potential: +25.14 mV 
Osmol: 382.2 mOsm/kg 
(n = 7-18) 
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dose of 16.3 mg/kg. 𝐶+𝑀𝑅𝑃 exposure was conducted up to 24 h before mice are euthanized 
by carbon dioxide (CO2) asphyxiation [70% (v/v) CO2 and 30% (v/v) O2]. Following animal 
sacrifice, vaginal tissues were collected, formalin fixed, embedded in paraffin, cut into 5-mm 
sections and analyzed, according to standard tissue processing procedures.  
 
Hematoxylin and eosin (H&E) staining 
To assess histopathological parameters such as epithelial cells morphology, cell 
populations and possible erosion in epithelial cell layer, mice reproductive system’ (vagina, 
cervix, fallopian tube, uterus and ovary) tissue sections were stained with hemotoxylin and 
eosin (H&E) (Sigma, Saint Louis, MO, USA). Stained tissue section were visualized on Nikon 
Labophot-2 microscope (Nikon Instruments, Inc., Melville, NY, USA) equipped with a 
PAXCam digital microscope camera and PAX-it! image management and analysis software 
(version 7.9, Midwest Information Systems, Inc., Villa Park, IL, USA). 
 
Immunohistochemical staining 
Immunohistochemistry staining was perform on vaginal tissue section to identify 
possible inflammation of mice genital tract following 𝐶+𝑀𝑅𝑃 treatment (24 h). It is generally 
accepted that an increased lymphocytes infiltration within the vagina epithelium is indicative 
of vaginal inflammation.413, 414 Furthermore, CD45, a receptor-linked protein, is a 
lymphocyte common antigen.415 Therefore, lymphocyte infiltration was assessed by staining 
the tissue using a primary anti-CD45 antibody and following the method described in 
immunohistochemistry protocol (ImmunoCruzTM mouse ABC Staining System, Santa Cruz 
Biotechnology, Dallas, TX, USA). Briefly, paraffin-embedded vaginal tissue sections were 
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deparaffinized and rehydrated in xylene, decreasing ethanol gradient (100%, 90%, and 70%) 
and deionized water. Antigen retrieval method was then conducted using heat steam method 
in citrate buffer/0.05%Tween-20 for 20 min. Tissue slides are further rinsed three times with 
TBS/0.05%Tween-20, incubated in 3% v/v H2O2 in PBS for 10 min, and blocked with 10% 
normal goat serum for 2 h (Vector Laboratories, Burlingame, CA, USA). Following the 
blocking step, vaginal tissue slides are incubated in the primary Anti-CD45 antibody (Santa 
Cruz Biotechnology, Inc., Dallas, TX, USA) diluted in 1.5% normal goat serum to 5 µg/mL. 
Slides were incubated overnight at 4 °C in a humidified chamber, rinsed with PBS and 
incubated in the biotinylated secondary antibody solution (5 µg/mL, Santa Cruz 
Biotechnology, Inc., Dallas, TX) at room temperature for 1 h. Tissues are then visualized using 
the DAB: Peroxidase Substrate Kit on Nikon Labophot-2 microscope (Nikon Instruments, Inc., 
Melville, NY, USA). Tissues were counter-stained with hematoxylin and treated with alcohol 
gradient and xylene before application of a coverslip mounted using cytoseal 60 mounting 
media (Richard Allan Scientific, Kalamazoo, MI).392, 393 
 
 Cytokines secretion in mice cervicovaginal lavage (CVL) and cervicovaginal tissue 
Following mice treatment with 𝐶+𝑀𝑅𝑃, cervicovaginal lavage fluid (CVL) and 
cervicovaginal (CV) tissue were collected after 24 h and analyzed for pro-inflammatory 
cytokines secretion. Thus, IL-1α, IL-1β, IL-6, Interferon gamma-induced protein 10 (IP-10), 
IL-7, tumor necrosis factor-alpha (TNF-α) and mice keratinocyte-derived chemokine (MKC) 
levels were determined using a high-sensitivity multiplexed bead-based immunoassay 
(Milliplex MAP Mouse Cytokine/Chemokine Magnetic Bead Panel, Millipore Corp., Billerica, 
MA; and Luminex MAGPIX instrument, Luminex Corp., Austin, TX, USA).319 Briefly, crude 
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vaginal lavage was performed by flushing mouse vaginal tract twice with 50 μL of PBS. The 
vaginal lavage was then centrifuge at 1000 rpm for 10 min at 4 °C, and the supernatant (CVL) 
was collected. After the vaginal lavage was collected, mice were euthanized by CO2 
asphyxiation and the CV tissues were collected. When not being used, CV tissues and CVL 
samples were stored at -20ºC to avoid any cytokines denaturation. For CV tissue extraction 
purposes, the homogenization buffer was prepared by mixing the protease inhibitors cocktail 
(Sigma, St. Louis, MO, USA) with the Tissue Extraction Reagent I (Invitrogen, Carlsbad, CA, 
USA). CV tissues samples were further homogenized in the homogenization buffer at 100 
mg/mL using the Omni Homogenizer (Omni International, Kennesaw, GA, USA) at full speed. 
For maximized protein extraction ,CV tissue homogenates were kept on ice for 1 h and tissue 
debris were further removed by centrifuging the extract cocktail at 14,000 rpm, for 15 min at 
4ºC. The supernatant was then collected and kept on ice. The extraction medium was used as 
matrix solution, and cytokines level were assayed from CV tissue extracts and CVL following 
the manufacturer protocol on Luminex MAGPIX instrument equipped with xPONENT® 
version 4.2 software (Luminex Corp., Austin, TX), as described in chapter 5. Thus, pre-mixed 
magnetic beads conjugated to antibodies for all 7 cytokines analytes were mixed with equal 
volumes (25 μl) of CV tissue extract and CVL supernatant (25 μl) in 96-well plates. Plates 
were protected from light and incubated on a microplate shaker overnight at 4 °C. Then, 
magnetic beads were washed twice with 200 μl of washing buffer. The detection antibodies 
were added to each well and the mixtures incubated at room temperature for 1 h. Streptavidin-
phycoerythrin conjugate compound was added to each well, and the mixtures were incubated 
for an additional 30 min at room temperature. The magnetic beads were subsequently washed 
and resuspended in the washing buffer for 5 min. Plates were then assayed on the Magpix 
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system with Luminex xPONENT software (version 4.2, Austin, TX). Median fluorescence 
intensities were analyzed using a 5-parameter logistic method from a standard curve of 
respective analytes to determine cytokines concentration in the supernatants. All assays were 
conducted in duplicate.383, 392 
 
Bio-retention of FITC labelled 𝑪+𝑴𝑹𝑷 in mouse genital tract 
 𝐶+𝑀𝑅𝑃 bio-retention in mice vaginal tract was assessed by treating C57Bl6 female 
mice with FITC labeled 𝐶+𝑀𝑅𝑃 at a concentration of 25 mg/kg. FITC labeled 𝐶+𝑀𝑅𝑃 bio-
retention in mice vaginal tract was studied at two different time points (15 min and 24 h), and 
data were compared to FITC labeled 1% hydroxyethycellulose (HEC) gel at the same time 
points. Post exposure, animals were sacrificed and the vaginal tract was removed, opened 
lengthwise and mounted on microscope glass slides. Fluorescence images of vaginal tissues 
were further acquired on Nikon Labophot-2 microscope (Nikon Instruments, Inc., Melville, 
NY, USA) equipped with PAXCam digital microscope camera and PAX-it! image 
management and analysis software (version 7.9, Midwest Information Systems, Inc., Villa 
Park, IL, USA).   
 
6.3 Results and discussion 
Figure 6-4 summarizes 𝐶+𝑀𝑅𝑃 average particle size (diameter), surface charge density 
(ζ-potential) and morphology information. Single Con A layer containing 𝐶+𝑀𝑅𝑃 formulation 
was previously shown to have a better in vitro mucoadhesion and an optimal drug release 
profile at low HIV-1 rgp120 concentrations (25 μg/ml).383 Therefore, a single Con A and 
glycogen layers containing 𝐶+𝑀𝑅𝑃 formulation was prepared and tested in this study. 𝐶+𝑀𝑅𝑃 
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Figure 6-4: 𝐶+𝑀𝑅𝑃 average particle size (A), surface charge density (B) and SEM imaging 
(C). SEM image scale bar is 2 μm. 
 
average particle size was 857.8 ± 93.1 nm (n=3) (figure 6-4A) with a polydispersity index of 
0.166. Although rarely attained with conventional layer-by-layer preparation techniques, PDI 
value lower than 0.05 is characteristic of monodispersed samples.416 Nonetheless, PDI value 
of 0.1 to 0.7 represents nearly monodisperse preparation, whereas PDI > 0.7 suggests broadly 
distributed samples.417 The ζ-potential was 2.37 ± 4.12 mV (figure 6-4B), characteristic of a 
neutrally charge nanoparticle formulation.418 The neutral charge was probably due to the 
presence of glycogen onto 𝐶+𝑀𝑅𝑃 surface. The SEM image (figure 6-4C) shows CaCO3 
particles covered with a distinctive, smooth layer of Con A/glycogen. The feature was similar 
to previously reported 𝐶+𝑀𝑅𝑃 particles.383 Furthermore, particle size approximated from SEM 
imaging (~800 nm, n=10) was consistent with DLS size measurements data.  
 Owing to CaCO3 phosphate binding properties and the co-precipitation process 
inherent to CaCO3 crystallization, TFV was encapsulated in 𝐶+𝑀𝑅𝑃 at 70.1%. TFV drug 
loading in 𝐶+𝑀𝑅𝑃 was determined to be 16.3% w/w. The ability for phosphate binders, such 
  
124 
   
as CaCO3, to form stable complex with phosphate containing molecules has previously been 
demonstrated and used as drug entrapment strategy.419-421  
The normal osmolality of vaginal and seminal secretions range between 250–380 
mOsm/kg and vaginal microbicide candidates’ osmolality should not exceed 400 mOsm/kg.321, 
322, 390 Hyperosmolar vaginal formulations are known to induce vaginal epithelial damage and 
increase the rate and extent of watery discharges.386, 389 𝐶+𝑀𝑅𝑃 osmolality was 304.33 ± 0.58 
mOsm/kg and was similar to normal osmolality recorded for vaginal and seminal secretions. 
Thus, 𝐶+𝑀𝑅𝑃 is not expected to induce any pronounce vaginal discharge or epithelial damage. 
PBS, N-9 and BZK osmolality were were 295 ± 0, 745.33 ± 45 and 482.2 ± 6.12 mOsm/k, 
respectively. In addition, mice behavior, body weight and temperature were evaluated daily 
during 𝐶+𝑀𝑅𝑃 treatment and no significant alterations were noted. 
 In order to confirm the diestrus-like state of mice treated with Depo-Provera; mice CVL 
were constantly collected, for up to 9 days, and analyzed for evidence of nucleated and 
cornified squamous epithelial cells and polymorph nuclear leukocytes. After each collection, 
CVL was stained with crystal violet and images showed a maintained diestrus-like state in 
treated mice, starting from day 3 (figure 6-5).  Control mice (not treated with Depo-Provera) 
showed distinctive changes in the estrous cycle with different cell types at different days 
(figure 6-5). In fact, in non-treated mice’s CVL, image acquired on days 1 showed evidence of 
predominantly nucleated epithelial cells, with some cornified squamous epithelial cells, these 
features are characteristic of the proestrus stage of the estrous cycle. Similar features were also 
noticeable in the Depo-Provera treated group on day 1. On day 2, a mixture of cornified 
squamous epithelial cells and leukocyte cells were visible in non-treated mice CVL, 
characteristic of the late estrus and metestrus stages of the estrous cycle. These cell types 
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Figure 6-5: Vaginal cytology assessment of the estrous stages in Depo-Provera treated and 
non-treated mice. Three cell types are identified: leukocytes (blue circle), cornified epithelial 
(red arrow), and nucleated epithelial (white arrow). 
 
remained visible on day 3 in non-treated mice CVL. On day 4, nucleated epithelial cells, 
cornified squamous epithelial cells and leukocytes were all visible in non-treated mice CVL, 
characteristic of diestrus-like stage, of the estrous cycle. As shown in figure 6-5, leukocytes 
were predominatly present in the Depo-Provera treated group from day 3 through 9, which 
confirmed the constant diestrus-like state in that group.394, 395  
When mice were treated with 𝐶+𝑀𝑅𝑃 for 24 h, histology analysis (figure 6-6) of 
reproductive organs (vagina, cervix, uterus, ovary and fallopian tube) did not show signs of 
abrasion of epithelial cell layer. In fact, the thickness of the vaginal epithelial cell layer (dark 
purple) was maintained in 𝐶+𝑀𝑅𝑃 treated mice and was comparable to the negative control 
(PBS) treated mice in all the reproductive organs analyzed. Similar observations were also 
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made in cervix, uterus, ovary and fallopian tube tissues. However, visible signs of epithelial 
damage, including thinning and stripping were noticeable in the positive control (N-9 and 
BZK) groups. These observation suggested that 𝐶+𝑀𝑅𝑃 treatment does not lead to an abrasion 
of the vaginal epithelial cell layer. 
 
Figure 6-6: Histology (H&E staining) of mouse reproductive organs’ tissues following 
treatment with 𝐶+𝑀𝑅𝑃 for 24 h. Thinning and stripping of epithelial cell layer in positive 
controls is indicated by red arrows. 
  
 Immunohistochemistry analysis of vaginal tissue sections revealed minimal (not 
significant) CD45+ cells infiltration in the epithelial cell layer of 𝐶+𝑀𝑅𝑃 treated mice. In fact, 
the leukocyte infiltration observed in 𝐶+𝑀𝑅𝑃 treated mice was similar to the one observed in 
PBS treated mice, suggesting that this may not be directly related to 𝐶+𝑀𝑅𝑃.  
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 Figure 6-7: Immunohistochemistry evaluation of vaginal tissue sections following treatment 
with 𝐶+𝑀𝑅𝑃 for 24 h. Black boxes indicated by red arrows show significant leukocyte (CD45+ 
cells) infiltration. 
 
In contrast, positive controls (N-9 and BZK) treated mice showed significant 
leukocytes infiltration in the vaginal epithelial cell layer (figure 6-7). These 
immunohistochemistry observations were consistent with the histology (H&E) observations. 
Thus, 𝐶+𝑀𝑅𝑃 does not induce major vaginal tissue inflammation in mice for up to 24 h. 
 A direct correlation between pro-inflammatory cytokine release and HIV vaginal 
infection/replication has been established.422-424 For example, binding of IL1 (α and β) to its 
receptor, IL1R1, results in an upregulation of other pro-inflammatory cytokines (TNFα, IL6 or 
IL8) release.357, 358 Many reports have also associated TNFα with an increase in HIV 
replication.359, 360 The pro-inflammatory cytokine IL7 is also known to facilitate HIV infection 
by prolonging the life of infected cells and preventing apoptosis of non-infected CD4+ T 
cells.362 Likewise, IL6 and IL8 have been shown to induce an upregulation in HIV  
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Figure 6-8: Pro-inflammatory cytokines (IL1α, IL1β, IL6, IL7, IP10, MKC and TNFα) levels measured in mice cervicovaginal 
lavage and vaginal tissue extract, following 𝐶+𝑀𝑅𝑃 treatment for 24 h, at a dose of 100 mg/kg.  Values are computed from triplicates 
(n=3 animals). One-way anova test is performed in GraphPad (version 6.0) to determine statistical signifiance. * (P ≤ 0.05) shows 
statistically significant difference from the negative control (PBS treated group). NS indicates non-significance (P > 0.05). 
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replication.425, 426 Furthermore, interferon-γ-inducible protein 10 (IP10) stimulates HIV 
replication by attracting activated T lymphocytes and monocytes.363, 364 Thus, vaginal HIV 
microbicide formulations should not induce an increase in pro-inflammatory cytokines’ 
level.427 In this study, seven (7) pro-inflammatory cytokines including, IL1α, IL1β, IL6, IL7, 
IP10, TNFα, as well as, the mouse functional analogue of human IL-8, MKC are evaluated in 
𝐶+𝑀𝑅𝑃 treated mice cervicovaginal lavage and vaginal tissue extract. As summarized in 
figure 6-8, no significant difference in pro-inflammatory cytokines IL1α, IL1β, IL7, IP10 and 
TNFα levels was noticed between 𝐶+𝑀𝑅𝑃 treated mice and the negative control group (PBS). 
Although statistically significant increases were observed in IL6 and MKC levels in both the 
cervicovaginal lavage and vaginal tissue extract, these were nonetheless within their standard 
value ranges in accordance with the homeostasis state.69-73 With the absence of visible signs of 
inflammations in vaginal and major reproductive organs, the increase in both cytokines could 
be due to external factors not investigated in this study (e.g. time dependent body metabolism 
of individual animal). In fact, stress and the normal circadian rhythm have been associated with 
strong variation in cytokines’ level, even in healthy individuals.428-432 The relative safety of 
MRP formulation, compared to the positive controls, could be due, in part, to its 
biocompatibility. In fact, it was shown that implantable Con A-based biosensors for sugar 
detection do not cause any health risks at Con A concentration < 10 mg/ml.187 In addition, 
glycogen, which is used as the principal storage form of glucose (energy) in animal cells, is 
well known for its safety and biocompatibility.433, 434 Furthermore, MRP isosmolality (304.33 
mOsmo/Kg) might also explain its relative safety in C57BL/6 mice. Hyposmolar and 
hyperosmolar vaginal formulations can induce severe epithelial damage (vaginal lesions and 
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epithelial cells’ rupture) and discomforts (increased vaginal discharge or dehydration) which 
could result in pronounce HIV infection.386, 389, 390 
Figure 6-9 summarizes FITC labeled 𝐶+𝑀𝑅𝑃 distribution (retention) in mice vaginal 
tract. Although a significant short time retention was initially observed, only few FITC labeled 
𝐶+𝑀𝑅𝑃 particles were visible after 24 h. In fact, compared to FITC labeled HEC gel, the result 
shows a significantly low long-term vaginal retention of FITC labeled 𝐶+𝑀𝑅𝑃. Thus, in 
contrast to the in vitro findings on porcine vaginal tissue (chapter 5), FITC labeled 𝐶+𝑀𝑅𝑃 
does not have a long residence time in mice vaginal tract. This could be due to structural or 
physiological differences between both vaginal tissues. Moreover, FITC labeled 𝐶+𝑀𝑅𝑃 may  
 
 
 
 
 
 
 
 
 
Figure 6-9: Vaginal retention of FITC labeled 𝐶+𝑀𝑅𝑃 and HEC gel in mice after 24 h. 
𝐶+𝑀𝑅𝑃 was applied at a dose of 25 mg/kg. 
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leak out of mice vaginal tract due to the natural mucus renewal cycle.25 This result also suggest 
that a potential clinical use of 𝐶+𝑀𝑅𝑃 will probably require either a precoital or multiple 
vaginal applications to ensure enough 𝐶+𝑀𝑅𝑃 particles and TFV in the vaginal cavity capable 
of eliciting a desired HIV preventive activity.  
 
6.4 Conclusion 
 In this study, the preclinical safety of mannose and HIV-1 gp120 responsive 
microbicide drug delivery system (𝐶+𝑀𝑅𝑃) was investigated on C57BL/6 mice model. TFV 
loaded 𝐶+𝑀𝑅𝑃 was prepared through the layer-by-layer deposition of Con A and glycogen 
onto a CaCO3-PSS core particle. The microbicide formulation was delivered vaginally at a 
dose of 100 mg/kg in PBS, and vaginal histology, immunohistochemistry evaluations and pro-
inflammatory cytokines release were investigated after 24 h. The vaginal retention of FITC 
labeled 𝐶+𝑀𝑅𝑃 was also evaluated, up to 24 h. Vaginal and major reproductive organs’ 
histology did not show major damage of the epithelial layer. This result was also consistent 
with immunohistochemistry evaluation of CD45+ cells infiltration in the vaginal epithelial 
layer, unlike the positive control treated groups (BZK and N-9). Thus, no visible signs of 
inflammation were observable after 24 h exposure. Furthermore, Furthermore, no biologically 
significant increase was observed in all the pro-inflammatory cytokines tested. In addition, it 
was also observed that FITC labeled 𝐶+𝑀𝑅𝑃 does not have a long-term retention in mice 
vaginal tract. This result suggested that a precoital or multiple vaginal application (i.e., BID) 
approaches of 𝐶+𝑀𝑅𝑃 should be investigated. 
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CHAPTER 7 
SUMMARY AND FUTURE STUDIES 
 
7.1 Summary 
 Since its discovery in 1983, Human Immunodeficiency Virus infection and Acquired 
Immune Deficiency Syndrome (HIV/AIDS) has remained a global epidemic threat. 
Unfortunately, despite intensive global campaigns aimed at raising awareness among the most 
vulnerable communities, a complete cure and eradication strategy is yet to be effective against 
HIV/AIDS. In fact, according to the 2017 UNAIDS fact sheet, it is estimated that 36.7 million 
[34. million – 39.8 million] of people are currently living with HIV worldwide. Advances in 
antiretroviral therapy research have significantly improve HIV/AIDS patients live and 
survival. Nonetheless, sexual transmission of HIV remains the major route (75 to 85%) by 
which all new HIV infections occur. In addition, women remain the most vulnerable population 
affected by HIV/AIDS infection. Novel vaginal and rectally applicable microbicide 
formulations have been proposed as a potential solution for the prevention of HIV sexual 
transmission with limited success. The current dissertation aimed to test the hypothesis that a 
lectin-based vaginal microbicide formulation can be developed to target HIV envelope 
glycoprotein (HIV gp120) for a safer and controlled drug release therapy.  
 In chapter 1 and 2, the scope of HIV epidemic, the general hypothesis of this 
dissertation and major considerations in vaginal microbicides formulation development are 
presented. Chapter 3 focuses on the review of anti-HIV lectins and their delivery strategies 
currently investigated. In Chapter 4, we investigated the use of quartz crystal microbalance 
(QCM) to study the binding affinity of the mannose binding lectin concanavalin A (Con A) to 
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a glucose based polysaccharide (glycogen from Oyster) and a mannose based polysaccharide 
(mannan from Saccharomyces cerevisiae). It was observed that the equilibrium dissociation 
constant for the interaction between Con A and glycogen (KD = 0.25 μM) was about 12 fold 
lower than the equilibrium dissociation constant describing the binding between Con A and 
mannan (KD = 2.89 μM). Thus Con A, a mannose specific lectin, was found to have a higher 
affinity to glycogen from Oyster, a glucose-base polysaccharide, than to mannan from 
Saccharomyces cerevisiae, a mannose-based polysaccharide. This observation was mainly 
attributed to steric effects, the molecular weight difference and the branching pattern of both 
polysaccharides.  
 Knowledge learned from the QCM study was applied in Chapter 5 for the development 
of a lectin-based mannose sensitive drug delivery system. Thus, HIV-1 gp120 and mannose 
responsive particles (MRP) were prepared via the layer-by-layer coating of a calcium 
carbonate (CaCO3) core template with the mannose specific lectin (Con A) and a 
polysaccharide cross-linker (Glycogen). Core dissolved MRP (𝐶−𝑀𝑅𝑃) and core containing 
MRP (𝐶+𝑀𝑅𝑃) were prepared, characterized and tested in vitro on Lactobacillus crispatus, 
Human vaginal keratinocytes (VK2/E6E7) and murine macrophage [RAW 264.7 (TIB-71)] 
cell lines. 𝐶+𝑀𝑅𝑃 average size and ζ-potential were 1130±15.72 nm [PDI = 0.153] and -
15.1±0.55 mV, (n=3). Similarly, 𝐶−𝑀𝑅𝑃 average size and ζ-potential were 1089±23.33 nm 
(n=3) and -14.2±0.25 mV (n=3). Tenofovir (TFV) encapsulation efficiency in CaCO3 core 
particle was 74.4% with drug loading of 16.3% w/w and 6.0% w/w in 𝐶+𝑀𝑅𝑃 and 𝐶−𝑀𝑅𝑃, 
respectively. Both 𝐶−𝑀𝑅𝑃 and 𝐶+𝑀𝑅𝑃 were nontoxic to L. crispatus and did not induce any 
significant pro-inflammatory nitric oxide release in VK2 and RAW 264.7 cell culture. 
Nonetheless, 𝐶−𝑀𝑅𝑃 was found to significantly affect VK2 and RAW 264.7 cells viability at 
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concentrations ≥ 100 µg/ml. Similarly, 𝐶−𝑀𝑅𝑃 significantly increased pro-inflammatory 
cytokines (IL1α, IL1β, IL6, IL7, MKC and TNFα) release at concentrations ≥ 100 µg/ml. 
Conversely, 𝐶+𝑀𝑅𝑃 did not induce any significant changes in VK2 and RAW 264.7 cells 
viability nor in pro-inflammatory cytokines’ levels, in the concentration range tested (≤ 1000 
µg/ml), for 24 h. Therefore, 𝐶+𝑀𝑅𝑃 was selected for further in vitro drug release studies as 
well as ex vivo vaginal mucoadhesion studies. In fact, it was observed that HIV gp120 triggers 
TFV release from 𝐶+𝑀𝑅𝑃 in a concentration dependent manner. TFV was released from 
𝐶+𝑀𝑅𝑃 which following Hixson–Crowell and Hopfenberg kinetic models, consistent with 
drug release from diminishing surface or matrix eroding drug particles. 𝐶+𝑀𝑅𝑃 was further 
optimized by varying the number of Con A layer in the formulation, and in order to achieve 
lower HIV gp120 sensitivity (≤ 100 µg/ml). Furthermore, bioadhesion studies, performed ex 
vivo on porcine vaginal tissue, demonstrated that fluorescein (FITC) labeled 𝐶+𝑀𝑅𝑃 adhere 
to vaginal tissue at rates varying between 10% ± 1 and 20% ± 2, depending on the number of 
Con A layers in the formulation. Thus, it was determined that the optimal MRP formulation 
consisted of 𝐶+𝑀𝑅𝑃 containing 1 Con A/glycogen bilayer with a TFV %LD of 16.3%, an 
%EE of ≥ 70%, an average size of ~850 nm and a surface charge density of +2.4 mV. 
 In chapter 6, the optimal 𝐶+𝑀𝑅𝑃 preclinical safety was evaluated in C57BL/6 mice 
model. Mice were initially treated with Depo-Provera to maintain them in a diestrus-like state. 
The microbicide formulation was delivered vaginally at a dose of 100 mg/kg in PBS, and 
vaginal histology, immunohistochemistry evaluations, as well as pro-inflammatory cytokines 
release (vaginal lavage and tissue extract) were investigated after 24 h. The vaginal retention 
of FITC labeled 𝐶+𝑀𝑅𝑃 was also evaluated, up to 24 h. Vaginal and major reproductive 
organs’ histology did not show major damage of the epithelial layer. This result was also 
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consistent with immunohistochemistry evaluation of CD45+ cells infiltration in the vaginal 
epithelial layer, unlike the positive control treated groups (BZK and N-9). Furthermore, no 
statistically significant increase was observed in, pro-inflammatory cytokines (IL1α, IL1β, 
IL7, IP10 and TNFα). In addition, it was observed that FITC labeled 𝐶+𝑀𝑅𝑃 does not have a 
long-term retention in mice vaginal tract. This result suggested that a precoital or multiple 
vaginal application approaches of 𝐶+𝑀𝑅𝑃 should be investigated. Overall, the preclinical data 
suggested that 𝐶+𝑀𝑅𝑃 induces minor vaginal cytotoxicity at 100 mg/kg.  
 
7.2. Future studies 
 The development and preclinical testing of 𝐶+𝑀𝑅𝑃 represents a major step in lectin-
based vaginal microbicide drug delivery and their potential to prevent HIV sexual 
transmission. However, further in-depth investigations of 𝐶+𝑀𝑅𝑃 are needed. In fact, 𝐶+𝑀𝑅𝑃 
long and short term stability needs to be thoroughly investigated. Furthermore, future studies 
also need to investigate a dose escalation of 𝐶+𝑀𝑅𝑃 to identify its MTD in C57BL/6 mice 
model. In addition, the pharmacokinetic of TFV released from 𝐶+𝑀𝑅𝑃 needs be investigated 
in C57BL/6 mice. More importantly, 𝐶+𝑀𝑅𝑃 efficacy against HIV virus replication will need 
to be investigated and compared to free TFV drug.  
 Although this dissertation focused on a model natural lectin (Con A), synthetic lectins, 
such as phenylboronic acids (PBA), could be evaluated for the prevention of HIV transmission 
through the so-called HIV virion capture therapy. The success of synthetic lectins will probably 
rely on novel drug delivery carriers such as closomers, dendrimers and liposomes, capable of 
achieving higher surface density of PBA, which was been shown to be critical for their 
microbicidal activity. 
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